CN109328074A - 嵌合抗原和t细胞受体及使用的方法 - Google Patents
嵌合抗原和t细胞受体及使用的方法 Download PDFInfo
- Publication number
- CN109328074A CN109328074A CN201780030898.9A CN201780030898A CN109328074A CN 109328074 A CN109328074 A CN 109328074A CN 201780030898 A CN201780030898 A CN 201780030898A CN 109328074 A CN109328074 A CN 109328074A
- Authority
- CN
- China
- Prior art keywords
- cell
- ser
- amino acid
- seq
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 93
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 92
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims description 87
- 210000004027 cell Anatomy 0.000 claims abstract description 338
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 178
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 91
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 91
- 239000002157 polynucleotide Substances 0.000 claims abstract description 91
- 239000000427 antigen Substances 0.000 claims description 212
- 102000036639 antigens Human genes 0.000 claims description 212
- 108091007433 antigens Proteins 0.000 claims description 212
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 167
- 230000027455 binding Effects 0.000 claims description 143
- 206010028980 Neoplasm Diseases 0.000 claims description 133
- 150000001413 amino acids Chemical class 0.000 claims description 99
- 201000011510 cancer Diseases 0.000 claims description 78
- 230000004940 costimulation Effects 0.000 claims description 77
- 108090000623 proteins and genes Proteins 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 239000002773 nucleotide Substances 0.000 claims description 61
- 125000003729 nucleotide group Chemical group 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 48
- 108020004414 DNA Proteins 0.000 claims description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 47
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 42
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 42
- 230000004913 activation Effects 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 33
- -1 CD8alpha Proteins 0.000 claims description 32
- 239000003446 ligand Substances 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 27
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 24
- 230000003834 intracellular effect Effects 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 22
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 20
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 20
- 230000019491 signal transduction Effects 0.000 claims description 19
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 18
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 18
- 102100038078 CD276 antigen Human genes 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 15
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 15
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 15
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 15
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 15
- 201000003444 follicular lymphoma Diseases 0.000 claims description 15
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 14
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 14
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 13
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 13
- 101710185679 CD276 antigen Proteins 0.000 claims description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 12
- 230000009870 specific binding Effects 0.000 claims description 12
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 11
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 11
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 11
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 11
- 208000007452 Plasmacytoma Diseases 0.000 claims description 11
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 102100024263 CD160 antigen Human genes 0.000 claims description 10
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 10
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims description 10
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 10
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 10
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 10
- 101000633782 Homo sapiens SLAM family member 8 Proteins 0.000 claims description 10
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims description 10
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 10
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 10
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 10
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 10
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 10
- 108010025832 RANK Ligand Proteins 0.000 claims description 10
- 102000014128 RANK Ligand Human genes 0.000 claims description 10
- 102100029214 SLAM family member 8 Human genes 0.000 claims description 10
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 10
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 claims description 10
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 10
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 9
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 9
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 8
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 8
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- 241000701161 unidentified adenovirus Species 0.000 claims description 8
- 102100027207 CD27 antigen Human genes 0.000 claims description 7
- 102100035793 CD83 antigen Human genes 0.000 claims description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 7
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 7
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 7
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 7
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 206010053869 POEMS syndrome Diseases 0.000 claims description 7
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 6
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 6
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 6
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 6
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 6
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 6
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 6
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 6
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 6
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 6
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 102000006495 integrins Human genes 0.000 claims description 6
- 108010044426 integrins Proteins 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 5
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 5
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 108010056102 CD100 antigen Proteins 0.000 claims description 5
- 108010017009 CD11b Antigen Proteins 0.000 claims description 5
- 102100038077 CD226 antigen Human genes 0.000 claims description 5
- 108010062802 CD66 antigens Proteins 0.000 claims description 5
- 102100027217 CD82 antigen Human genes 0.000 claims description 5
- 101710139831 CD82 antigen Proteins 0.000 claims description 5
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 5
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 5
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 5
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 5
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 5
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims description 5
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims description 5
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims description 5
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims description 5
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 5
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 5
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 5
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 5
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 5
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 5
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 5
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 5
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 5
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 5
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 5
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 108010073807 IgG Receptors Proteins 0.000 claims description 5
- 102000009490 IgG Receptors Human genes 0.000 claims description 5
- 102100039904 Integrin alpha-D Human genes 0.000 claims description 5
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 5
- 108010041100 Integrin alpha6 Proteins 0.000 claims description 5
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims description 5
- 102100033016 Integrin beta-7 Human genes 0.000 claims description 5
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 5
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 5
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 5
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 5
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 5
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 5
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 5
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 5
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 5
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 5
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 5
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 5
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 5
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 5
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 5
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 5
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 5
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 5
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 5
- 230000009257 reactivity Effects 0.000 claims description 5
- 206010000830 Acute leukaemia Diseases 0.000 claims description 4
- 101710186708 Agglutinin Proteins 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 4
- 101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 claims description 4
- 101710146024 Horcolin Proteins 0.000 claims description 4
- 101710189395 Lectin Proteins 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 108091008877 NK cell receptors Proteins 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 239000000910 agglutinin Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 230000003393 splenic effect Effects 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 4
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 3
- 208000023761 AL amyloidosis Diseases 0.000 claims description 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 102100037904 CD9 antigen Human genes 0.000 claims description 3
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 3
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 3
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 3
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 3
- 241000192019 Human endogenous retrovirus K Species 0.000 claims description 3
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 3
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 108010008707 Mucin-1 Proteins 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 102100023123 Mucin-16 Human genes 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 3
- 208000002774 Paraproteinemias Diseases 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims description 3
- 102100035721 Syndecan-1 Human genes 0.000 claims description 3
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 3
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 108010074605 gamma-Globulins Proteins 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 230000000527 lymphocytic effect Effects 0.000 claims description 3
- 201000000564 macroglobulinemia Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 3
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000010626 plasma cell neoplasm Diseases 0.000 claims description 3
- 210000003720 plasmablast Anatomy 0.000 claims description 3
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 3
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 3
- ZUXNHFFVQWADJL-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(2-methoxyethyl)-n-(4-phenyl-1,3-thiazol-2-yl)benzamide Chemical compound N=1C(C=2C=CC=CC=2)=CSC=1N(CCOC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZUXNHFFVQWADJL-UHFFFAOYSA-N 0.000 claims description 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 3
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 230000007096 poisonous effect Effects 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 abstract description 24
- 235000001014 amino acid Nutrition 0.000 description 110
- 229940024606 amino acid Drugs 0.000 description 102
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 70
- 235000018102 proteins Nutrition 0.000 description 61
- 239000002253 acid Substances 0.000 description 34
- 230000000694 effects Effects 0.000 description 34
- 238000010361 transduction Methods 0.000 description 26
- 230000026683 transduction Effects 0.000 description 26
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 22
- 108010002350 Interleukin-2 Proteins 0.000 description 21
- 102000000588 Interleukin-2 Human genes 0.000 description 21
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 21
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 21
- 238000003501 co-culture Methods 0.000 description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 21
- 102000014150 Interferons Human genes 0.000 description 18
- 108010050904 Interferons Proteins 0.000 description 18
- 229940079322 interferon Drugs 0.000 description 18
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 15
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 13
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 13
- 238000004520 electroporation Methods 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 13
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- 241000713666 Lentivirus Species 0.000 description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 8
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 8
- 230000006037 cell lysis Effects 0.000 description 8
- 239000005482 chemotactic factor Substances 0.000 description 8
- 230000000139 costimulatory effect Effects 0.000 description 8
- 229960004397 cyclophosphamide Drugs 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 7
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 7
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 7
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 7
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 7
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 7
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 7
- 108010008355 arginyl-glutamine Proteins 0.000 description 7
- 230000005754 cellular signaling Effects 0.000 description 7
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 6
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 6
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 6
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 6
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 6
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229960000639 pazopanib Drugs 0.000 description 6
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 5
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 5
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 5
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 5
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 5
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 5
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 5
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 5
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 5
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000006471 dimerization reaction Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 4
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 4
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000001398 Granzyme Human genes 0.000 description 4
- 108060005986 Granzyme Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 4
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 4
- 241000880493 Leptailurus serval Species 0.000 description 4
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 4
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229960004630 chlorambucil Drugs 0.000 description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 108010015792 glycyllysine Proteins 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 229960001101 ifosfamide Drugs 0.000 description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229940047122 interleukins Drugs 0.000 description 4
- 229950001845 lestaurtinib Drugs 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 4
- 229960001156 mitoxantrone Drugs 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229960003787 sorafenib Drugs 0.000 description 4
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- NKCZYEDZTKOFBG-GUBZILKMSA-N Gln-Gln-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NKCZYEDZTKOFBG-GUBZILKMSA-N 0.000 description 3
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 3
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 3
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 3
- RVGMVLVBDRQVKB-UWVGGRQHSA-N Gly-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN RVGMVLVBDRQVKB-UWVGGRQHSA-N 0.000 description 3
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 3
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 3
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 3
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 3
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 3
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 102000027581 NK cell receptors Human genes 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 101710160107 Outer membrane protein A Proteins 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- IUVYJBMTHARMIP-PCBIJLKTSA-N Phe-Asp-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IUVYJBMTHARMIP-PCBIJLKTSA-N 0.000 description 3
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 3
- SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 3
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 3
- GSCVDSBEYVGMJQ-SRVKXCTJSA-N Ser-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)O GSCVDSBEYVGMJQ-SRVKXCTJSA-N 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 3
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 3
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 3
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 3
- OLWFDNLLBWQWCP-STQMWFEESA-N Tyr-Gly-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O OLWFDNLLBWQWCP-STQMWFEESA-N 0.000 description 3
- OVBMCNDKCWAXMZ-NAKRPEOUSA-N Val-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N OVBMCNDKCWAXMZ-NAKRPEOUSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229960003896 aminopterin Drugs 0.000 description 3
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 3
- 108010018006 histidylserine Proteins 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 229960002411 imatinib Drugs 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 3
- 229960000681 leflunomide Drugs 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229960004584 methylprednisolone Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 108010029020 prolylglycine Proteins 0.000 description 3
- 229960004622 raloxifene Drugs 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000011218 segmentation Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229960001196 thiotepa Drugs 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 3
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 2
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 2
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 2
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 2
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 2
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 2
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 2
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 2
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 2
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 2
- FQWNGSKQHPNIQG-UHFFFAOYSA-N 3-[[bis(2-chloroethyl)amino-(2-chloroethoxy)phosphoryl]amino]propan-1-ol Chemical compound OCCCNP(=O)(OCCCl)N(CCCl)CCCl FQWNGSKQHPNIQG-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 2
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 2
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 2
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 2
- DIIGDGJKTMLQQW-IHRRRGAJSA-N Arg-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N DIIGDGJKTMLQQW-IHRRRGAJSA-N 0.000 description 2
- 108010051330 Arg-Pro-Gly-Pro Proteins 0.000 description 2
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 2
- ISJWBVIYRBAXEB-CIUDSAMLSA-N Arg-Ser-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISJWBVIYRBAXEB-CIUDSAMLSA-N 0.000 description 2
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- VDCIPFYVCICPEC-FXQIFTODSA-N Asn-Arg-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O VDCIPFYVCICPEC-FXQIFTODSA-N 0.000 description 2
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 2
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 2
- GKKUBLFXKRDMFC-BQBZGAKWSA-N Asn-Pro-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O GKKUBLFXKRDMFC-BQBZGAKWSA-N 0.000 description 2
- DATSKXOXPUAOLK-KKUMJFAQSA-N Asn-Tyr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DATSKXOXPUAOLK-KKUMJFAQSA-N 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 2
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 2
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 2
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- CMPHFUWXKBPNRS-WDSOQIARSA-N His-Val-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CNC=N1 CMPHFUWXKBPNRS-WDSOQIARSA-N 0.000 description 2
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- HUWYGQOISIJNMK-SIGLWIIPSA-N Ile-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HUWYGQOISIJNMK-SIGLWIIPSA-N 0.000 description 2
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 102100034872 Kallikrein-4 Human genes 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 2
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 2
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 2
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 2
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 2
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 2
- FVKRQMQQFGBXHV-QXEWZRGKSA-N Met-Asp-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FVKRQMQQFGBXHV-QXEWZRGKSA-N 0.000 description 2
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- MTFJSAGADRTKCI-UHFFFAOYSA-N N-(pyridin-2-ylmethylidene)hydroxylamine Chemical compound ON=CC1=CC=CC=N1 MTFJSAGADRTKCI-UHFFFAOYSA-N 0.000 description 2
- 108010066427 N-valyltryptophan Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 2
- 229930187135 Olivomycin Natural products 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 108010057150 Peplomycin Proteins 0.000 description 2
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 2
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 2
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 2
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 2
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- WOLQREOUPKZMEX-UHFFFAOYSA-N Pteroyltriglutamic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 2
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- WXUBSIDKNMFAGS-IHRRRGAJSA-N Ser-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WXUBSIDKNMFAGS-IHRRRGAJSA-N 0.000 description 2
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 2
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 2
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 2
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 2
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 2
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 2
- FLMYSKVSDVHLEW-SVSWQMSJSA-N Ser-Thr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLMYSKVSDVHLEW-SVSWQMSJSA-N 0.000 description 2
- YXEYTHXDRDAIOJ-CWRNSKLLSA-N Ser-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N)C(=O)O YXEYTHXDRDAIOJ-CWRNSKLLSA-N 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 101710190759 Serum amyloid A protein Proteins 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 229920000519 Sizofiran Polymers 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 2
- KRPKYGOFYUNIGM-XVSYOHENSA-N Thr-Asp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O KRPKYGOFYUNIGM-XVSYOHENSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000003819 Toceranib Substances 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- OOEUVMFKKZYSRX-LEWSCRJBSA-N Tyr-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OOEUVMFKKZYSRX-LEWSCRJBSA-N 0.000 description 2
- NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 description 2
- IIJWXEUNETVJPV-IHRRRGAJSA-N Tyr-Arg-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N)O IIJWXEUNETVJPV-IHRRRGAJSA-N 0.000 description 2
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 2
- CKHQKYHIZCRTAP-SOUVJXGZSA-N Tyr-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CKHQKYHIZCRTAP-SOUVJXGZSA-N 0.000 description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 2
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 2
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 2
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 2
- 229950002684 aceglatone Drugs 0.000 description 2
- 229930188522 aclacinomycin Natural products 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 229960004176 aclarubicin Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 229960001445 alitretinoin Drugs 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 2
- 229950000242 ancitabine Drugs 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 230000003388 anti-hormonal effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000009831 antigen interaction Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010068380 arginylarginine Proteins 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229950011321 azaserine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 150000001541 aziridines Chemical class 0.000 description 2
- 229950005567 benzodepa Drugs 0.000 description 2
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960002938 bexarotene Drugs 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 108091006004 biotinylated proteins Proteins 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229960003736 bosutinib Drugs 0.000 description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 108700002839 cactinomycin Proteins 0.000 description 2
- 229950009908 cactinomycin Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 2
- 229950009823 calusterone Drugs 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960002115 carboquone Drugs 0.000 description 2
- 229930188550 carminomycin Natural products 0.000 description 2
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 2
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 2
- 229960003261 carmofur Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 229950001725 carubicin Drugs 0.000 description 2
- 229960000419 catumaxomab Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 229950008249 chlornaphazine Drugs 0.000 description 2
- 229960001480 chlorozotocin Drugs 0.000 description 2
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 229950004239 defosfamide Drugs 0.000 description 2
- 229960005052 demecolcine Drugs 0.000 description 2
- 229960002923 denileukin diftitox Drugs 0.000 description 2
- 108010017271 denileukin diftitox Proteins 0.000 description 2
- 229950003913 detorubicin Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 229950002389 diaziquone Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 108010054812 diprotin A Proteins 0.000 description 2
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 2
- 229950004683 drostanolone propionate Drugs 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 229950000549 elliptinium acetate Drugs 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229950011487 enocitabine Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229950002973 epitiostanol Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 2
- 229950002017 esorubicin Drugs 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 2
- 229960005237 etoglucid Drugs 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 229960004783 fotemustine Drugs 0.000 description 2
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003694 hair properties Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229940015872 ibandronate Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 2
- 229950008097 improsulfan Drugs 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 108010024383 kallikrein 4 Proteins 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000012004 kinetic exclusion assay Methods 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 2
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 2
- 229950008745 losoxantrone Drugs 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 2
- 229950008612 mannomustine Drugs 0.000 description 2
- 229960004655 masitinib Drugs 0.000 description 2
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229950009246 mepitiostane Drugs 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 2
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 2
- 229950009847 meturedepa Drugs 0.000 description 2
- 229960005485 mitobronitol Drugs 0.000 description 2
- 229960003539 mitoguazone Drugs 0.000 description 2
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 2
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 2
- 229950010913 mitolactol Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 2
- 229950010718 mopidamol Drugs 0.000 description 2
- 229940014456 mycophenolate Drugs 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
- 229960002653 nilutamide Drugs 0.000 description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 2
- 229960001420 nimustine Drugs 0.000 description 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 2
- 229960004378 nintedanib Drugs 0.000 description 2
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 2
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 2
- 229950008607 nitracrine Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 2
- 229950005848 olivomycin Drugs 0.000 description 2
- 229950011093 onapristone Drugs 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 2
- 229950003180 peplomycin Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 2
- 229950001100 piposulfan Drugs 0.000 description 2
- 229960001221 pirarubicin Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229960004694 prednimustine Drugs 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960002185 ranimustine Drugs 0.000 description 2
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 2
- 229960000460 razoxane Drugs 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229950004892 rodorubicin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 229950001403 sizofiran Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229950006315 spirogermanium Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960005353 testolactone Drugs 0.000 description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229960005048 toceranib Drugs 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 2
- 229950001353 tretamine Drugs 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 2
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 2
- 229960001670 trilostane Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- 229960001099 trimetrexate Drugs 0.000 description 2
- 229950000212 trioxifene Drugs 0.000 description 2
- 229960000875 trofosfamide Drugs 0.000 description 2
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 2
- 108010084932 tryptophyl-proline Proteins 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 2
- 229950009811 ubenimex Drugs 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 2
- 229950006929 uredepa Drugs 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229950009268 zinostatin Drugs 0.000 description 2
- 229960000641 zorubicin Drugs 0.000 description 2
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QWWVBNODQCWBAZ-WHFBIAKZSA-N (2r)-2-amino-3-[(2r)-2-carboxy-2-(methylamino)ethyl]sulfanylpropanoic acid Chemical compound CN[C@H](C(O)=O)CSC[C@H](N)C(O)=O QWWVBNODQCWBAZ-WHFBIAKZSA-N 0.000 description 1
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 description 1
- WOLQREOUPKZMEX-BZSNNMDCSA-N (2s)-2-[[(4s)-4-[[(4s)-4-[[4-[(2-amino-4-oxo-1h-pteridin-6-yl)methylamino]benzoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-BZSNNMDCSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- LMGGOGHEVZMZCU-FGJMKEJPSA-N (2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,7,12-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-2-carboxylic acid Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(O)=O)C1 LMGGOGHEVZMZCU-FGJMKEJPSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
- 101710111653 2-methylisocitrate lyase Proteins 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-UHFFFAOYSA-N 7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(=O)CO)CC1OC1CC(N)C(O)C(C)O1 AOJJSUZBOXZQNB-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010066817 Activation syndrome Diseases 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 101710133359 Agglutinin receptor Proteins 0.000 description 1
- 101710105075 Agglutinin-2 Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 description 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
- XQJAFSDFQZPYCU-UWJYBYFXSA-N Ala-Asn-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N XQJAFSDFQZPYCU-UWJYBYFXSA-N 0.000 description 1
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- UHMQKOBNPRAZGB-CIUDSAMLSA-N Ala-Glu-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N UHMQKOBNPRAZGB-CIUDSAMLSA-N 0.000 description 1
- NJWJSLCQEDMGNC-MBLNEYKQSA-N Ala-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)N)O NJWJSLCQEDMGNC-MBLNEYKQSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 1
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- 102000009131 Alpha-Ketoglutarate-Dependent Dioxygenase AlkB Homolog 3 Human genes 0.000 description 1
- 108010087979 Alpha-Ketoglutarate-Dependent Dioxygenase AlkB Homolog 3 Proteins 0.000 description 1
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
- KMSHNDWHPWXPEC-BQBZGAKWSA-N Arg-Asp-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KMSHNDWHPWXPEC-BQBZGAKWSA-N 0.000 description 1
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
- SKTGPBFTMNLIHQ-KKUMJFAQSA-N Arg-Glu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SKTGPBFTMNLIHQ-KKUMJFAQSA-N 0.000 description 1
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 1
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 1
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 1
- JEEFEQCRXKPQHC-KKUMJFAQSA-N Asn-Leu-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JEEFEQCRXKPQHC-KKUMJFAQSA-N 0.000 description 1
- VITDJIPIJZAVGC-VEVYYDQMSA-N Asn-Met-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VITDJIPIJZAVGC-VEVYYDQMSA-N 0.000 description 1
- DPWDPEVGACCWTC-SRVKXCTJSA-N Asn-Tyr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O DPWDPEVGACCWTC-SRVKXCTJSA-N 0.000 description 1
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- WNGZKSVJFDZICU-XIRDDKMYSA-N Asp-Leu-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N WNGZKSVJFDZICU-XIRDDKMYSA-N 0.000 description 1
- UZFHNLYQWMGUHU-DCAQKATOSA-N Asp-Lys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZFHNLYQWMGUHU-DCAQKATOSA-N 0.000 description 1
- FQHBAQLBIXLWAG-DCAQKATOSA-N Asp-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N FQHBAQLBIXLWAG-DCAQKATOSA-N 0.000 description 1
- KOWYNSKRPUWSFG-IHPCNDPISA-N Asp-Phe-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)NC(=O)[C@H](CC(=O)O)N KOWYNSKRPUWSFG-IHPCNDPISA-N 0.000 description 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 1
- GHAHOJDCBRXAKC-IHPCNDPISA-N Asp-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N GHAHOJDCBRXAKC-IHPCNDPISA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 1
- 102000004634 CD30 Ligand Human genes 0.000 description 1
- 108010017987 CD30 Ligand Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 108010007056 CKGGRAKDC-GG-D(KLAKLAK)2 Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- GEEXORWTBTUOHC-FXQIFTODSA-N Cys-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N GEEXORWTBTUOHC-FXQIFTODSA-N 0.000 description 1
- SWJYSDXMTPMBHO-FXQIFTODSA-N Cys-Pro-Ser Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SWJYSDXMTPMBHO-FXQIFTODSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000741267 Enterobacteriaceae bacterium Species 0.000 description 1
- 102100023721 Ephrin-B2 Human genes 0.000 description 1
- 108010044090 Ephrin-B2 Proteins 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- MWLYSLMKFXWZPW-ZPFDUUQYSA-N Gln-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O MWLYSLMKFXWZPW-ZPFDUUQYSA-N 0.000 description 1
- TWHDOEYLXXQYOZ-FXQIFTODSA-N Gln-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N TWHDOEYLXXQYOZ-FXQIFTODSA-N 0.000 description 1
- AAOBFSKXAVIORT-GUBZILKMSA-N Gln-Asn-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O AAOBFSKXAVIORT-GUBZILKMSA-N 0.000 description 1
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 1
- GPISLLFQNHELLK-DCAQKATOSA-N Gln-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N GPISLLFQNHELLK-DCAQKATOSA-N 0.000 description 1
- AJDMYLOISOCHHC-YVNDNENWSA-N Gln-Gln-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AJDMYLOISOCHHC-YVNDNENWSA-N 0.000 description 1
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 1
- LVNILKSSFHCSJZ-IHRRRGAJSA-N Gln-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LVNILKSSFHCSJZ-IHRRRGAJSA-N 0.000 description 1
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 1
- VOLVNCMGXWDDQY-LPEHRKFASA-N Gln-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O VOLVNCMGXWDDQY-LPEHRKFASA-N 0.000 description 1
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- VOUSELYGTNGEPB-NUMRIWBASA-N Gln-Thr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O VOUSELYGTNGEPB-NUMRIWBASA-N 0.000 description 1
- CSMHMEATMDCQNY-DZKIICNBSA-N Gln-Val-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CSMHMEATMDCQNY-DZKIICNBSA-N 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 1
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 1
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 1
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 description 1
- QJVZSVUYZFYLFQ-CIUDSAMLSA-N Glu-Pro-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O QJVZSVUYZFYLFQ-CIUDSAMLSA-N 0.000 description 1
- DCBSZJJHOTXMHY-DCAQKATOSA-N Glu-Pro-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DCBSZJJHOTXMHY-DCAQKATOSA-N 0.000 description 1
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 1
- TZXOPHFCAATANZ-QEJZJMRPSA-N Glu-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N TZXOPHFCAATANZ-QEJZJMRPSA-N 0.000 description 1
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 1
- JPAACTMBBBGAAR-HOTGVXAUSA-N Gly-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)CN)CC(C)C)C(O)=O)=CNC2=C1 JPAACTMBBBGAAR-HOTGVXAUSA-N 0.000 description 1
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 1
- OJNZVYSGVYLQIN-BQBZGAKWSA-N Gly-Met-Asp Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O OJNZVYSGVYLQIN-BQBZGAKWSA-N 0.000 description 1
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102100028721 Hermansky-Pudlak syndrome 5 protein Human genes 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- BIAKMWKJMQLZOJ-ZKWXMUAHSA-N His-Ala-Ala Chemical compound C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O BIAKMWKJMQLZOJ-ZKWXMUAHSA-N 0.000 description 1
- LJUIEESLIAZSFR-SRVKXCTJSA-N His-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N LJUIEESLIAZSFR-SRVKXCTJSA-N 0.000 description 1
- BXOLYFJYQQRQDJ-MXAVVETBSA-N His-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)N BXOLYFJYQQRQDJ-MXAVVETBSA-N 0.000 description 1
- HIJIJPFILYPTFR-ACRUOGEOSA-N His-Tyr-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HIJIJPFILYPTFR-ACRUOGEOSA-N 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LHFKHAVGGJJQFF-UEOYEZOQSA-N Hydroxy-alpha-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UEOYEZOQSA-N 0.000 description 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- ASCFJMSGKUIRDU-ZPFDUUQYSA-N Ile-Arg-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O ASCFJMSGKUIRDU-ZPFDUUQYSA-N 0.000 description 1
- LWWILHPVAKKLQS-QXEWZRGKSA-N Ile-Gly-Met Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N LWWILHPVAKKLQS-QXEWZRGKSA-N 0.000 description 1
- DMSVBUWGDLYNLC-IAVJCBSLSA-N Ile-Ile-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DMSVBUWGDLYNLC-IAVJCBSLSA-N 0.000 description 1
- IIWQTXMUALXGOV-PCBIJLKTSA-N Ile-Phe-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N IIWQTXMUALXGOV-PCBIJLKTSA-N 0.000 description 1
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 1
- JDCQDJVYUXNCGF-SPOWBLRKSA-N Ile-Ser-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N JDCQDJVYUXNCGF-SPOWBLRKSA-N 0.000 description 1
- HXIDVIFHRYRXLZ-NAKRPEOUSA-N Ile-Ser-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)N HXIDVIFHRYRXLZ-NAKRPEOUSA-N 0.000 description 1
- WKSHBPRUIRGWRZ-KCTSRDHCSA-N Ile-Trp-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N WKSHBPRUIRGWRZ-KCTSRDHCSA-N 0.000 description 1
- WJBOZUVRPOIQNN-KJYZGMDISA-N Ile-Trp-His Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)C1=CN=CN1 WJBOZUVRPOIQNN-KJYZGMDISA-N 0.000 description 1
- DZMWFIRHFFVBHS-ZEWNOJEFSA-N Ile-Tyr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N DZMWFIRHFFVBHS-ZEWNOJEFSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 1
- ZURHXHNAEJJRNU-CIUDSAMLSA-N Leu-Asp-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZURHXHNAEJJRNU-CIUDSAMLSA-N 0.000 description 1
- QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 1
- FMEICTQWUKNAGC-YUMQZZPRSA-N Leu-Gly-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O FMEICTQWUKNAGC-YUMQZZPRSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- KVOFSTUWVSQMDK-KKUMJFAQSA-N Leu-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1 KVOFSTUWVSQMDK-KKUMJFAQSA-N 0.000 description 1
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 1
- PXHCFKXNSBJSTQ-KKUMJFAQSA-N Lys-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)O PXHCFKXNSBJSTQ-KKUMJFAQSA-N 0.000 description 1
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 1
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 1
- UETQMSASAVBGJY-QWRGUYRKSA-N Lys-Gly-His Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 UETQMSASAVBGJY-QWRGUYRKSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 1
- QBEPTBMRQALPEV-MNXVOIDGSA-N Lys-Ile-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN QBEPTBMRQALPEV-MNXVOIDGSA-N 0.000 description 1
- ZXFRGTAIIZHNHG-AJNGGQMLSA-N Lys-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N ZXFRGTAIIZHNHG-AJNGGQMLSA-N 0.000 description 1
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 1
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 1
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 1
- FPQMQEOVSKMVMA-ACRUOGEOSA-N Lys-Tyr-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CCCCN)N)O FPQMQEOVSKMVMA-ACRUOGEOSA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026851 Marrow hyperplasia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- DBOMZJOESVYERT-GUBZILKMSA-N Met-Asn-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N DBOMZJOESVYERT-GUBZILKMSA-N 0.000 description 1
- YLLWCSDBVGZLOW-CIUDSAMLSA-N Met-Gln-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O YLLWCSDBVGZLOW-CIUDSAMLSA-N 0.000 description 1
- UOENBSHXYCHSAU-YUMQZZPRSA-N Met-Gln-Gly Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O UOENBSHXYCHSAU-YUMQZZPRSA-N 0.000 description 1
- IUYCGMNKIZDRQI-BQBZGAKWSA-N Met-Gly-Ala Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O IUYCGMNKIZDRQI-BQBZGAKWSA-N 0.000 description 1
- UZWMJZSOXGOVIN-LURJTMIESA-N Met-Gly-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(=O)NCC(O)=O UZWMJZSOXGOVIN-LURJTMIESA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- IIHMNTBFPMRJCN-RCWTZXSCSA-N Met-Val-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IIHMNTBFPMRJCN-RCWTZXSCSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101000753280 Mus musculus Angiopoietin-1 receptor Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101100286588 Mus musculus Igfl gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- UUWCIPUVJJIEEP-SRVKXCTJSA-N Phe-Asn-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N UUWCIPUVJJIEEP-SRVKXCTJSA-N 0.000 description 1
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 1
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- BPIMVBKDLSBKIJ-FCLVOEFKSA-N Phe-Thr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BPIMVBKDLSBKIJ-FCLVOEFKSA-N 0.000 description 1
- BTAIJUBAGLVFKQ-BVSLBCMMSA-N Phe-Trp-Val Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=CC=C1 BTAIJUBAGLVFKQ-BVSLBCMMSA-N 0.000 description 1
- ZYNBEWGJFXTBDU-ACRUOGEOSA-N Phe-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N ZYNBEWGJFXTBDU-ACRUOGEOSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- HJSCRFZVGXAGNG-SRVKXCTJSA-N Pro-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1 HJSCRFZVGXAGNG-SRVKXCTJSA-N 0.000 description 1
- QGOZJLYCGRYYRW-KKUMJFAQSA-N Pro-Glu-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QGOZJLYCGRYYRW-KKUMJFAQSA-N 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 1
- NTXFLJULRHQMDC-GUBZILKMSA-N Pro-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 NTXFLJULRHQMDC-GUBZILKMSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- CWZUFLWPEFHWEI-IHRRRGAJSA-N Pro-Tyr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O CWZUFLWPEFHWEI-IHRRRGAJSA-N 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000005464 Radotinib Substances 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100038689 Scm-like with four MBT domains protein 1 Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- OBXVZEAMXFSGPU-FXQIFTODSA-N Ser-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)CN=C(N)N OBXVZEAMXFSGPU-FXQIFTODSA-N 0.000 description 1
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 1
- KMWFXJCGRXBQAC-CIUDSAMLSA-N Ser-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N KMWFXJCGRXBQAC-CIUDSAMLSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- FKZSXTKZLPPHQU-GQGQLFGLSA-N Ser-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CO)N FKZSXTKZLPPHQU-GQGQLFGLSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- AMRRYKHCILPAKD-FXQIFTODSA-N Ser-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N AMRRYKHCILPAKD-FXQIFTODSA-N 0.000 description 1
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 1
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 1
- OVQZAFXWIWNYKA-GUBZILKMSA-N Ser-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)N OVQZAFXWIWNYKA-GUBZILKMSA-N 0.000 description 1
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- GLQFKOVWXPPFTP-VEVYYDQMSA-N Thr-Arg-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GLQFKOVWXPPFTP-VEVYYDQMSA-N 0.000 description 1
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 1
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 1
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 1
- GUHLYMZJVXUIPO-RCWTZXSCSA-N Thr-Met-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GUHLYMZJVXUIPO-RCWTZXSCSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- BZTSQFWJNJYZSX-JRQIVUDYSA-N Thr-Tyr-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O BZTSQFWJNJYZSX-JRQIVUDYSA-N 0.000 description 1
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- AVYVKJMBNLPWRX-WFBYXXMGSA-N Trp-Ala-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 AVYVKJMBNLPWRX-WFBYXXMGSA-N 0.000 description 1
- YRXXUYPYPHRJPB-RXVVDRJESA-N Trp-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N YRXXUYPYPHRJPB-RXVVDRJESA-N 0.000 description 1
- KIMOCKLJBXHFIN-YLVFBTJISA-N Trp-Ile-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O)=CNC2=C1 KIMOCKLJBXHFIN-YLVFBTJISA-N 0.000 description 1
- UJGDFQRPYGJBEH-AAEUAGOBSA-N Trp-Ser-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N UJGDFQRPYGJBEH-AAEUAGOBSA-N 0.000 description 1
- UIRVSEPRMWDVEW-RNXOBYDBSA-N Trp-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N UIRVSEPRMWDVEW-RNXOBYDBSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 1
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 1
- TZXFLDNBYYGLKA-BZSNNMDCSA-N Tyr-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 TZXFLDNBYYGLKA-BZSNNMDCSA-N 0.000 description 1
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 1
- RYSNTWVRSLCAJZ-RYUDHWBXSA-N Tyr-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RYSNTWVRSLCAJZ-RYUDHWBXSA-N 0.000 description 1
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- XYNFFTNEQDWZNY-ULQDDVLXSA-N Tyr-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N XYNFFTNEQDWZNY-ULQDDVLXSA-N 0.000 description 1
- LMKKMCGTDANZTR-BZSNNMDCSA-N Tyr-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LMKKMCGTDANZTR-BZSNNMDCSA-N 0.000 description 1
- XGZBEGGGAUQBMB-KJEVXHAQSA-N Tyr-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)N)O XGZBEGGGAUQBMB-KJEVXHAQSA-N 0.000 description 1
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- MDXLPNRXCFOBTL-BZSNNMDCSA-N Tyr-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MDXLPNRXCFOBTL-BZSNNMDCSA-N 0.000 description 1
- LDKDSFQSEUOCOO-RPTUDFQQSA-N Tyr-Thr-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LDKDSFQSEUOCOO-RPTUDFQQSA-N 0.000 description 1
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
- AEOFMCAKYIQQFY-YDHLFZDLSA-N Tyr-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AEOFMCAKYIQQFY-YDHLFZDLSA-N 0.000 description 1
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- JFAWZADYPRMRCO-UBHSHLNASA-N Val-Ala-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JFAWZADYPRMRCO-UBHSHLNASA-N 0.000 description 1
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 1
- XJFXZQKJQGYFMM-GUBZILKMSA-N Val-Cys-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)N XJFXZQKJQGYFMM-GUBZILKMSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- ILMVQSHENUZYIZ-JYJNAYRXSA-N Val-Met-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N ILMVQSHENUZYIZ-JYJNAYRXSA-N 0.000 description 1
- WMRWZYSRQUORHJ-YDHLFZDLSA-N Val-Phe-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WMRWZYSRQUORHJ-YDHLFZDLSA-N 0.000 description 1
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- USXYVSTVPHELAF-RCWTZXSCSA-N Val-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N)O USXYVSTVPHELAF-RCWTZXSCSA-N 0.000 description 1
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 1
- GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical class ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 108010035879 albumin-bilirubin complex Proteins 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000011130 autologous cell therapy Methods 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 235000019846 buffering salt Nutrition 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000022033 carcinoma of urethra Diseases 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- MWPDWPGAFJXUBZ-UHFFFAOYSA-N hypochlorous acid quinoline Chemical compound ClO.N1=CC=CC2=CC=CC=C12 MWPDWPGAFJXUBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 201000007294 immune system cancer Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003394 isomerase inhibitor Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 210000001501 megacaryocyte Anatomy 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
- ZOGSYTPLAROSTP-UHFFFAOYSA-N n-[bis(ethylamino)phosphoryl]ethanamine Chemical compound CCNP(=O)(NCC)NCC ZOGSYTPLAROSTP-UHFFFAOYSA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 201000003913 parathyroid carcinoma Diseases 0.000 description 1
- 208000017954 parathyroid gland carcinoma Diseases 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010079891 prostein Proteins 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229950004043 radotinib Drugs 0.000 description 1
- DUPWHXBITIZIKZ-UHFFFAOYSA-N radotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3N=CC=NC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DUPWHXBITIZIKZ-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000001869 rapid Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 108700031632 somatrem Proteins 0.000 description 1
- 229960005325 sonidegib Drugs 0.000 description 1
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229960000940 tivozanib Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
- 108010000998 wheylin-2 peptide Proteins 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70589—CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/17—Hinge-spacer domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明提供了包含本文公开的细胞外结构域的嵌合抗原受体(CAR)或T细胞受体(TCR)。本发明的一些方面涉及多核苷酸,所述多核苷酸编码包含本文公开的细胞外结构域的嵌合抗原受体(CAR)或T细胞受体(TCR)。本发明的其他方面涉及包含所述CAR或所述TCR的细胞及其在T细胞疗法中的用途。
Description
相关申请的交叉引用
本申请要求2016年4月1日提交的美国临时专利申请号62/317,258的权益,该临时专利申请通过引用整体并入本文。
序列表
本申请包含序列表,该序列表已经以ASCII格式电子提交,并且通过引用整体并入本文。2017年3月30日创建的所述ASCII拷贝命名为K-1031_02_SL.txt,大小为414,963字节。
发明背景
人类癌症就其本质而言是由已经经历了遗传或表观遗传转化而变成异常癌细胞的正常细胞组成。此时,癌细胞开始表达与正常细胞表达的蛋白质和其他抗原不同的蛋白质和其他抗原。这些异常的肿瘤抗原可以被身体的先天免疫系统用于特异性靶向和杀死癌细胞。然而,癌细胞采用各种机制来阻止免疫细胞如T和B淋巴细胞成功靶向癌细胞。
目前的疗法T细胞疗法依赖于经富集或经修饰的人T细胞来靶向并杀死患者中的癌细胞。为了增加T细胞靶向和杀死特定癌细胞的能力,已经开发了方法来工程化改造T细胞以表达将T细胞导向特定靶癌细胞的构建体。嵌合抗原受体(CAR)和工程化T细胞受体(TCR),其包含能够与特定肿瘤抗原相互作用的结合结构域,允许T细胞靶向并杀死表达特定肿瘤抗原的癌细胞。
存在对用于靶向和杀死癌细胞的改进的CAR和TCR的需求。
发明概述
本发明通过提供包含表达特异性靶向并杀死癌细胞的抗原受体(CAR)或T细胞受体(TCR)的经基因工程化改造的免疫细胞的组合物和方法解决了该需求。
CAR可以包含例如,(i)抗原特异性组分(“抗原结合分子”),(ii)一个或多个共刺激结构域(其包括铰链结构域),和(iii)一个或多个活化结构域。每个结构域可以是异种的,也就是说,由衍生自不同蛋白质链的序列组成。表达CAR的免疫细胞(例如T细胞)可以用于各种疗法,包括癌症疗法。
如下文(包括实施例部分)更详细描述的,与包含包括完整铰链结构域(“CHD”)的共刺激结构域的CAR相比,包含包括截短铰链结构域(“THD”)的共刺激结构域的CAR提供了出乎意料的优越性质。可以将编码此类CAR的多核苷酸转导到T细胞中,而CAR在T细胞例如患者自身的T细胞中得到表达。当将经转导的T细胞移植回患者时,CAR指导T细胞识别并结合存在于癌细胞表面上的表位,从而允许癌细胞而不是非癌细胞的结合。该结合导致T细胞中细胞溶解机制的活化,其特异性杀死结合的癌细胞。在本发明之前,包含THD的CAR优于包含CHD的CAR不为人所知。因此,本发明满足了对用于治疗癌症的新型和改进疗法存在的未满足的需求。
本发明的一方面是编码嵌合抗原受体(CAR)或T细胞受体(TCR)的分离的多核苷酸,其包含(i)抗原结合分子,(ii)共刺激结构域,和(iii)活化结构域。所述共刺激结构域可以包含细胞外结构域、跨膜结构域和细胞内结构域,其中所述细胞外结构域包含截短铰链结构域,所述截短铰链结构域基本上由以下各项组成或由以下各项组成:(i)与SEQ IDNO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列,和任选地(ii)一至六个氨基酸。
在一些实施方案中,所述一至六个氨基酸为异源的氨基酸。
在一些实施方案中,所述截短铰链结构域基本上由以下组成或由以下组成:与SEQID NO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在一些实施方案中,所述氨基酸序列由以下核苷酸序列编码:与SEQ ID NO:2至少约60%,至少约70%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
在一些实施方案中,所述跨膜结构域为以下各项的跨膜结构域:4-1BB/CD137、T细胞受体的alpha链、T细胞受体的beta链、CD3epsilon、CD4、CD5、CD8alpha、CD9、CD16、CD19、CD22、CD33、CD37、CD45、CD64、CD80、CD86、CD134、CD137、CD154或T细胞受体的zeta链,或它们的任何组合。
在一些实施方案中,所述跨膜结构域包含与SEQ ID NO:5至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在一些实施方案中,所述跨膜结构域由以下核苷酸序列编码:与SEQ ID NO:4至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
在一些实施方案中,所述细胞内结构域包含以下各项的信号传导区:4-1BB/CD137、活化性NK细胞受体、B7-H3、BAFFR、BLAME(SLAMF8)、BTLA、CD100(SEMA4D)、CD103、CD160(BY55)、CD18、CD19、CD19a、CD2、CD247、CD27、CD276(B7-H3)、CD29、CD3delta、CD3epsilon、CD3gamma、CD30、CD4、CD40、CD49a、CD49D、CD49f、CD69、CD7、CD84、CD8alpha、CD8beta、CD96(Tactile)、CD1 1a、CD1 1b、CD1 1c、CD1 1d、CDS、CEACAM1、CRT AM、细胞因子受体、DAP-10、DNAM1(CD226)、Fc gamma受体、GADS、GITR、HVEM(LIGHTR)、IA4、ICAM-1、ICAM-1、Ig alpha(CD79a)、IL2R beta、IL2R gamma、IL7R alpha、免疫球蛋白样蛋白质、诱导性T细胞共刺激分子(ICOS)、整合素、ITGA4、ITGA4、ITGA6、ITGAD、ITGAE、ITGAL、ITGAM、ITGAX、ITGB2、ITGB7、ITGBl、KIRDS2、LAT、LFA-1、LFA-1、与CD83特异性结合的配体、LIGHT、LIGHT(肿瘤坏死因子超家族成员14;TNFSF14)、LTBR、Ly9(CD229)、淋巴细胞功能相关抗原-1(LFA-1(CD1 la/CD18)、MHC I类分子、NKG2C、NKG2D、NKp30、NKp44、NKp46、NKp80(KLRF1)、OX-40、PAG/Cbp、程序性死亡-1(PD-1)、PSGL1、SELPLG(CD162)、信号传导淋巴细胞活化分子(SLAM蛋白)、SLAM(SLAMF1;CD150;IPO-3)、SLAMF4(CD244;2B4)、SLAMF6(NTB-A;Lyl08)、SLAMF7、SLP-76、TNF受体蛋白、TNFR2、Toll配体受体、TRANCE/RANKL、VLA1或VLA-6,或它们的组合。
在一些实施方案中,所述细胞内结构域包含4-1BB/CD137信号传导区。
在一些实施方案中,所述细胞内结构域包含与SEQ ID NO:7至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在一些实施方案中,所述细胞内结构域包含由以下核苷酸序列编码的氨基酸序列:与SEQ ID NO:6至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
在一些实施方案中,所述抗原结合分子包含重链可变区(VH)和轻链可变区(VL),其中所述VH包含3个互补决定区(CDR)并且所述VL包含3个CDR。
在一些实施方案中,所述抗原结合分子特异性结合选自由以下各项组成的组的抗原:5T4、甲胎蛋白、B细胞成熟抗原(BCMA)、CA-125、癌胚抗原、CD19、CD20、CD22、CD23、CD30、CD33、CD56、CD123、CD138、c-Met、CSPG4、C型凝集素样分子1(CLL-1)、EGFRvIII、上皮肿瘤抗原、ERBB2、FLT3、叶酸结合蛋白、GD2、GD3、结合的HER1-HER2、结合的HER2-HER3、HER2/Neu、HERV-K、HIV-1包膜糖蛋白gp41、HIV-1包膜糖蛋白gpl20、IL-llRalpha、kappa链、lambda链、黑色素瘤相关抗原、间皮素、MUC-1、突变的p53、突变的ras、前列腺特异性抗原、ROR1或VEGFR2,或它们的组合。
在一些实施方案中,所述抗原结合分子特异性结合BCMA、CLL-1或FLT3。
在一些实施方案中,所述活化结构域包含与SEQ ID NO:9或SEQ ID NO:251至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在一些实施方案中,所述活化结构域由以下核苷酸序列编码:与SEQ ID NO:8至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
在一些实施方案中,所述CAR或TCR进一步包含前导肽。
在一些实施方案中,所述前导肽包含与SEQ ID NO:11至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在一些实施方案中,所述前导肽由以下核苷酸序列编码:与SEQ ID NO:10至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
本发明的另一方面是包含上述方面或实施方案的多核苷酸的载体。
在一些实施方案中,所述载体为腺病毒载体、腺病毒相关载体、DNA载体、慢病毒载体、质粒、逆转录病毒载体或RNA载体,或它们的任何组合。
而本发明的另一方面是由上述方面或实施方案的多核苷酸或上述方面或实施方案的载体编码的多肽。
在另一方面,本发明是包含上述方面或实施方案的多核苷酸、上述方面或实施方案的载体,或上述方面或实施方案的多肽,或它们的任何组合的细胞。
在一些实施方案中,所述细胞为T细胞。
在一些实施方案中,所述T细胞为同种异体T细胞、自体T细胞、工程化自体T细胞(eACTTM)或肿瘤浸润淋巴细胞(TIL)。
在一些实施方案中,所述T细胞为CD4+T细胞。
在一些实施方案中,所述T细胞为CD8+T细胞。
在一些实施方案中,所述T细胞为体外细胞。
在一些实施方案中,所述T细胞为自体T细胞。
本发明的一个方面是包含上述方面或实施方案的多核苷酸、包含上述方面或实施方案的载体、包含上述方面或实施方案的多肽或包含上述方面或实施方案的细胞的组合物。
在一些实施方案中,所述组合物经配制以递送至受试者,任选地,所述组合物包含至少一种药学上可接受的赋形剂。
本发明的另一方面是制备表达CAR或TCR的细胞的方法,所述方法包含在适合的条件下用上述方面或实施方案的多核苷酸转导细胞。
在一些实施方案中,所述方法进一步包含分离所述细胞。
而本发明的另一方面是诱导针对肿瘤的免疫力的方法,所述方法包含向受试者施用有效量的细胞,所述细胞包含上述方面或实施方案的多核苷酸、包含上述方面或实施方案的载体,或上述方面或实施方案的多肽,或它们的任何组合。
在另一方面,本发明是治疗有需要的受试者中癌症的方法,所述方法包含向受试者施用上述方面或实施方案的多核苷酸、上述方面或实施方案的载体、上述方面或实施方案的多肽、上述方面或实施方案的细胞或上述方面或实施方案的组合物。
在一些实施方案中,所述癌症为血液学癌症。
在一些实施方案中,所述癌症为白细胞的癌症。
在一些实施方案中,所述癌症为浆细胞的癌症。
在一些实施方案中,所述癌症为白血病、淋巴瘤或骨髓瘤。
在一些实施方案中,所述癌症为急性淋巴母细胞白血病(ALL)(包括非T细胞ALL)、急性髓样白血病、B细胞幼淋巴细胞白血病、B细胞急性淋巴细胞白血病(“BALL”)、母细胞性浆细胞样树突状细胞肿瘤、伯基特淋巴瘤、慢性淋巴细胞白血病(CLL)、慢性髓细胞性白血病(CML)、慢性髓样白血病、慢性或急性白血病、弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤(FL)、毛细胞白血病、霍奇金病、恶性淋巴细胞增生性疾病、MALT淋巴瘤、套细胞淋巴瘤、边缘区淋巴瘤、意义不明的单克隆丙种球蛋白病(MGUS)、多发性骨髓瘤、骨髓增生异常和骨髓增生异常综合征、非霍奇金淋巴瘤(NHL)、浆细胞增生性疾病(包括无症状性骨髓瘤(郁积型多发性骨髓瘤或惰性骨髓瘤))、浆母细胞性淋巴瘤、浆细胞样树突状细胞肿瘤、浆细胞瘤(包括浆细胞恶液质;单发性骨髓瘤;单发性浆细胞瘤;髓外浆细胞瘤;和多发性浆细胞瘤)、POEMS综合征(也称为Crow-Fukase综合征;Takatsuki病;和PEP综合征)、原发性纵隔大B细胞淋巴瘤(PMBC)、小细胞或大细胞滤泡性淋巴瘤、脾边缘区淋巴瘤(SMZL)、系统性淀粉样蛋白轻链淀粉样变、T细胞急性淋巴细胞白血病(“TALL”)、T细胞淋巴瘤、转化滤泡性淋巴瘤或瓦氏巨球蛋白血症,或它们的组合。
一般而言,本发明涉及工程化自体细胞疗法(Engineered Autologous CellTherapy),缩写为“eACTTM”,也称为过继细胞转移。eACTTM是一种过程,通过该过程收集患者自身的T细胞并随后进行基因工程化改造以识别和靶向在一种或多种特定癌细胞的细胞表面上表达的一种或多种抗原。可以将T细胞工程化改造以表达例如CAR或TCR。将CAR阳性(CAR+)T细胞工程化改造以表达CAR。CAR可以包含,例如对特定肿瘤抗原具有特异性的细胞外单链可变片段(scFv),其直接或间接地与包含至少一个共刺激结构域的细胞内信号传导部分连接,共刺激结构域直接或间接地与至少一个活化结构域连接;组分可以按任何顺序排列。共刺激结构域可以衍生自本领域已知的共刺激蛋白质例如SEQ ID NO:1,并且活化结构域可以衍生自例如CD3-zeta的任何形式。在一些实施方案中,将CAR设计为具有两个、三个、四个或更多个共刺激结构域。在一些实施方案中,将CAR进行工程化改造使得共刺激结构域以单独的多肽链形式表达。CART细胞疗法和构建体的实例描述于美国专利公开号2013/0287748、2014/0227237、2014/0099309和2014/0050708;国际专利公开号WO2012033885、WO2012079000、WO2014127261、WO2014186469、WO2015080981、W02015142675、WO2016044745和WO2016090369;以及Sadelain et al,Cancer Discovery,3:388-398(2013),其每一个通过引用整体并入本文。
本文描述的任何方面或实施方案可以与本文公开的任何其他方面或实施方案组合。虽然已经结合本发明的详细描述描述了本发明,但是前面的描述旨在说明而不是限制本发明的范围,本发明的范围由所附权利要求的范围限定。其他方面、优点和修改在以下权利要求的范围内。
本文提及的专利和科学文献建立了本领域技术人员可获得的知识。本文引用的所有美国专利和公开或未公开的美国专利申请通过引用并入本文。本文引用的所有公开的外国专利和专利申请在此通过引用并入本文。本文引用的所有其他公开的参考文献、词典、文件、手稿和科学文献在此通过引用并入本文。
根据附图和以下详细说明,包括实施例和权利要求,本发明的其他特征和优点将显而易见。
附图说明
从以下结合附图的详细描述中将更清楚地领会以上和进一步的特征。然而,附图仅用于说明目的而不是为了限制。
图1A显示了具有SEQ ID NO:1的氨基酸序列的共刺激蛋白质。标记了共刺激蛋白质的铰链结构域(实线下划线)、跨膜结构域(点下划线)和信号传导结构域(短线下划线)。用粗体表示新的截短铰链结构域(“THD”)。图1B和1C提供了具有SEQ ID NO:1的氨基酸序列的共刺激蛋白质的细胞外结构域的带状示意图。图1B显示了SEQ ID NO:1的氨基酸序列内的区域的实例,其用于在CAR的背景中获得铰链区的一个实施方案,即含有SEQ ID NO:1的氨基酸114至152的区域(本文称为完整铰链结构域或“CHD”;用黑色和深灰色标记)。图1C显示了含有SEQ ID NO:1的氨基酸123至152的THD(用黑色标记)。在图1B中,用深灰色标记并圈出从图1C排除的铰链区的部分。
图2A-2H显示了本文公开的八个实例结合分子的CLUTSTAL W(2.83)多序列比对。图2A显示了包含VH结构域的实例抗CLL-1结合分子的序列比对。显示了CDR和框架区FR,如通过Chothia编号所确定的(图2A)。图2B是提供图2A中所示的每个VH和CDR的SEQ ID NO的表格。图2C显示了包含VL结构域的实例抗CLL-1结合分子的序列比对。显示了CDR和FR,如通过Chothia编号所确定的(图2C)。图2D是提供图2C中所示的每个VH和CDR序列的SEQ ID NO的表格。图2E显示了包含VH结构域的实例抗BCMA结合分子的序列比对。显示了互补决定区(CDR)和框架区(FR),如通过Chothia编号所确定的(图2E)。图2F是提供图2E中所示的每个VH和CDR的SEQ ID NO的表格。图2G显示了包含VL结构域的实例抗BCMA结合分子的序列比对。显示了CDR和FR,如通过Chothia编号所确定的(图2G)。图2H是提供图2G中所示的每个VH和CDR序列的SEQ ID NO的表格。
图3描绘了用编码各种CAR的mRNA电穿孔的原代人T细胞中的CAR表达。显示了从具有完整铰链结构域(“CHD”)的CAR获得的数据并显示了从具有截短铰链结构域(“THD”)的CAR获得的数据。
图4A-4X显示了通过与所示靶细胞系共培养16小时后电穿孔的抗FLT3CAR T细胞的IFNγ、IL-2和TNFα产生。图4A-4B、4G-4H、4M-4N和4S-4T分别显示了与Namalwa、EoL-1、HL60和MV4;11靶细胞共培养后的IFNγ产生。图4C-4D、4I-4J、4O-4P和4U-4V分别显示了与Namalwa、EoL-1、HL60和MV4;11靶细胞共培养后的IL-2产生。图4E-4F、4K-4L、4Q-4R和4W-4X分别显示了与Namalwa、EoL-1、HL60和MV4;11靶细胞共培养后的TNFα产生。
图5A-5H显示了共培养16小时后电穿孔的抗FLT3CART细胞对Namalwa(图5A-5B)、EoL1(图5C-5D)、HL60(图5E-5F)和MV4;11(图5G-5H)靶细胞系的细胞溶解活性。
图6A-6B描绘了来自两个健康供体的慢病毒转导的原代人T细胞中的CAR表达。
图7A-7F显示了在与所示靶细胞系共培养16小时后,来自两个健康供体的慢病毒转导的CAR T细胞的IFNγ(图7A-7B)、TNFα(图7C-7D)和IL-2(图7E-7F)产生。
图8A-8D显示了与Namalwa(图8A)、EoL1(图8B)、MV4;11(图8C)和HL60(图8D)靶细胞系共培养16、40、64、88或112小时的来自表达抗FLT3CAR构建体的两个健康供体随时间的平均细胞溶解活性。
图9A-9B描绘了在与CD3-CD28珠子或所示靶细胞系共培养5天后,来自两个健康供体的CFSE标记的慢病毒转导的CART细胞的增殖。
图10A-10D描绘了用于体内研究的慢病毒转导的原代人T细胞中的CAR表达。图10E-10F显示了一式两份实施的在异种模型中静脉内注射对照(模拟品)或抗FLT3CART细胞(10E3-CHD、10E3-THD或8B5-THD)后,经标记的急性髓样白血病(AML)细胞的测量的生物发光成像的图示。图10G提供了图10E中各个数据点的p值。图10H-10K显示了小鼠的存活曲线,所述小鼠注射了模拟品或10E3-CHD(图10H)、模拟品或10E3-THD(图10I)、模拟品或8B5-THD(图10J),或10E3-THD或8B5-THD(图10K)CAR T细胞。
图11A-11B显示了在mRNA电穿孔后6小时由蛋白质L测定的CLL-1 CAR表达。
图12A-12C显示了来自mRNA电穿孔后24小时的来自不同CLL-1 CAR-T细胞构建体的细胞因子释放测定的结果。如所示,显示了与Namalwa、MV4;11、U937、HL60和EoL-1细胞共培养的对照(单独的靶物、模拟品、GFP和CD19 CAR T细胞)和抗CLL-1 CAR T细胞(24C1_HL-THD、24C1_HL_CHD、24C8_HL-CHD和24C8_HL_THD)的IL-2(图12A)、IFNγ(图12B)和TNFα(图12C)产生水平。
图13A-13E显示了mRNA电穿孔后24小时的不同的CLL-1 CAR-T细胞构建体的细胞溶解活性。将用对照构建体(模拟品、GFP和CD19 CAR)或抗CLL-1 CAR构建体(24C8_HL-CHD和24C8_HL_THD)电穿孔的T细胞与Namalwa(图13A)、MV;411(图13B)、EoL-1(图13C)、HL-60(图13D)和U937靶细胞共培养,并测定了每个靶细胞系的特异性溶解的百分比。
图14A-14C显示了来自与不同的细胞系共培养16小时后的来自不同的经转导的抗CLL-1 CAR T细胞的细胞因子释放测定的结果。如所示,显示了对于与Namalwa、HL-60或MV4;11靶细胞共培养的对照(单独的靶物和模拟品)和经转导的抗CLL-1 CAR T细胞(10E3_THD和24C1_LH_THD)的IFNγ(图14A)、IL-2(图14B)和TNFα(图14C)产生水平。
图15A-15C显示了来自与Namalwa(图15A)、MV4;11(图15B)或HL-60(图15C)靶细胞共培养16小时和40小时后的抗CLL-1 CAR T细胞(C1_24C1_LH_THD)的细胞溶解活性。
图16A-16F显示了在与EoL-1(黑色)、NCI-H929(浅灰色)或MM1S(灰色)靶细胞系共培养16小时后,来自两个健康供体的慢病毒转导的CART细胞的IFNγ、TNFα和IL-2产生。图16A和16B显示了来自第一供体(图16A)和第二供体(图16B)的慢病毒转导的CART细胞中的IFNγ(pg/ml;y轴)产生。图16C和16D显示了来自第一供体(图16C)和第二供体(图16D)的慢病毒转导的CART细胞中的TNFα(pg/ml;y轴)产生。图16E和16F显示了来自第一供体(图16E)和第二供体(图16F)的慢病毒转导的CART细胞中的IL-2产生(pg/ml;y轴)。
图17A-17F显示了与EoL1(图17A和17B)、NCI-H929(图17C和17D)或MM1S(图17E和17F)靶细胞共培养16小时、40小时、64小时、88小时或112小时的来自表达所示的CAR的两个健康供体随时间的平均细胞溶解活性(作为剩余活的靶细胞的百分比;y轴)。图17A和17B显示了与EoL1靶细胞共培养16小时、40小时、64小时、88小时或112小时的来自第一供体(图17A)和第二供体(图17B)的经转导的CART细胞的平均细胞溶解活性。图17C和17D显示了与NCI-H929靶细胞共培养16小时、40小时、64小时、88小时或112小时的来自第一供体(图17C)和第二供体(图17D)的经转导的CART细胞的平均细胞溶解活性。图17E和17F显示了与MM1S靶细胞共培养16小时、40小时、64小时、88小时或112小时的来自第一供体(图17E)和第二供体(图17F)的经转导的CART细胞的平均细胞溶解活性。
图18A和18B显示了在与CD3-CD28珠子(顶行)、EoL-1(第二行)、NCI-H929(第三行)或MM1S(底行)靶细胞系共培养6天后,来自第一健康供体(图18A)和第二健康供体(图18B)的CFSE标记的慢病毒转导的CAR T细胞的增殖。
图19A和图19B是显示本发明的嵌合抗原受体(CAR)的热稳定性的图。图19A:在磷酸缓冲盐(PBS)溶液中,包含具有截短铰链结构域(“THD”)的细胞外结构域的CAR相对于包含具有完整铰链结构域(“CHD”)的细胞外结构域的CAR,具有更高的解链温度。图19B:在存在50mM NaCl的情况下,包含具有THD的细胞外结构域的CAR相对于包含具有CHD的细胞外结构域的CAR,具有更高的解链温度。
发明详述
本发明涉及包含新的截短铰链结构域(“THD”)的新的多肽和编码其的多核苷酸。本发明的一些方面涉及编码包含本文所公开的THD的嵌合抗原受体(CAR)或T细胞受体(TCR)的多核苷酸。本发明也提供了包含此类多核苷酸的载体(例如病毒载体)和包含此类载体的组合物。本发明进一步提供了编码此类CAR或TCR的多核苷酸和包含此类多核苷酸的组合物。本发明另外提供了包含此类多核苷酸的和/或用此类病毒载体转导的工程化细胞(例如T细胞)以及包含此类工程化细胞的组合物。本发明提供了包括多个工程化T细胞的组合物(例如药物组合物)。本发明提供了用于制备此类工程化T细胞和组合物的方法以及此类工程化T细胞和组合物的用途(例如在治疗黑色素瘤中)。并且,本发明提供了诱导针对肿瘤的免疫力的方法,所述方法包含向受试者施用有效量的包含本发明的多核苷酸、载体或多肽的细胞。本发明的其他方面涉及包含CAR或TCR的细胞及其在T细胞疗法例如自体细胞疗法(eACTTM))中用于治疗患有癌症的患者的用途。
定义
为了更容易理解本发明,首先在下面定义某些术语。在整个说明书中阐述了对以下术语和其他术语的附加定义。
如在本说明书和所附权利要求中所使用的,单数形式“一个”、“一种”和“所述”包括复数指示物,除非上下文另有明确规定。
除非在上下文中明确说明或显而易见,否则如本文所用,术语“或”应当理解为包含性的并且涵盖“或”和“和”两者。
本文使用的术语“和/或”视为具有或不具有另一个的两个指定特征或组件中的每一个的具体公开。因此,如在短语例如“A和/或B”中所使用的术语“和/或”旨在包括A和B;A或B;A(单独);和B(单独)。同样地,如在短语例如“A、B和/或C”中所使用的术语“和/或”旨在涵盖以下方面的每一个:A、B和C;A、B或C;A或C;A或B;B或C;A和C;A和B;B和C;A(单独);B(单独);和C(单独)。
如本文所使用的术语“例如(e.g.)”和“即(i.e.)”仅作为实例使用,而没有意图限制,并且不应当诠释为仅涉及在说明书中明确列举的那些项目。
术语“或更多”、“至少”、“超过”等,例如“至少一个”应当理解为包括但不限于至少1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59、60、61、62、63、64、65、66、67、68、69、70、71、72、73、74、75、76、77、78、79、80、81、82、83、84、85、86、87、88、89、90、91、92、93、94、95、96、97、98、99、100、101、102、103、104、105、106、107、108、109、110、111、112、113、114、115、116、117、118、119、120、121、122、123、124、125、126、127、128、129、130、131、132、133、134、135、136、137、138、139、140、141、142、143、144、145、146、147、148、149或150、200、300、400、500、600、700、800、900、1000、2000、3000、4000、5000或超过所述值。还包括其间任何更大的数字或分数。
相反地,术语“不超过”包括小于所述值的每个值。例如,“不超过100个核苷酸”包括100、99、98、97、96、95、94、93、92、91、90、89、88、87、86、85、84、83、82、81、80、79、78、77、76、75、74、73、72、71、70、69、68、67、66、65、64、63、62、61、60、59、58、57、56、55、54、53、52、51、50、49、48、47、46、45、44、43、42、41、40、39、38、37、36、35、34、33、32、31、30、29、28、27、26、25、24、23、22、21、20、19、18、17、16、15、14、13、12、11、10、9、8、7、6、5、4、3、2、1和0个核苷酸。还包括其间任何更小的数字或分数。
术语“多个”、“至少两个”、“两个或更多个”、“至少第二个”等应当理解为包括但不限于至少2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59、60、61、62、63、64、65、66、67、68、69、70、71、72、73、74、75、76、77、78、79、80、81、82、83、84、85、86、87、88、89、90、91、92、93、94、95、96、97、98、99、100、101、102、103、104、105、106、107、108、109、110、111、112、113、114、115、116、117、118、119、120、121、122、123、124、125、126、127、128、129、130、131、132、133、134、135、136、137、138、139、140、141、142、143、144、145、146、147、148、149或150、200、300、400、500、600、700、800、900、1000、2000、3000、4000、5000或更多。还包括其间任何更大的数字或分数。
在整个说明书中,词语“包含(comprising)”或变形将理解为暗指包括所述要素、整数或步骤,或要素、整数或步骤的组,但不排除任何其他要素、整数或步骤,或要素、整数或步骤的组。应当理解的是,在本文中无论何处用语言“包含”描述方面,还提供了以“由......组成”和/或“基本上由......组成”描述的其他类似方面。
除非明确说明或从上下文中显而易见,如本文所用,术语“约”是指如本领域普通技术人员测定的特定值或组成的可接受误差范围内的值或组成,其将部分取决于如何测量或测定值或组成,即测量系统的局限性。例如,“约”或“基本上由.......组成”可以表示按本领域实践的1个内或超过1个标准偏差。“约”或“基本上由......组成”可以表示高达10%的范围(即±10%)。因此,“约”可以理解为在10%、9%、8%、7%、6%、5%、4%、3%、2%、1%、0.5%、0.1%、0.05%、0.01%或0.001%内大于或小于所述值。例如,约5mg可以包括4.5mg和5.5mg之间的任何量。此外,特别是关于生物系统或过程,该术语可以表示高达一个数量级或高达5倍的值。当在本公开中提供特定值或组成时,除非另有说明,否则应当假定“约”或“基本上由......组成”的含义在该特定值或组成的可接受的误差范围内。
如文本所述,除非另有说明,否则任何浓度范围、百分比范围、比率范围或整数范围应当理解为包括所叙述范围内的任何整数的值,并且在适当时包括其分数(例如整数的十分之一和百分之一)。
使用其国际单位制(SI)接受的形式提供本文所使用的单位、前缀和符号。数字范围包括定义范围的数字。
除非另外定义,否则本文所使用的所有技术和科学术语具有与本公开所涉及领域的普通技术人员通常理解的含义相同的含义。例如,Juo,“The Concise Dictionary ofBiomedicine and Molecular Biology”,2nd ed.,(2001),CRC Press;“The Dictionaryof Cell&Molecular Biology”,5th ed.,(2013),Academic Press;和“The OxfordDictionary Of Biochemistry And Molecular Biology”,Cammack et al.eds.,2nd ed,(2006),Oxford University Press为本领域技术人员提供了用于本公开中使用的许多术语的通用词典。
“施用”是指使用本领域技术人员已知的任何各种方法和递送系统将药剂物理导入受试者。本文公开的制剂的例示性施用途径包括静脉内、肌肉内、皮下、腹膜内、脊柱或其他肠胃外施用途径,例如通过注射或输液。本文所使用的短语“肠胃外施用”表示除肠内和局部施用外的施用方式,通常通过注射以及包括但不限于静脉内、肌肉内、动脉内、鞘内、淋巴管内、病灶内、囊内、眶内、心内、皮内、腹膜内、经气管、皮下、表皮下、关节内、囊下、蛛网膜下、脊柱内、硬膜外和胸骨内注射和输液,以及体内电穿孔。在一些实施方案中,经由非肠胃外途径例如口服施用制剂。其他非肠胃外途径包括局部、表皮或粘膜施用途径,例如鼻内、阴道、直肠、舌下或局部。也可以实施施用,例如,一次,多次,和/或在一个或多个长时期。
术语“抗体”(Ab)包括但不限于,特异性结合抗原的糖蛋白免疫球蛋白。通常,抗体可以包含通过二硫键相互连接的至少两条重(H)链和两条轻(L)链,或其抗原结合分子。每条H链包含重链可变区(本文缩写为VH)和重链恒定区。重链恒定区包含三个恒定结构域,CH1、CH2和CH3。每条轻链包含轻链可变区(本文缩写为VL)和轻链恒定区。轻链恒定区包含一个恒定结构域,CL。VH和VL区域可以进一步细分为高变的区域,称为互补决定区(CDR),散步着更保守的区域,称为框架区(FR)。每个VH和VL包含三个CDR和四个FR,以下列顺序从氨基末端到羧基末端排列:FR1、CDR1、FR2、CDR2、FR3、CDR3和FR4。重链和轻链的可变区含有与抗原相互作用的结合结构域。Ab的恒定区可以介导免疫球蛋白与宿主组织或因子的结合,包括免疫系统的各种细胞(例如效应细胞)和经典补体系统的第一组分(C1q)。
抗体可以包括例如,单克隆抗体、重组产生的抗体、单特异性抗体、多特异性抗体(包括双特异性抗体)、人抗体、工程化抗体、人源化抗体、嵌合抗体、免疫球蛋白、合成抗体、包含两个重链和两个轻链分子的四聚体抗体、抗体轻链单体、抗体重链单体、抗体轻链二聚体、抗体重链二聚体、抗体轻链-抗体重链对、胞内抗体、抗体融合物(本文有时称为“抗体缀合物”)、异缀合抗体、单结构域抗体、单价抗体、单链抗体或单链Fv(scFv)、骆驼源化抗体、亲和体、Fab片段、F(ab’)2片段、二硫键连接的Fv(sdFv)、抗独特型(抗Id)抗体(包括例如,抗-抗Id抗体)、微抗体、结构域抗体、合成抗体(本文有时称为“抗体模拟物”)和以上任何的抗原结合片段。在某些实施方案中,本文所述的抗体是指多克隆抗体群。
免疫球蛋白可以衍生自任何公知的同种型,包括但不限于IgA、分泌型IgA、IgG、IgE和IgM。IgG亚类也是本领域技术人员熟知的并且包括但不限于人IgG1、IgG2、IgG3和IgG4。“同种型”是指由重链恒定区基因编码的Ab类或亚类(例如,IgM或IgG1)。术语“抗体”包括,举例来说,天然存在的和非天然存在的Ab两者;单克隆和多克隆Ab;嵌合和人源化Ab;人或非人Ab;完全合成的Ab;和单链Ab。非人Ab可通过重组方法人源化以降低其在人体内的免疫原性。在没有明确说明的情况下,除非上下文另有说明,否则术语“抗体”还包括抗原结合片段或任何前述免疫球蛋白的抗原结合部分,并且包括单价和二价片段,以及单链Ab。
“抗原结合分子”、“抗原结合部分”或“抗体片段”是指包含从该分子所源于的抗体的抗原结合部分(例如,CDR)的任何分子。抗原结合分子可以包括抗原互补决定区(CDR)。抗体片段的实例包括但不限于,从抗原结合分子形成的Fab、Fab′、F(ab′)2和Fv片段、dAb、线性抗体、scFv抗体和多特异性抗体。肽体(即,包含肽结合结构域的Fc融合分子)是适合的抗原结合分子的另一个实例。在一些实施方案中,抗原结合分子结合肿瘤细胞上的抗原。在一些实施方案中,抗原结合分子结合参与过度增殖性疾病的细胞上的抗原或结合病毒或细菌抗原。在某些实施方案中,抗原结合分子结合BCMA、CLL-1或FLT3。在进一步的实施方案中,抗原结合分子是特异性结合抗原的抗体片段,包括其一个或多个的互补决定区(CDR)。在进一步的实施方案中,抗原结合分子是单链可变片段(scFv)。在一些实施方案中,抗原结合分子包含高亲和性多聚体(avimer)或由高亲和性多聚体组成。
如本文所用,术语“可变区”或“可变结构域”可互换使用,并且在本领域中常见。可变区通常是指抗体的一部分,通常是轻链或重链的一部分,通常是成熟重链中约氨基末端110至120个氨基酸和成熟轻链中约90至115个氨基酸,其在抗体之间的序列差别很大,并且用于特定抗体对其特定抗原的结合和特异性。序列的可变性集中在称为互补决定区(CDR)的那些区域中,而可变结构域中更高度保守的区域称为框架区(FR)。不希望受任何特定机制或理论的束缚,认为轻链和重链的CDR主要负责抗体与抗原的相互作用和特异性。在某些实施方案中,可变区为人可变区。在某些实施方案中,可变区包含啮齿动物或鼠CDR和人框架区(FR)。在特定实施方案中,可变区为灵长类动物(例如非人灵长类动物)可变区。在某些实施方案中,可变区包含啮齿动物或鼠CDR和灵长类动物(例如非人灵长类动物)框架区(FR)。
术语“VL”和“VL结构域”可互换使用以指抗体或其抗原结合分子的轻链可变区。
术语“VH”和“VH结构域”可互换使用以指抗体或其抗原结合分子的重链可变区。
通常使用CDR的许多定义:Kabat编号、Chothia编号、AbM编号或contact编号。AbM定义是Oxford Molecular的AbM抗体建模软件使用的两者之间的折衷。contact定义基于对可用复杂晶体结构的分析。
表1:CDR编号
术语“Kabat编号”和类似术语在本领域中是公认的,并且是指在抗体的重链和轻链可变区或其抗原结合分子中氨基酸残基的编号系统。在某些方面,抗体的CDR可以根据Kabat编号系统确定(参见例如Kabat EA&Wu TT(1971)Ann NY Acad Sci 190:382-391和Kabat EA et al.,(1991)Sequences of Proteins of Immunological Interest,FifthEdition,U.S.Department of Health and Human Services,NIH Publication No.91-3242)。使用Kabat编号系统,抗体重链分子内的CDR通常存在于氨基酸位置31至35(其在35之后任选地可以包括一个或两个额外的氨基酸(在Kabat编号方案中称为35A和35B))(CDR1)、氨基酸位置50至65(CDR2)和氨基酸位置95至102(CDR3)。使用Kabat编号系统,抗体轻链分子内的CDR通常存在于氨基酸位置24至34(CDR1)、氨基酸位置50至56(CDR2)和氨基酸位置89至97(CDR3)。在具体的实施方案中,本文所述抗体的CDR已根据Kabat编号方案确定。
在某些方面,抗体的CDR可以根据Chothia编号方案确定,其是指免疫球蛋白结构环的位置(参见例如Chothia C&Lesk AM,(1987),J Mol Biol 196:901-917;Al-LazikaniB et al.,(1997)J Mol Biol 273:927-948;Chothia C et al.,(1992)J Mol Biol 227:799-817;Tramontano A et al.,(1990)J Mol Biol 215(1):175-82;和美国专利号7,709,226)。通常,当使用Kabat编号惯例时,Chothia CDR-H1环存在于重链氨基酸26至32、33或34,Chothia CDR-H2环存在于重链氨基酸52至56,并且Chothia CDR-H3环存在于重链氨基酸95至102,而Chothia CDR-L1环存在于轻链氨基酸24至34,Chothia CDR-L2环存在于轻链氨基酸50至56,并且Chothia CDR-L3环存在于轻链氨基酸89至97。当使用Kabat编号惯例编号时,Chothia CDR-HI环的末端在H32和H34之间变化,取决于环的长度(这是因为Kabat编号方案将插入放置在H35A和H35B;如果35A和35B都不存在,则环结束于32;如果仅存在35A,则环结束于33;如果35A和35B两者都存在,则环结束于34)。在具体的实施方案中,本文所述抗体的CDR已根据Chothia编号方案确定。
如本文所用,术语“恒定区”和“恒定结构域”是可互换的并且具有本领域常见的含义。恒定区是抗体部分,例如轻链和/或重链的羧基末端部分,其不直接参与抗体与抗原的结合,但可以表现出各种效应器功能,例如与Fc受体的相互作用。免疫球蛋白分子的恒定区通常相对于免疫球蛋白可变结构域具有更保守的氨基酸序列。
如本文所用,当用于提及抗体时,术语“重链”基于恒定结构域的氨基酸序列可以指任何不同类型,例如alpha(α)、delta(δ)、epsilon(ε)、gamma(γ)和mu(μ),其分别产生IgA、IgD、IgE、IgG和IgM类抗体,包括IgG的亚类,例如IgG1、IgG2、IgG3和IgG4。
如本文所用,当用于提及抗体时,术语“轻链”基于恒定结构域的氨基酸序列可以指任何不同类型,例如kappa(κ)或lambda(λ)。轻链氨基酸序列是本领域中公知的。在具体的实施方案中,轻链为人轻链。
“结合亲和力”通常是指分子(例如抗体)的单一结合位点与其结合配偶体(例如抗原)之间的非共价相互作用的总和的强度。除非另有说明,如本文所用,“结合亲和力”是指内在结合亲和力,其反映结合对的成员(例如,抗体和抗原)之间的1∶1相互作用。分子X对其配偶体Y的亲和力通常可以由解离常数(KD)表示。亲和力可以以本领域已知的多种方式测量和/或表达,包括但不限于平衡解离常数(KD)和平衡缔合常数(KA)。KD由koff/kon的商计算,而KA由kon/koff的商计算。kon是指例如抗体与抗原的结合速率常数,而koff是指例如抗体与抗原的解离。kon和koff可以通过本领域普通技术人员已知的技术例如或KinExA测定。
如本文所用,“保守氨基酸取代”是指氨基酸残基被具有相似侧链的氨基酸残基取代的氨基酸取代。本领域已经定义了具有侧链的氨基酸残基家族。这些家族包括具有以下侧链的氨基酸:碱性侧链(例如赖氨酸、精氨酸、组氨酸),酸性侧链(例如天冬氨酸、谷氨酸),不带电荷的极性侧链(例如甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪氨酸、半胱氨酸、色氨酸),非极性侧链(例如丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸),beta分支侧链(例如苏氨酸、缬氨酸、异亮氨酸)和芳香族侧链(例如酪氨酸、苯丙氨酸、色氨酸、组氨酸)。在某些实施方案中,可以用具有相似侧链的氨基酸残基取代抗体或其抗原结合分子的CDR内或框架区内的一个或多个氨基酸残基。
如本文所用,术语“异源”表示来自除天然存在的序列之外的任何来源。例如,作为具有SEQ ID NO:1的氨基酸序列的共刺激蛋白质(例如相应的人共刺激蛋白质)的一部分所包括的异源序列是不作为野生型人共刺激蛋白质天然存在(即不与之对齐)的氨基酸。例如,异源核苷酸序列是指野生型人共刺激蛋白质编码序列以外的核苷酸序列。
如本文所用,术语“表位”是本领域的术语并且是指抗体可以特异性结合的抗原的局部区域。表位可以是例如多肽的连续氨基酸(线性或连续表位)或者表位可以例如来自多肽或多个多肽的两个或更多个非连续区域(构象、非线性、不连续的或非连续的表位)。在某些实施方案中,可以通过例如核磁共振波谱法(NMR波谱法)、X射线衍射晶体学研究、ELISA测定、氢/氘交换与质谱联用(例如液相色谱电喷雾质谱法)、基于阵列的寡肽扫描测定和/或诱变作图(例如定点诱变作图)测定抗体结合的表位。对于X射线晶体学,可以使用本领域任何已知方法完成结晶(例如,Giegé R et al.,(1994)Acta Crystallogr D BiolCrystallogr 50(Pt 4):339-350;McPherson A(1990)Eur J Biochem 189:1-23;ChayenNE(1997)Structure 5:1269-1274;McPherson A(1976)J Biol Chem 251:6300-6303)。抗体:抗原晶体可以使用公知的X射线衍射技术进行研究,并且可以使用计算机软件例如X-PLOR(Yale University,1992,由Molecular Simulations,Inc.行销;参见例如MethEnzymol(1985)volumes 114&115,eds Wyckoff HW et al.,;U.S.2004/0014194)和BUSTER(Bricogne G(1993)Acta Crystallogr D Biol Crystallogr 49(Pt 1):37-60;BricogneG(1997)Meth Enzymol 276A:361-423,ed Carter CW;Roversi P et al.,(2000)ActaCrystallogr D Biol Crystallogr 56(Pt 10):1316-1323)进行精制。可以使用本领域技术人员已知的任何方法完成诱变作图研究。关于诱变技术,包括丙氨酸扫描诱变技术的描述,参见例如Champe M et al.,(1995)J Biol Chem 270:1388-1394和Cunningham BC&Wells JA(1989)Science 244:1081-1085。
如本文所用,如果抗原与第一结合分子、抗体或其抗原结合分子之间的相互作用阻断、限制、抑制或以其他方式降低参考结合分子、参考抗体或其抗原结合分子与抗原相互作用的能力,则抗原结合分子、抗体或其抗原结合分子与参考抗体或其抗原结合分子“交叉竞争”。交叉竞争可以是完全的,例如结合分子与抗原的结合完全阻断了参考结合分子结合抗原的能力,或者其可以是部分的,例如结合分子与抗原的结合降低了参考结合分子结合抗原的能力。在某些实施方案中,与参考抗原结合分子交叉竞争的抗原结合分子结合与参考抗原结合分子相同或重叠的表位。许多类型的竞争性结合测定可以用于确定一种抗原结合分子是否与另一种竞争,例如:固相直接或间接放射免疫测定(RIA);固相直接或间接酶免疫测定(EIA);夹心法竞争分析(Stahli et al.,1983,Methods in Enzymology 9:242-253);固相直接生物素-抗生物素蛋白EIA(Kirkland et al.,1986,J.Immunol.137:3614-3619);固相直接标记分析、固相直接标记夹心法分析(Harlow and Lane,1988,Antibodies,A Laboratory Manual,Cold Spring Harbor Press);使用1-125标记的固相直接标记RIA(Morel et al.,1988,Molec.Immunol.25:7-15);固相直接生物素-抗生物素蛋白EIA(Cheung,et al.,1990,Virology176:546-552);以及直接标记RIA(Moldenhaueret al.,1990,Scand.J.Immunol.32:77-82)。
如本文所用,术语“免疫特异性结合”、“免疫特异性识别”、“特异性结合”和“特异性识别”在抗体的背景下是类似的术语并且是指结合抗原(例如表位或免疫复合物)的分子,因为本领域技术人员理解此类结合。例如,特异性结合抗原的分子可以与其他肽或多肽结合,通常具有较低的亲和力,如通过例如免疫测定、KinExA 3000仪器(Sapidyne Instruments,Boise,ID)或本领域已知的其他测定法测定的。在具体的实施方案中,特异性结合抗原的分子以比当该分子与另一个抗原结合时的KA大至少2个对数(log)、2.5个对数、3个对数、4个对数或更大的KA与抗原结合。
在另一个实施方案中,特异性结合抗原的分子以约1x 10-7M的解离常数(Kd)结合。在一些实施方案中,当Kd为约1x 10-9M至约5x 10-9M时,抗原结合分子以“高亲和力”特异性结合抗原。在一些实施方案中,当Kd为1x 10-10 M至约5x10-10 M时,抗原结合分子以“非常高的亲和力”特异性结合抗原。在一个实施方案中,抗原结合分子具有10-9M的Kd。在一个实施方案中,解离速率小于约1x 10-5。在其他实施方案中,抗原结合分子以约1x 10-7M至约1x10-13M之间的Kd与人BCMA结合。在又一个实施方案中,抗原结合分子以约1x 10-10M至约5x10-10M的Kd与人BCMA结合。
在具体的实施方案中,本文提供的是抗体或其抗原结合分子,该抗体或其抗原结合分子以比另一种靶抗原(例如非人BCMA或非人CLL-1)更高的亲和力与靶人抗原(例如人BCMA或人CLL-1)结合。在某些实施方案中,本文提供的是抗体或其抗原结合分子,该抗体或其抗原结合分子以比另一种靶抗原高5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%或更高的亲和力与靶人抗原(例如人BCMA或人CLL-1)结合,如通过例如放射免疫测定、表面等离激元共振或动力学排除测定法测量的。在具体的实施方案中,本文所述的与靶人抗原结合的抗体或其抗原结合分子将以少于10%、15%或20%的抗体或其抗原结合分子与人抗原的结合,与另一种靶抗原结合,如通过例如放射免疫测定、表面等离激元共振或动力学排除测定法测量的。
“抗原”是指引发免疫应答或能够被抗体或抗原结合分子结合的任何分子。免疫应答可以牵涉抗体产生或特异性免疫活性细胞的活化或这两者。本领域技术人员将容易理解任何大分子(包括几乎所有蛋白质或肽)均可以充当抗原。抗原可以内源性表达,即由基因组DNA表达或可以重组表达。抗原可以对某些组织,例如癌细胞是特异性的或者其可以广泛地表达。此外,较大分子的片段可以起抗原作用。在一个实施方案中,抗原为肿瘤抗原。在一个具体的实施方案中,抗原为BCMA、FLT3或CLL-1的全部或片段。
术语“中和”是指结合配体并防止或降低该配体的生物效应的抗原结合分子、scFv、抗体或其片段。在一些实施方案中,抗原结合分子、scFv、抗体或其片段直接阻断配体上的结合位点或者通过间接方式改变配体的结合能力(例如配体的结构或能量改变)。在一些实施方案中,抗原结合分子、scFv、抗体或其片段防止与其结合的蛋白质行使生物学功能。
如本文所用,术语“BCMA”指B细胞成熟抗原,其可以包括但不限于天然BCMA、BCMA的同种型或BCMA的种间BCMA同系物。BCMA(也称为TNFRSF17、CD269及TNFRSF13A)为肿瘤坏死因子(TNF)-受体超家族的成员。BCMA在多发性骨髓瘤细胞的表面上表达,然而在健康组织中则高度局限于浆细胞及成熟B细胞的亚类。人BCMA(hBCMA)的氨基酸序列提供于NCBI登录号Q02223.2(GI:313104029)中。如本文所用,BCMA包括人BCMA和非人BCMA同系物,及其变体、片段或翻译后经修饰的形式,包括但不限于BCMA的N-及O-连接的糖基化形式。BCMA蛋白可以进一步包括包含BCMA的细胞外结构域的全部或一部分(例如hBCMA的氨基酸1-54的全部或一部分)的片段。
如本文所用,术语“CLL-1”是指C型凝集素样分子1,其可以包括但不限于天然CLL-1、CLL-1的同种型或CLL-1的种间CLL-1同系物。CLL-1(也称为C型凝集素结构域家族12成员A、CLEC12A、树突状细胞相关凝集素2、DCAL-2、髓样抑制性C型凝集素样受体和MICL)是调节信号级联反应并介导靶MAP激酶的酪氨酸磷酸化的细胞表面受体。例如在急性髓样白血病(AML)细胞中观察到CLL-1表达。人CLL-1(hCLL-1)的氨基酸序列提供于UniProtKB/Swiss-Prot登录号Q5QGZ9.3(GI:308153619)。如本文所用,CLL-1包括人CLL-1和非人CLL-1同系物,及其变体、片段或翻译后经修饰的形式,包括但不限于CLL-1的N-及O-连接的糖基化形式。
如本文所用,术语“FLT3”是指Fms样酪氨酸激酶3(FLT-3),其可以包括但不限于天然FLT3、FLT3的同种型或FLT3的种间FLT3同系物。FLT3(也称为分化抗原群135(CD135)、受体型酪氨酸蛋白激酶FLT3、FMS相关酪氨酸激酶3、干细胞酪氨酸激酶1、FL细胞因子受体、生长因子受体酪氨酸激酶III型、STK1或胎肝激酶2(Flk2))是属于受体酪氨酸激酶III类的细胞因子受体。CD135是细胞因子Flt3配体(FLT3L)的受体。FLT3在各种造血祖细胞的表面上和急性髓样白血病(AML)细胞的表面上表达。人FLT3(hFLT3)的氨基酸序列提供于UniProtKB/Swiss-Prot登录号P36888(GI:156630887)。如本文所用,FLT3包括人FLT3和非人FLT3同系物,及其变体、片段或翻译后经修饰的形式,包括但不限于FLT3的N-及O-连接的糖基化形式。
术语“自体”是指源自其稍后重新导入到其中的同一个体的任何物质。例如,本文所述的工程化自体细胞疗法(eACTTM)的方法牵涉从患者收集淋巴细胞,然后将其工程化改造以表达例如CAR构建体,然后再施用回同一患者。
术语“同种异体”是指源自一个个体然后被导入相同物种的另一个个体的任何物质,例如同种异体T细胞移植。
术语“转导”和“经转导的”是指一种过程,通过该过程将外源DNA经由病毒载体导入到细胞中(参见Jones et al.、“Genetics:principles and analysis,”Boston:Jones&Bartlett Publ.(1998))。在一些实施方案中,载体为逆转录病毒载体、DNA载体、RNA载体、腺病毒载体、杆状病毒载体、EB病毒载体、乳多空病毒载体、牛痘病毒载体、单纯疱疹病毒载体、腺病毒相关载体、慢病毒载体或它们的任何组合。
如本文所用,术语“截短的”是指少于整体的任何事物。例如,截短铰链结构域(或者在本文中称为“THD”)氨基酸序列可以包括比全长或完整铰链结构域(“CHD”)短的任何氨基酸序列。在一些实施方案中,THD基本上由以下组成或者由以下组成:SEQ ID NO:1的氨基酸118-152、119-152、120-152、121-152、122-152、123-152、124-152、125-152、126-152、127-152、128-1 52、129-152或130-152。在一个实施方案中,THD基本上由SEQ ID NO:3组成或者由SEQ ID NO:3组成,其由SEQ ID NO:1的氨基酸123至152组成。
“癌症”是指一大组各种疾病,其特征为异常细胞在体内不受控制的生长。不受调节的细胞分裂和生长导致形成入侵相邻组织且也可以通过淋巴系统或血流转移到身体远程部分的恶性肿瘤。“癌症”或“癌症组织”可以包括肿瘤。可以通过本发明的方法治疗的癌症的实例包括但不限于免疫系统的癌症,包括淋巴瘤、白血病、骨髓瘤及其他白细胞恶性肿瘤。在一些实施方案中,本发明的方法可以用于缩小例如源自下组的肿瘤的肿瘤大小:骨癌、胰腺癌、皮肤癌、头或颈癌、皮肤或眼内恶性黑色素瘤、子宫癌、卵巢癌、直肠癌、肛门区癌、胃癌、睾丸癌、子宫癌、输卵管癌、子宫内膜癌、子宫颈癌、阴道癌、外阴癌、多发性骨髓瘤、霍奇金病、非霍奇金淋巴瘤(NHL)、原发性纵隔大B细胞淋巴瘤(PMBC)、弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤(FL)、转化滤泡性淋巴瘤、脾边缘区淋巴瘤(SMZL)、食道癌、小肠癌、内分泌系统癌症、甲状腺癌、甲状旁腺癌、肾上腺癌、软组织肉瘤、尿道癌、阴茎癌、慢性或急性白血病、急性髓样白血病、慢性髓样白血病、急性淋巴母细胞白血病(ALL)(包括非T细胞ALL)、慢性淋巴细胞白血病(CLL)、儿童实体瘤、淋巴细胞性淋巴瘤、膀胱癌、肾或输尿管癌、肾盂癌、中枢神经系统(CNS)肿瘤、原发性CNS淋巴瘤、肿瘤血管生成、脊柱轴肿瘤、脑干神经胶质瘤、垂体腺瘤、卡波西氏肉瘤、表皮样癌、鳞状细胞癌、T细胞淋巴瘤、由环境诱发的癌症(包括由石棉诱发的那些)、其他B细胞恶性肿瘤以及所述癌症的组合。在一个具体的实施方案中,癌症为多发性骨髓瘤。特定癌症可以对化学疗法或放射疗法有响应或者癌症可以是难治性的。难治性癌症是指不易于通过外科手术干预的癌症,并且癌症或是最初对化学疗法或放射疗法无响应,或是癌症随时间变成无响应。
如本文所用,“抗肿瘤效应”是指可以呈现为肿瘤体积缩小、肿瘤细胞数目减少、肿瘤细胞增殖减少、转移的数目减少、总体或无进展存活期增加、期望寿命增加或各种与肿瘤相关的生理症状改善的生物效应。抗肿瘤效应也可以指肿瘤发生的预防,例如疫苗。
如本文所用,“细胞因子”是指响应与特定抗原的接触由一种细胞释放的非抗体蛋白质,其中细胞因子与第二细胞相互作用以介导在第二细胞中的应答。细胞因子可以由细胞内源性表达或对受试者施用。细胞因子可以由免疫细胞(包括巨噬细胞、B强胞、T细胞和肥大细胞)释放以传播免疫应答。细胞因子可以诱导受体细胞中的各种应答。细胞因子可以包括稳态细胞因子、趋化因子、促炎细胞因子、效应器和急性期蛋白质。例如,稳态细胞因子(包括白细胞介素(IL)7和IL-15)促进免疫细胞存活和增殖,而促炎细胞因子可以促进炎症应答。稳态细胞因子的实例包括但不限于IL-2、IL-4、IL-5、IL-7、IL-10、IL-12p40、IL-12p70、IL-15及干扰素(IFN)gamma。促炎细胞因子的实例包括但不限于IL-1a、IL-1b、IL-6、IL-13、IL-17a、肿瘤坏死因子(TNF)-alpha、TNF-beta、成纤维细胞生长因子(FGF)2、粒细胞巨噬细胞集落刺激因子(GM-CSF)、可溶性细胞间黏附分子1(sICAM-1)、可溶性血管黏附分子1(sVCAM-1)、血管内皮生长因子(VEGF)、VEGF-C、VEGF-D以及胎盘生长因子(PLGF)。效应器的实例包括但不限于颗粒酶A、颗粒酶B、可溶性Fas配体(sFasL)以及穿孔蛋白(perforin)。急性期蛋白质的实例包括但不限于C反应蛋白(CRP)及血清淀粉样蛋白A(SAA)。
“趋化因子”是介导细胞趋化作用或定向运动的一类细胞因子。趋化因子的实例包括但不限于IL-8、IL-16、嗜酸性粒细胞趋化因子、嗜酸性粒细胞趋化因子-3、巨噬细胞衍生的趋化因子(MDC或CCL22)、单核细胞趋化蛋白1(MCP-1或CCL2)、MCP-4、巨噬细胞炎症蛋白1α(MIP-1α、MIP-1a)、MIP-1β(MIP-1b)、gamma-诱导蛋白10(IP-10)以及胸腺和活化调节的趋化因子(TARC或CCL17)。
治疗剂(例如工程化CART细胞)的“治疗有效量”、“有效剂量”、“有效量”或“治疗有效剂量”是当单独使用或与另一治疗剂组合使用时保护受试者免于疾病发作或者促进疾病消退的任何量,所述疾病消退的证据为疾病症状的严重性降低、疾病无症状期的频率和持续期间增加或防止由于疾病折磨导致的损伤或残疾。可以使用熟练从业人员已知的各种方法评估治疗剂促进疾病消退的能力,例如在临床试验期间在人受试者中评估、在用于预测在人体中的效力的动物模型系统中评估或通过在体外分析中测定试剂的活性评估。
如本文所用,术语“淋巴细胞”包括自然杀伤(NK)细胞、T细胞或B细胞。NK细胞是代表固有免疫系统的主要组分的一类细胞毒性(cytotoxic)(细胞毒性(cell toxic))淋巴细胞。NK细胞排斥肿瘤以及病毒感染的细胞。其通过细胞凋亡或程序性细胞死亡的过程发挥作用。由于其不需要活化来杀死细胞,因而称为“自然杀伤”。T细胞在细胞介导的免疫(无抗体参与)中发挥主要作用。它的T细胞受体(TCR)将自身与其他淋巴细胞类型区分开来。胸腺(免疫系统的专门器官)主要负责T细胞的成熟。有六种类型的T细胞,即:辅助性T细胞(例如CD4+细胞)、细胞毒性T细胞(也称为TC、细胞毒性T淋巴细胞、CTL、T杀伤细胞、溶细胞性T细胞、CD8+T细胞或杀伤T细胞)、记忆T细胞((i)干细胞样记忆TSCM细胞(如初始细胞)为CD45RO-、CCR7+、CD45RA+、CD62L+(L选择素)、CD27+、CD28+以及IL-7Rα+,但它们也表达大量的CD95、IL-2Rβ、CXCR3以及LFA-1,并且显示许多记忆细胞独特的功能属性;(ii)中央记忆TCM细胞表达L-选择素和CCR7,它们分泌IL-2,但不分泌IFNγ或IL-4,以及(iii)效应记忆TEM细胞,然而,不表达L-选择蛋白或CCR7,但产生效应细胞因子,如IFNγ和IL-4)、调节性T细胞(Treg、抑制性T细胞或CD4+CD25+调节性T细胞)、自然杀伤T细胞(NKT)以及GammaDeltaT细胞。另一方面,B细胞在体液免疫中发挥主要作用(有抗体参与)。其生成抗体和抗原并执行抗原呈递细胞(APC)的作用,并且在通过抗原相互作用的活化后转变成记忆B细胞。在哺乳动物中,未成熟的B细胞在骨髓中形成,该处为B细胞名字的来源。
术语“经基因工程化改造的”或“经工程化改造的”是指修饰细胞的基因组的方法,包括但不限于删除编码或非编码区或其部分,或插入编码区或其部分。在一些实施方案中,经修饰的细胞为淋巴细胞(例如T细胞),其可以从患者或供体取得。细胞可以经修饰以表达外源构建体,例如掺入到细胞的基因组中的嵌合抗原受体(CAR)或T细胞受体(TCR)。
“免疫应答”是指免疫系统的细胞(例如T淋巴细胞、B淋巴细胞、自然杀伤(NK)细胞、巨噬细胞、嗜酸性粒细胞、肥大细胞、树突状细胞以及中性粒细胞)和由这些细胞中的任一种或肝脏产生的可溶性大分子(包括Ab、细胞因子和补体)的作用,该作用导致选择性靶向、结合、损害、破坏和/或排除脊椎动物体内的入侵病原体、被病原体感染的细胞或组织、癌细胞或其他异常细胞,或者在自身免疫或病理性炎症的情况下,正常的人细胞或组织。
术语“免疫疗法”是指患有疾病或处于感染疾病或疾病复发的风险的受试者的治疗,该治疗通过包含诱导、增强、抑制或以其他方式修饰免疫应答的方法进行。免疫疗法的实例包括但不限于T细胞疗法。T细胞疗法可以包括过继性T细胞疗法、肿瘤浸润淋巴细胞(TIL)免疫疗法、自体细胞疗法、工程化自体细胞疗法(eACTTM)以及同种异体T细胞移植。然而,本领域技术人员将认为本文所公开的调理方法将增强任何移植的T细胞疗法的有效性。T细胞疗法的实例描述于美国专利公开号2014/0154228和2002/0006409、美国专利号5,728,388以及国际公开号WO 2008/081035中。
免疫疗法的T细胞可以来自本领域已知的任何来源。例如,T细胞可以在体外从造血干细胞群分化,或者可以从受试者获得T细胞。T细胞可以从例如外周血单核细胞(PBMC)、骨髓、淋巴结组织、脐带血、胸腺组织、来自感染部位的组织、腹水、胸腔积液、脾组织以及肿瘤获得。此外,T细胞可以源自本领域中可获得的一个或多个T细胞系。T细胞也可以使用本领域技术人员已知的任何数目的技术(例如FICOLLTM分离和/或单采术(apheresis))从受试者收集的血液单位取得。分离用于T细胞疗法的T细胞的另外的方法公开于美国专利公开号2013/0287748,其通过引用整体并入本文。
术语“工程化自体细胞疗法”(其可缩写为“eACTTM”,也称为过继细胞转移)是收集患者自身的T细胞,随后将其经遗传改变以识别并靶向一种或多种在一种或多种特定的肿瘤细胞或恶性肿瘤的细胞表面上表达的抗原的过程。T细胞可以经工程化改造以表达例如嵌合抗原受体(CAR)或T细胞受体(TCR)。CAR阳性(+)T细胞经工程化改造以表达对特定肿瘤抗原具有特异性的细胞外单链可变片段(scFv),其连接到包含至少一个共刺激结构域和至少一个活化结构域的细胞内信号传导部分。共刺激结构域可以源自天然存在的共刺激结构域,例如具有SEQ ID NO:1的氨基酸序列或其变体(例如具有截短铰链结构域(“THD”)的变体)的,而活化结构域可以源自例如CD3-zeta。在某些实施方案中,CAR设计成具有两个、三个、四个或更多个共刺激结构域。CAR scFv可以设计成靶向例如CD19,该CD19是由B细胞谱系(包括所有正常B细胞和B细胞恶性肿瘤,包括但不限于NHL、CLL和非T细胞ALL)的细胞表达的跨膜蛋白。在一些实施方案中,CAR经工程化改造从而使共刺激结构域以单独的多肽链形式表达。实例CART细胞疗法和构建体描述于美国专利公开号2013/0287748、2014/0227237、2014/0099309以及2014/0050708中,这些参考文献通过引用整体并入本文。
如本文所用,“患者”包括任何患有癌症(例如淋巴瘤或白血病)的人。本文中,术语“受试者”和“患者”可互换使用。
如本文所用,术语“体外细胞”是指在体外培养的任何细胞。特别地,体外细胞可以包括T细胞。
术语“肽”、“多肽”和“蛋白质”可互换使用并且是指通过肽键共价连接的由氨基酸残基组成的化合物。蛋白质或肽含有至少两个氨基酸并且可以包含蛋白质或肽的序列的氨基酸的最大数量没有限制。多肽包括任何包含两个或更多个通过肽键彼此连接的氨基酸的肽或蛋白质。如本文所用,该术语是指短链(其在本领域中也通常称为例如肽、寡肽和寡聚体)和较长的链(其在本领域中通常称为蛋白质,其具有许多类型)两者。“多肽”包括例如生物活性片段、基本上同源的多肽、寡肽、同源二聚体、异源二聚体、多肽的变体、经修饰的多肽、衍生物、类似物、融合蛋白等。多肽包括天然的肽、重组的肽、合成的肽或它们的组合。
如本文所用,“刺激”是指由刺激分子与其关联配体的结合所诱发的初级应答,其中结合介导信号转导事件。“刺激分子”是指T细胞上的分子,例如与存在于抗原呈递细胞上的关联刺激配体特异性结合的T细胞受体(TCR)/CD3复合物。“刺激配体”是指当存在于抗原呈递细胞(例如APC、树突状细胞、B细胞等)上时可以与T细胞上的刺激分子特异性结合,从而介导T细胞的初级应答(包括但不限于活化、启动免疫应答、增殖等)的配体。刺激配体包括但不限于抗CD3抗体(例如OKT3)、装载有肽的MHC I类分子、超激动性抗CD2抗体以及超激动性抗CD28抗体。
如本文所用,“共刺激信号”是指与初级信号(例如TCR/CD3连接)组合时导致T细胞应答(例如但不限于增殖和/或关键分子的上调或下调)的信号。
如本文所用,“共刺激配体”包括与T细胞上的关联共刺激分子特异性结合的抗原呈递细胞上的分子。共刺激配体的结合提供介导T细胞应答(包括但不限于增殖、活化、分化等)的信号。共刺激配体诱导除了由刺激分子提供的初级信号(例如由T细胞受体(TCR)/CD3复合物与装载有肽的主要组织相容性复合体(MHC)分子的结合提供)外的信号。共刺激配体可以包括但不限于,3/TR6、4-1BB配体、结合Toll配体受体的激动剂或抗体、B7-1(CD80)、B7-2(CD86)、CD30配体、CD40、CD7、CD70、CD83、疱疹病毒侵入介质(HVEM),人白细胞抗原G(HLA-G)、ILT4、免疫球蛋白样转录物(ILT)3、诱导性共刺激配体(ICOS-L)、细胞内黏附分子(ICAM)、特异性结合B7-H3的配体、淋巴毒素beta受体、MHC I类链相关蛋白A(MICA)、MHC I类链相关蛋白B(MICB)、OX40配体、PD-L2或程序性死亡(PD)Ll。共刺激配体包括但不限于,与存在于T细胞上的共刺激分子特异性结合的抗体,该存在于T细胞上的共刺激分子例如但不限于4-1BB、B7-H3、CD2、CD27、CD28、CD30、CD40、CD7、ICOS、与CD83特异性结合的配体、淋巴细胞功能相关抗原-1(LFA-1)、自然杀伤细胞受体C(NKG2C)、OX40、PD-1或肿瘤坏死因子超家族成员14(TNFSF14或LIGHT)。
“共刺激分子”是在T细胞上特异性结合共刺激配体,从而介导T细胞的共刺激反应(例如但不限于增殖)的关联结合配偶体。共刺激分子包括但不限于4-1BB/CD137、B7-H3、BAFFR、BLAME(SLAMF8)、BTLA、CD33、CD 45、CD100(SEMA4D)、CD103、CD134、CD137、CD154、CD16、CD160(BY55)、CD18、CD19、CD19a、CD2、CD22、CD247、CD27、CD276(B7-H3)、CD28、CD29、CD3(alpha;beta;delta;epsilon;gamma;zeta)、CD30、CD37、CD4、CD4、CD40、CD49a、CD49D、CD49f、CD5、CD64、CD69、CD7、CD80、CD83配体、CD84、CD86、CD8alpha、CD8beta、CD9、CD96(Tactile)、CDl-la、CDl-lb、CDl-lc、CDl-ld、CDS、CEACAM1、CRT AM、DAP-10、DNAM1(CD226)、Fc gamma受体、GADS、GITR、HVEM(LIGHTR)、IA4、ICAM-1、ICAM-1、ICOS、Ig alpha(CD79a)、IL2R beta、IL2R gamma、IL7R alpha、整合素、ITGA4、ITGA4、ITGA6、ITGAD、ITGAE、ITGAL、ITGAM、ITGAX、ITGB2、ITGB7、ITGBl、KIRDS2、LAT、LFA-1、LFA-1、LIGHT、LIGHT(肿瘤坏死因子超家族成员14;TNFSF14)、LTBR、Ly9(CD229)、淋巴细胞功能相关抗原-1(LFA-1(CDl la/CD18)、MHC I类分子、NKG2C、NKG2D、NKp30、NKp44、NKp46、NKp80(KLRF1)、OX40、PAG/Cbp、PD-1、PSGL1、SELPLG(CD162)、信号传导淋巴细胞活化分子,SLAM(SLAMF1;CD150;IPO-3)、SLAMF4(CD244;2B4)、SLAMF6(NTB-A;Ly108)、SLAMF7、SLP-76、TNF、TNFr、TNFR2、Toll配体受体、TRANCE/RANKL、VLA1或VLA-6,或它们的片段、截短或组合。
本文中,术语“减少”和“降低”可互换使用并且表示小于原来的任何变化。“减少”和“降低”是相对的术语,需要在测量前和测量后间进行比较。“减少”和“降低”包括完全耗竭。
受试者的“治疗”或“处理”是指在受试者上进行任何类型的干预或过程,或对该受试者施用活性剂以达到逆转、减轻、改善、抑制、减缓或预防症状、并发症或病症或与疾病相关的生化指标的发作、进展、发展、严重或复发的目的。在一个实施方案中,“治疗”或“处理”包括部分缓解。在另一个实施方案中,“治疗”或“处理”包括完全缓解。
为了计算同一性百分比,相比较的序列通常以能使该序列间产生最大匹配的方式比对。可以用于测定同一性百分比的计算机程序的一个实例为GCG程序包,其包括GAP(Devereux et al.,1984,Nucl.Acid Res.12:387;Genetics Computer Group,Universityof Wisconsin,Madison,Wis.)。计算机算法GAP用于比对要测定的序列同一性百分比的两个多肽或多核苷酸。比对序列以使其各自的氨基酸或核苷酸最佳匹配(如通过算法测定的“匹配跨距(matched span)”)。在某些实施方案中,算法也使用标准比较矩阵(参见Dayhoffet al.,1978,Atlas of Protein Sequence and Structure 5:345-352,用于PAM250比较矩阵;Henikoff et al.,1992,Proc.Natl.Acad.Sci.U.S.A.89:10915-10919,用于BLOSUM 62比较矩阵)。
本发明的各种方面进一步详细描述于下列小节中。
I.嵌合抗原受体和T细胞受体
嵌合抗原受体(CAR或CAR-T)和T细胞受体(TCR)是经基因工程化改造的受体。这些工程化受体可以根据本领域已知的技术容易地插入到并且被免疫细胞(包括T细胞)表达。使用CAR,可以设定单一受体以识别特定抗原,并且当与该抗原结合时,活化免疫细胞以攻击并破坏携带该抗原的细胞。当这些抗原存在于肿瘤细胞上,表达CAR的免疫细胞可以靶向并杀死肿瘤细胞。
本发明的一个方面涉及编码包含共刺激结构域的嵌合抗原受体(CAR)或T细胞受体(TCR)的多核苷酸,该共刺激结构域包含含有截短铰链结构域(“THD”)的新的细胞外结构域,以及包含共刺激结构域的工程化T细胞,该共刺激结构域包含新的THD。共刺激结构域可以进一步包含跨膜结构域和/或细胞内结构域。在一些实施方案中,由本发明的多核苷酸编码的CAR或TCR进一步包含与靶抗原特异性结合的抗原结合分子。在一些实施方案中,由该多核苷酸编码的CAR或TCR进一步包含活化结构域。在一个具体的实施方案中,由该多核苷酸编码的CAR或TCR包含(i)与靶抗原特异性结合的抗原结合分子,(ii)包含细胞外结构域、跨膜结构域和细胞内结构域的共刺激结构域,以及(iii)活化结构域,其中细胞外结构域包含本文所述的THD(例如SEQ ID NO:3)、基本上由本文所述的THD(例如SEQ ID NO:3)组成或由本文所述的THD(例如SEQ ID NO:3)组成。
在一些实施方案中,根据本发明的CAR的定向包含与共刺激结构域和活化结构域串联的抗原结合结构域(例如scFv)。共刺激结构域可以包含一个或多个细胞外部分、跨膜部分和细胞内部分。在其他实施方案中,多个共刺激结构域可以串联利用。
I.A.共刺激结构域
嵌合抗原受体整合共刺激(信号传导)结构域以提高其效力。参见美国专利号7,741,465和6,319,494,以及Krause et al.and Finney et al.(supra),Song et al.,Blood 119:696-706(2012);Kalos et al.,Sci Transl.Med.3:95(2011);Porter et al.,N.Engl.J.Med.365:725-33(2011),和Gross et al.,Annu.Rev.Pharmacol.Toxicol.56:59-83(2016)。具有SEQ ID NO:1的氨基酸序列的共刺激蛋白质是在T细胞上天然存在的共刺激蛋白质。该共刺激蛋白质的完整天然氨基酸序列描述于NCBI参考序列:NP_006130.1。参见图1A。该共刺激蛋白质的完整天然核酸序列描述于NCBI参考序列:NM_006139.1。
新的细胞外结构域:本公开显示共刺激蛋白质的包含截短铰链结构域(“THD”)的新的细胞外结构域可以改善CAR或TCR的一个或多个性质。在一些实施方案中,THD结构域是完整铰链结构域(“CHD”)的截短版本。在某些实施方案中,编码THD的分离的多核苷酸包含(i)与SEQ ID NO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列,其中THD结构域不含有SEQ ID NO:1的氨基酸1至122。
在其他实施方案中,THD基本上由以下组成或者由以下组成:与SEQ ID NO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。在其他实施方案中,THD基本上由以下核苷酸序列编码的氨基酸序列组成,或者由以下核苷酸序列编码的氨基酸序列组成:与SEQ ID NO:3至少约60%,至少约70%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
在一些实施方案中,编码THD的分离的多核苷酸基本上由以下各项组成或者由以下各项组成:(i)与SEQ ID NO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列,和(ii)任选地±一个氨基酸、±两个氨基酸、±三个氨基酸、±四个氨基酸、±五个氨基酸或±六个氨基酸。在一些实施方案中,编码THD的分离的多核苷酸基本上由以下各项组成或者由以下各项组成:(i)与SEQ ID NO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列,和(ii)任选地一或两个氨基酸、一至三个氨基酸、一至四个氨基酸、一至五个氨基酸或一至六个氨基酸。可以从THD中的氨基酸序列添加或缺失的一至六个氨基酸可以在N-末端处、C-末端处或N-末端和C-末端两者。
在一些实施方案中,编码THD的分离的多核苷酸基本上由以下各项组成或者由以下各项组成:(i)与SEQ ID NO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列,和(ii)另外一个N-末端氨基酸,另外两个N-末端氨基酸,另外三个N-末端氨基酸,另外四个N-末端氨基酸,另外五个N-末端氨基酸或另外六个N-末端氨基酸。
在一些实施方案中,另外的氨基酸可以是N-末端氨基酸。在一些实施方案中,另外的氨基酸可以是异源的。在其他实施方案中,另外的氨基酸是天然存在的共刺激蛋白质序列的一部分。
在一些实施方案中,THD基本上由以下组成或者由以下组成:与SEQ ID NO:1的氨基酸123至152、SEQ ID NO:1的氨基酸122至152、SEQ ID NO:1的氨基酸121至152、SEQ IDNO:1的氨基酸120至152、SEQ ID NO:1的氨基酸119至152、SEQ ID NO:1的氨基酸118至152或SEQ ID NO:1的氨基酸117至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在其他实施方案中,THD基本上由以下组成或者由以下组成:与SEQ ID NO:1的氨基酸124至152、SEQ ID NO:1的氨基酸125至152、SEQ ID NO:1的氨基酸126至152、SEQ IDNO:1的氨基酸127至152、SEQ ID NO:1的氨基酸128至152、SEQ ID NO:1的氨基酸129至152或SEQ ID NO:1的氨基酸130至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-116。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-117。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-118。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-119。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-120。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-121。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-122。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-123。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-124。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-125。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-126。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-127。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-128。在一些实施方案中,THD不包含SEQ ID NO:1的氨基酸1-129。
THD的相应氨基酸序列如SEQ ID NO.3LDNEKSNGTI IHVKGKHLCP SPLFPGPSKP中所示。编码THD的细胞外部分的核苷酸序列如 中所示。
在某些实施方案中,编码CAR或TCR中的共刺激结构域的多核苷酸包含与SEQ IDNO:3至少约60%,至少约70%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列,其中该核苷酸序列编码THD并且其中该CAR或TCR不包含SEQ ID NO:1的氨基酸1-122。
在一个具体的实施方案中,THD基本上由以下组成或者由以下组成:与SEQ ID NO:3的氨基酸序列至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。在具体的实施方案中,编码THD的多核苷酸基本上由以下组成或者由以下组成:与SEQ ID NO:2的核苷酸序列至少约60%,至少约65%,至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
在一些实施方案中,THD进一步包含免疫球蛋白家族的成员(例如IgG1、IgG2、IgG3、IgG4、IgA、IgD、IgE、IgM或它们的片段)的一些或全部。
在一些实施方案中,THD衍生自人完整铰链结构域(“CHD”),例如衍生自具有SEQID NO:1的氨基酸序列的共刺激蛋白质。在其他实施方案中,THD衍生自啮齿动物、鼠或灵长类动物(例如非人灵长类动物)的共刺激蛋白质的CHD。在一些实施方案中,THD衍生自嵌合共刺激蛋白质的CHD。
跨膜结构域:用于本发明的CAR或TCR的共刺激结构域可以进一步包含跨膜结构域和/或细胞内信号传导结构域。该跨膜结构域可以设计成与CAR的细胞外结构域融合。类似地,其可以与CAR的细胞内结构域融合。在一个实施方案中,使用天然与CAR中的结构域之一相关的跨膜结构域。在一些情况下,跨膜结构域可以经过选择或通过氨基酸取代进行修饰以避免此类结构域与相同或不同的表面膜蛋白的跨膜结构域结合以使其与受体复合物的其他成员的相互作用最小化。跨膜结构域可以源自天然来源或来自合成来源。当来源为天然来源时,结构域可以源自任何膜结合蛋白或跨膜蛋白。本发明中特定用途的跨膜区可以衍生自(即包含)4-1BB/CD137、活化性NK细胞受体、免疫球蛋白蛋白质、B7-H3、BAFFR、BLAME(SLAMF8)、BTLA、CD100(SEMA4D)、CD103、CD160(BY55)、CD18、CD19、CD19a、CD2、CD247、CD27、CD276(B7-H3)、CD28、CD29、CD3delta、CD3epsilon、CD3gamma、CD30、CD4、CD40、CD49a、CD49D、CD49f、CD69、CD7、CD84、CD8alpha、CD8beta、CD96(Tactile)、CD1 1a、CD1 1b、CD11c、CD1 1d、CDS、CEACAM1、CRT AM、细胞因子受体、DAP-10、DNAM1(CD226)、Fc gamma受体、GADS、GITR、HVEM(LIGHTR)、IA4、ICAM-1、ICAM-1、Ig alpha(CD79a)、IL-2R beta、IL-2Rgamma、IL-7R alpha、诱导性T细胞共刺激分子(ICOS)、整合素、ITGA4、ITGA4、ITGA6、ITGAD、ITGAE、ITGAL、ITGAM、ITGAX、ITGB2、ITGB7、ITGB1、KIRDS2、LAT、LFA-1、LFA-1、与CD83特异性结合的配体、LIGHT、LIGHT、LTBR、Ly9(CD229)、淋巴细胞功能相关抗原-1(LFA-1;CDl-la/CD18)、MHC class 1molecule、NKG2C、NKG2D、NKp30、NKp44、NKp46、NKp80(KLRF1)、OX-40、PAG/Cbp、程序性死亡-1(PD-1)、PSGL1、SELPLG(CD162)、信号传导淋巴细胞活化分子(SLAM蛋白)、SLAM(SLAMF1;CD150;IPO-3)、SLAMF4(CD244;2B4)、SLAMF6(NTB-A;Lyl08)、SLAMF7、SLP-76、TNF受体蛋白、TNFR2、TNFSF14、Toll配体受体、TRANCE/RANKL、VLA1或VLA-6,或它们的片段、截短或组合。
任选地,短接头可以形成任何或一些CAR的细胞外、跨膜和细胞内结构域之间的连接。
在一个具体的实施方案中,共刺激蛋白质的跨膜结构域的核苷酸序列如 中所示。
在一个实施方案中,编码共刺激结构域内的跨膜结构域的多核苷酸包含与SEQ IDNO:4的核苷酸序列至少约60%,至少约65%,至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
共刺激蛋白质的跨膜结构域的氨基酸序列如SEQ ID NO.5:FWVLVVVGGVLACYSLLVTV AFIIFWV中所示。
在一个具体的实施方案中,共刺激结构域内的跨膜结构域包含与SEQ ID NO:5的氨基酸序列至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在另一个实施方案中,跨膜结构域衍生自(即包含)CD8。在一个实施方案中,CD8细胞外结构域和跨膜结构域的核苷酸序列如 中所示。
在一些实施方案中,编码共刺激结构域内的跨膜结构域的多核苷酸包含与CD8跨膜结构域的核苷酸序列至少约60%,至少约65%,至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
CD8细胞外结构域和跨膜结构域的氨基酸序列如 中所示。
在一个具体的实施方案中,共刺激结构域内的跨膜结构域包含与CD8跨膜结构域的氨基酸序列至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
细胞内(信号传导)结构域:本发明的工程化T细胞的细胞内(信号传导)结构域可以对活化结构域提供信号传导,该活化结构域然后活化免疫细胞的至少一个正常效应器功能。T细胞的效应器功能可以是例如细胞溶解活性或辅助活性,包括分泌细胞因子。
在某些实施方案中,适合的细胞内信号传导结构域包括(即包含)但不限于,4-1BB/CD137、活化性NK细胞受体、免疫球蛋白蛋白质、B7-H3、BAFFR、BLAME(SLAMF8)、BTLA、CD100(SEMA4D)、CD103、CD160(BY55)、CD18、CD19、CD19a、CD2、CD247、CD27、CD276(B7-H3)、CD28、CD29、CD3 delta、CD3 epsilon、CD3 gamma、CD30、CD4、CD40、CD49a、CD49D、CD49f、CD69、CD7、CD84、CD8alpha、CD8beta、CD96(Tactile)、CD1 1a、CD1 1b、CD1 1c、CD1 1d、CDS、CEACAM1、CRT AM、细胞因子受体、DAP-10、DNAM1(CD226)、Fc gamma受体、GADS、GITR、HVEM(LIGHTR)、IA4、ICAM-1、ICAM-1、Ig alpha(CD79a)、IL-2R beta、IL-2R gamma、IL-7Ralpha、诱导性T细胞共刺激分子(ICOS)、整合素、ITGA4、ITGA4、ITGA6、ITGAD、ITGAE、ITGAL、ITGAM、ITGAX、ITGB2、ITGB7、ITGB1、KIRDS2、LAT、LFA-1、LFA-1、与CD83特异性结合的配体、LIGHT、LIGHT、LTBR、Ly9(CD229),Lyl08)、淋巴细胞功能相关抗原-1(LFA-1;CDl-la/CD18)、MHC 1类分子、NKG2C、NKG2D、NKp30、NKp44、NKp46、NKp80(KLRF1)、OX-40、PAG/Cbp、程序性死亡-1(PD-1)、PSGL1、SELPLG(CD162)、信号传导淋巴细胞活化分子(SLAM蛋白)、SLAM(SLAMF1;CD150;IPO-3)、SLAMF4(CD244;2B4)、SLAMF6(NTB-A、SLAMF7、SLP-76、TNF受体蛋白、TNFR2、TNFSF14、Toll配体受体、TRANCE/RANKL、VLA1或VLA-6,或它们的片段、截短或组合。
编码细胞内信号传导结构域的核苷酸序列的实例如 中所示。
在一个实施方案中,编码共刺激结构域内的细胞内信号传导结构域的多核苷酸包含与SEQ ID NO:6的核苷酸序列至少约60%,至少约65%,至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
细胞内信号传导结构域的实例如SEQ ID NO.7:RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS中所示。
在一个具体的实施方案中,共刺激结构域内的细胞内信号传导结构域包含与SEQID NO:7的氨基酸序列至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
在一些实施方案中,共刺激结构域包含、基本上由以下各项组成或者由以下各项组成:细胞外THD,以及共刺激蛋白质的跨膜和细胞内结构域。例如,编码共刺激结构域的核苷酸序列如 中所示。
在一些实施方案中,编码共刺激结构域的多核苷酸包含、基本上由以下组成或者由以下组成:与SEQ ID NO:240的核苷酸序列至少约60%,至少约65%,至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列,其中该共刺激结构域不包含SEQ ID NO:1的氨基酸1至122、SEQ ID NO:1的氨基酸1至121、SEQ ID NO:1的氨基酸1至120、SEQ ID NO:1的氨基酸1至119、SEQ ID NO:1的氨基酸1至118或SEQ ID NO:1的氨基酸1至118。
共刺激结构域的相应氨基酸序列如 中所示。
在一些实施方案中,共刺激结构域包含、基本上由以下组成或者由以下组成:与SEQ ID NO:241的氨基酸序列至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列,其中该共刺激结构域不包含SEQ ID NO:1的氨基酸1至122、SEQ ID NO:1的氨基酸1至121、SEQ ID NO:1的氨基酸1至120、SEQ ID NO:1的氨基酸1至119、SEQ ID NO:1的氨基酸1至118或SEQ ID NO:1的氨基酸1至118。
I.B.活化结构域
CD3是天然T细胞上的T细胞受体的元件,并且已经显示为CAR中的重要的细胞内活化元件。在一个实施方案中,CD3为CD3zeta,其核苷酸序列如 中所示。
在一些实施方案中,编码活化结构域的多核苷酸包含与SEQ ID NO:8的核苷酸序列至少约60%,至少约65%,至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
细胞内CD3zeta的相应氨基酸如 中所示。
在一些实施方案中,活化结构域包含与SEQ ID NO:9的氨基酸序列至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
在一些实施方案中,活化结构域包含与以下氨基酸序列至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列:
I.C.抗原结合分子
可以通过掺入与靶抗原相互作周的抗原结合分子来工程化改造CAR以结合抗原(例如细胞表面抗原)。在一些实施方案中,抗原结合分子是其抗体片段,例如一个或多个单链抗体片段(“scFv”)。scFv是具有连接在一起的抗体的重链和轻链的可变区的单链抗体片段。参见美国专利号7,741,465和6,319,494,以及Eshhar et al.,Cancer ImmunolImmunotherapy(1997)45:131-136。scFv保留亲本抗体与靶抗原特异性相互作用的能力。scFv在嵌合抗原受体中有用,因为它们可以经工程化改造以与其他CAR组分一起作为单链的一部分表达。同上。还参见Krause et al.,J.Exp.Med.,Volume 188,No.4,1998(619-626);Finney et al.,Journal of Immunology,1998,161:2791-2797。应当领会,抗原结合分子通常包含在CAR的细胞外部分中,使得它能够识别并结合感兴趣的抗原。具有对超过一个感兴趣的抗原的特异性的双特异性和多特异性CAR考虑在本发明的范围内。
在一些实施方案中,多核苷酸编码包含本发明的THD和特异性结合靶抗原的抗原结合分子的CAR或TCR。在一些实施方案中,靶抗原为肿瘤抗原。在一些实施方案中,抗原选自肿瘤相关表面抗原,例如5T4、甲胎蛋白(AFP)、B7-1(CD80)、B7-2(CD86)、BCMA、B-人绒毛膜促性腺素、CA-125、癌胚抗原(CEA)、癌胚抗原(CEA)、CD123、CD133、CD138、CD19、CD20、CD22、CD23、CD24、CD25、CD30、CD33、CD34、CD4、CD40、CD44、CD56、CD8、CLL-1、c-Met、CMV特异性抗原、CSPG4、CTLA-4、二涎酸神经节苷脂GD2(disialoganglioside GD2)、导管上皮黏蛋白(ductal-epithelial mucine)、EBV特异性抗原、EGFR变体III(EGFRvIII)、ELF2M、内皮联蛋白、肝配蛋白B2、表皮生长因子受体(EGFR)、上皮细胞黏附分子(EpCAM)、上皮肿瘤抗原、ErbB2(HER2/neu)、成纤维细胞相关蛋白(fap)、FLT3、叶酸结合蛋白、GD2、GD3、神经胶质瘤相关抗原、鞘糖脂、gp36、HBV特异性抗原、HCV特异性抗原、HER1-HER2、结合的HER2-HER3、HERV-K、高分子量-黑色素瘤相关抗原(HMW-MAA)、HIV-1包膜糖蛋白gp41、HPV特异性抗原、人端粒酶逆转录酶、IGFI受体、IGF-II、IL-11Ralpha、IL-13R-a2、流感病毒特异性抗原;CD38、胰岛素生长因子(IGFl)-l、肠羧基酯酶、kappa链、LAGA-la、lambda链、拉沙病毒特异性抗原、凝集素反应性AFP、谱系特异性或组织特异性抗原例如CD3、MAGE、MAGE-A1、主要组织相容性复合体(MHC)分子、呈递肿瘤特异性肽表位的主要组织相容性复合体(MHC)分子、M-CSF、黑色素瘤相关抗原、间皮素、间皮素、MN-CA IX、MUC-1、mut hsp70-2、突变的p53、突变的p53、突变的ras、中性粒细胞弹性蛋白酶、NKG2D、Nkp30、NY-ESO-1、p53、PAP、prostase、prostase特异性抗原(PSA)、前列腺癌肿瘤抗原-1(PCTA-1)、前列腺特异性抗原、prostein、PSMA、RAGE-1、ROR1、RU1、RU2(AS)、表面黏附分子、存活和端粒酶、TAG-72、纤连蛋白的额外结构域(extra domain)A(EDA)和额外结构域B(EDB)和生腱蛋白C的Al结构域(TnC Al)、甲状腺球蛋白、肿瘤基质抗原、血管内皮生长因子受体-2(VEGFR2)、病毒特异性表面抗原例如HIV特异性抗原(例如HIV gpl20)、以及这些表面标志物的任何衍生物或变体。在某些实施方案中,抗原结合分子特异性结合BCMA。在其他实施方案中,抗原结合分子特异性结合CLL-1。在其他实施方案中,抗原结合分子特异性结合FLT3。
在一些实施方案中,抗原结合分子特异性结合BCMA。在某些实施方案中,抗原结合分子包含(a)包含选自SEQ ID NO:13-20的氨基酸序列的VH CDR1;(b)包含选自SEQ ID NO:21-28的氨基酸序列的VH CDR2;(c)包含选自SEQ ID NO:29-36的氨基酸序列的VH CDR3;(d)包含选自SEQ ID NO:37-44的氨基酸序列的VL CDR1;(e)包含选自SEQ ID NO:45-52的氨基酸序列的VL CDR2;和/或(f)包含选自SEQ ID NO:53-60的氨基酸序列的VL CDR3。
在一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:13的氨基酸的VHCDR1;(b)包含SEQ ID NO:21的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:29的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:37的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:45的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:53的氨基酸序列的VL CDR3。
在另一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:14的氨基酸的VHCDR1;(b)包含SEQ ID NO:22的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:30的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:38的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:46的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:54的氨基酸序列的VL CDR3。
在另一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:15的氨基酸的VHCDR1;(b)包含SEQ ID NO:23的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:31的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:39的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:47的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:55的氨基酸序列的VL CDR3。
在另一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:16的氨基酸的VHCDR1;(b)包含SEQ ID NO:24的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:32的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:40的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:48的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:56的氨基酸序列的VL CDR3。
在另一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:17的氨基酸的VHCDR1;(b)包含SEQ ID NO:25的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:33的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:41的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:49的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:57的氨基酸序列的VL CDR3。
在另一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:18的氨基酸的VHCDR1;(b)包含SEQ ID NO:26的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:34的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:42的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:50的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:58的氨基酸序列的VL CDR3。
在另一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:19的氨基酸的VHCDR1;(b)包含SEQ ID NO:27的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:35的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:43的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:51的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:59的氨基酸序列的VL CDR3。
在另一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:20的氨基酸的VHCDR1;(b)包含SEQ ID NO:28的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:36的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:44的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:52的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:60的氨基酸序列的VL CDR3。
在某些实施方案中,抗原结合分子包含VH和VL,所述VH包含选自由SEQ ID NO:77-84组成的组的氨基酸序列,和所述VL包含选自由SEQ ID NO:85-92组成的组的氨基酸序列。在一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:77的氨基酸序列和所述VL包含SEQ ID NO:85的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:78的氨基酸序列和所述VL包含SEQ ID NO:86的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:79的氨基酸序列和所述VL包含SEQ ID NO:87的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:80的氨基酸序列和所述VL包含SEQ ID NO:88的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:81的氨基酸序列和所述VL包含SEQ ID NO:89的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:82的氨基酸序列和所述VL包含SEQ ID NO:90的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:83的氨基酸序列和所述VL包含SEQID NO:91的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQID NO:84的氨基酸序列和所述VL包含SEQ ID NO:92的氨基酸序列。
在一个具体的实施方案中,本发明的多核苷酸包含与选自由SEQ ID NO:61-68组成的组的核苷酸序列至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。在另一个实施方案中,本发明的多核苷酸包含与选自由SEQ ID NO:69-76组成的组的核苷酸序列至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
其他已知抗BCMA抗体或其抗原结合分子可以用作包含本发明的THD的CAR或TCR的抗原结合分子。此类BCMA抗体或其抗原结合分子的非限制性实例包括描述于2015年10月22日公开的WO2015158671A1和2016年1月28日公开的WO2016014565A2的抗体或抗原结合分子。
在一些实施方案中,抗原结合分子特异性结合CLL-1。在某些实施方案中,抗原结合分子包含(a)包含选自SEQ ID NO:93-96的氨基酸序列的VH CDR1;(b)包含选自SEQ IDNO:97-100的氨基酸序列的VH CDR2;(c)包含选自SEQ ID NO:101-104的氨基酸序列的VHCDR3;(d)包含选自SEQ ID NO:105-108的氨基酸序列的VL CDR1;(e)包含选自SEQ ID NO:109-112的氨基酸序列的VL CDR2;和/或(f)包含选自SEQ ID NO:113-116的氨基酸序列的VL CDR3。
在一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:93的氨基酸的VHCDR1;(b)包含SEQ ID NO:97的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:101的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:105的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:109的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:113的氨基酸序列的VL CDR3。
在一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:94的氨基酸的VHCDR1;(b)包含SEQ ID NO:98的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:102的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:106的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:110的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:114的氨基酸序列的VL CDR3。
在一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:95的氨基酸的VHCDR1;(b)包含SEQ ID NO:99的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:103的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:107的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:111的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:115的氨基酸序列的VL CDR3。
在一个实施方案中,抗原结合分子包含(a)包含SEQ ID NO:96的氨基酸的VHCDR1;(b)包含SEQ ID NO:100的氨基酸序列的VH CDR2;(c)包含SEQ ID NO:104的氨基酸序列的VH CDR3;(d)包含SEQ ID NO:108的氨基酸序列的VL CDR1;(e)包含SEQ ID NO:112的氨基酸序列的VL CDR2;和/或(f)包含SEQ ID NO:116的氨基酸序列的VL CDR3。
在某些实施方案中,抗原结合分子包含VH和VL,所述VH包含选自由SEQ ID NO:125-128组成的组的氨基酸序列和所述VL包含选自由SEQ ID NO:129-132组成的组的氨基酸序列。在一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:125的氨基酸序列和所述VL包含SEQ ID NO:129的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:126的氨基酸序列和所述VL包含SEQ ID NO:130的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:127的氨基酸序列和所述VL包含SEQ ID NO:131的氨基酸序列。在另一个实施方案中,抗原结合分子包含VH和VL,所述VH包含SEQ ID NO:128的氨基酸序列和所述VL包含SEQ ID NO:132的氨基酸序列。
在一个具体的实施方案中,本发明的多核苷酸包含与选自由SEQ ID NO:117-120组成的组的核苷酸序列至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。在另一个实施方案中,本发明的多核苷酸包含与选自由SEQ ID NO:121-124组成的组的核苷酸序列至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
抗CLL-1抗体或其抗原结合分子的其他实例包括描述于2016年1月28日公开的WO2016014535和2016年2月25日公开的US 2016/0051651 A1的抗体或抗原结合分子。
由本发明的多核苷酸编码的抗原结合分子可以为单链或双链。在一些实施方案中,抗原结合分子为单链。在某些实施方案中,抗原结合分子选自由以下各项组成的组:scFv、Fab、Fab′、Fv、F(ab′)2、dab或它们的任何组合。在一个具体的实施方案中,抗原结合分子包含scFv。
在某些实施方案中,抗原结合分子包含单链,其中重链可变区和轻链可变区通过接头连接。在一些实施方案中,VH位于接头的N末端而VL位于接头的C末端。在其他实施方案中,VL位于接头的N末端而VH位于接头的C末端。在一些实施方案中,接头包含至少约5个,至少约8个,至少约10个,至少约13个,至少约15个,至少约18个,至少约20个,至少约25个,至少约30个,至少约35个,至少约40个,至少约45个,至少约50个,至少约60个,至少约70个,至少约80个,至少约90个或至少约100个氨基酸。在一些实施方案中,接头包含至少约18个氨基酸。在某些实施方案中,接头包含与氨基酸序列GSTSGSGKPGSGEGSTKG(SEQ ID NO:12)或氨基酸序列GGGGSGGGGSGGGGS(SEQ ID NO:237)至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或100%相同的氨基酸序列。在一个实施方案中,接头为Whitlow接头。在某些实施方案中,结合分子包含单链,其中重链可变区和轻链可变区通过接头连接,其中接头包含SEQ ID NO:12的氨基酸序列。
在一些实施方案中,抗原结合分子以小于1x 10-6M、小于1x 10-7M、小于1x 10-8M或小于1x 10-9M的KD结合靶抗原(例如人BCMA、人FLT3或人CLL-1)。在一个具体的实施方案中,抗原结合分子以小于1x 10-7M的KD结合靶抗原(例如人BCMA、人FLT3或人CLL-1)。在另一个实施方案中,抗原结合分子以小于1x 10-8M的KD结合靶抗原(例如人BCMA、人FLT3或人CLL-1)。在一些实施方案中,抗原结合分子以约1x 10-7M、约2x 10-7M、约3x 10-7M、约4x 10-7M、约5x 10-7M、约6x 10-7M、约7x 10-7M、约8x 10-7M、约9x 10-7M、约1x 10-8M、约2x 10-8M、约3x10-8M、约4x 10-8M、约5x 10-8M、约6x 10-8M、约7x 10-8M、约8x 10-8M、约9x 10-8M、约1x 10- 9M、约2x 10-9M、约3x 10-9M、约4x 10-9M、约5x 10-9M、约6x 10-9M、约7x 10-9M、约8x 10-9M、约9x 10-9M、约1x 10-10M或约5x 10-10M的KD结合靶抗原(例如人BCMA、人FLT3或人CLL-1)。在某些实施方案中,KD计算为koff/kon的商,并且如通过例如表面等离激元共振技术所测量的,使用单价抗体例如Fab片段来测定kon和koff。在其他实施方案中,KD计算为koff/kon的商,并且如通过例如表面等离激元共振技术所测量的,使用二价抗体例如Fab片段来测定kon和koff。
在一些实施方案中,抗原结合分子以小于1x 10-4M-1s-1、小于2x 10-4M-1s-1、小于3x10-4M-1s-1、小于4x 10-4M-1s-1、小于5x 10-4M-1s-1、小于6x 10-4M-1s-1、小于7x 10-4M-1s-1、小于8x 10-4M-1s-1、小于9x 10-4M-1s-1、小于1x 10-5M-1s-1、小于2x 10-5M-1s-1、小于3x 10-5M-1s-1、小于4x 10-5M-1s-1、小于5x 10-5M-1s-1、小于6x 10-5M-1s-1、小于7x 10-5M-1s-1、小于8x 10-5M- 1s-1、小于9x 10-5M-1s-1、小于1x 10-6M-1s-1、小于2x 10-6M-1s-1、小于3x 10-6M-1s-1、小于4x10-6M-1s-1、小于5x 10-6M-1s-1、小于6x 10-6M-1s-1、小于7x 10-6M-1s-1、小于8x 10-6M-1s-1、小于9x 10-6M-1s-1或小于1x 10-7M-1s-1的结合速率(kon)结合靶抗原(例如人BCMA、人FLT3或人CLL-1)。在某些实施方案中,如通过例如表面等离激元共振技术所测量的,使用单价抗体例如Fab片段来测定kon。在其他实施方案中,如通过例如表面等离激元共振技术所测量的,使用二价抗体来测定kon。
在一些实施方案中,抗原结合分子以小于1x 10-2s-1、小于2x 10-2s-1、小于3x 10- 2s-1、小于4x 10-2s-1、小于5x 10-2s-1、小于6x 10-2s-1、小于7x 10-2s-1、小于8x 10-2s-1、小于9x 10-2s-1、小于1x 10-3s-1、小于2x 10-3s-1、小于3x 10-3s-1、小于4x 10-3s-1、小于5x 10-3s-1、小于6x 10-3s-1、小于7x 10-3s-1、小于8x 10-3s-1、小于9x 10-3s-1、小于1x 10-4s-1、小于2x10-4s-1、小于3x 10-4s-1、小于4x 10-4s-1、小于5x 10-4s-1、小于6x 10-4s-1、小于7x 10-4s-1、小于8x 10-4s-1、小于9x 10-4s-1、小于1x 10-4s-1或小于5x 10-4s-1的解离速率(koff)结合靶抗原(例如人BCMA、人FLT3或人CLL-1)。在某些实施方案中,如通过例如表面等离激元共振技术所测量的,使用单价抗体例如Fab片段来测定koff。在其他实施方案中,如通过例如表面等离激元共振技术所测量的,使用二价抗体来测定koff。
在一些实施方案中,多核苷酸编码TCR,其中TCR进一步包含第四互补决定区(CD4)。在某些实施方案中,多核苷酸编码TCR,其中TCR进一步包含恒定区。在一些实施方案中,恒定区选自以下各项的恒定区:IgG1、IgG2、IgG3、IgG4、IgA、IgD、IgE和IgM。
I.D.开关结构域(Switch Domain)
应当领会,通过用自杀基因转导免疫细胞(含有一种或多种CAR或TCR)可以使不良事件最小化。也可以需要将诱导性“开(on)”或“加速器”开关掺入到免疫细胞中。适合的技术包括在用本发明的CAR构建体转导细胞之前、之后或同时使用诱导性胱天蛋白酶-9(美国申请2011/0286980)或胸苷激酶。导入自杀基因和/或“开”开关的另外的方法包括TALENS、锌指、RNAi、siRNA、shRNA、反义技术和本领域已知的其他技术。
根据本发明,另外的开-关或其他类型的控制开关技术可以并入本文。这些技术可以采用二聚化结构域和任选此类结构域二聚化的活化剂。这些技术包括例如,Wu et al.,Science 2014 350(6258)描述的在某些细胞中利用FKBP/Rapalog二聚化系统的那些,其内容通过引用整体并入本文。另外的二聚化对可以包括环孢霉素-A/亲环素受体、雌激素/雌激素受体(任选地使用他莫昔芬)、糖皮质激素/糖皮质激素受体、四环素/四环素受体、维生素D/维生素D受体。二聚化技术的其他实例可以在例如WO 2014/127261、WO 2015/090229、US 2014/0286987、US 2015/0266973、US 2016/0046700、美国专利号8,486,693、US 2014/0171649和US 2012/0130076中找到,其内容进一步通过引用整体并入本文。
I.E.前导肽
在一些实施方案中,本发明的多核苷酸编码的CAR或TCR可以进一步包含前导肽(本文中也称为“信号肽”)。在某些实施方案中,前导肽包含与氨基酸序列MALPVTALLLPLALLLHAARP(SEQ ID NO:11)至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或100%相同的氨基酸序列。在一些实施方案中,前导肽包含SEQ ID NO:11的氨基酸序列。
在一些实施方案中,本发明的多核苷酸编码CAR或TCR,其中CAR或TCR包含前导肽(P)、抗原结合分子(B)、共刺激蛋白质的细胞外结构域(E)、跨膜结构域(T)、共刺激区(C)和活化结构域(A),其中CAR根据如下配置:P-B-E-T-C-A。在一些实施方案中,抗原结合分子包含VH和VL,其中CAR根据如下配置:P-VH-VL-E-T-C-A或P-VL-VH-E-T-C-A。在一些实施方案中,VH和VL通过接头(L)连接,其中CAR根据如下配置(从N-末端至C-末端):P-VH-L-VL-E-T-C-A或P-VH-L-VL-E-T-C-A。
在一些实施方案中,本发明的多核苷酸编码CAR,其中CAR包含与选自表2的氨基酸序列至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或100%相同的氨基酸序列。在某些实施方案中,本发明的多核苷酸编码CAR,其中CAR包含选自表2的氨基酸序列。
表2实例CAR序列
在一些实施方案中,本发明的多核苷酸编码CAR,其中CAR包含与选自由以下各项组成的组的氨基酸序列至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或100%相同的氨基酸序列:SEQ ID NO:134、136、138、140、142、144、146、148、150、152、154、156、158、160、162、164、166、168、178、180、190、192、202、204、214、216、226和228。在某些实施方案中,CAR包含选自由以下各项组成的组的氨基酸序列:SEQ ID NO:134、136、138、140、142、144、146、148、150、152、154、156、158、160、162、164、166、168、178、180、190、192、202、204、214、216、226和228。
在一些实施方案中,本发明的多核苷酸包含与选自由以下各项组成的组的核苷酸序列至少约50%,至少约60%,至少约65%,至少约70%,至少约75%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或100%相同的核苷酸序列:SEQ ID NO:133、135、137、139、141、143、145、147、149、151、153、155、157、159、161、163、165、167、177、179、189、191、201、203、213、215、225和227。在某些实施方案中,多核苷酸包含选自由以下各项组成的组的核苷酸序列:SEQ ID NO:133、135、137、139、141、143、145、147、149、151、153、155、157、159、161、163、165、167、177、179、189、191、201、203、213、215、225和227。
II.载体、细胞和药物组合物
在某些方面,本文提供了包含本发明的多核苷酸的载体。在一些实施方案中,本发明涉及载体或一组载体,其如上所述,包含编码CAR或TCR的多核苷酸,该CAR或TCR包含截短铰链结构域(“THD”)。
本领域已知的任何载体可以适于本发明。在一些实施方案中,载体为病毒载体。在一些实施方案中,载体为逆转录病毒载体、DNA载体、鼠白血病病毒载体、SFG载体、质粒、RNA载体、腺病毒载体、杆状病毒载体、EB病毒载体、乳多空病毒载体、牛痘病毒载体、单纯疱疹病毒载体、腺病毒相关载体(AAV)、慢病毒载体或它们的任何组合。
在实施方案中,本发明的内容中可以采用的载体为pGAR并且具有如下编码序列:
pGAR载体图谱如下所示:
适合的另外的例示性载体包括例如,pBABE-puro、pBABE-neo largeTcDNA、pBABE-hygro-hTERT、pMKO.1GFP、MSCV-IRES-GFP、pMSCV PIG(Puro IRES GFP空质粒)、pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE、MSCV IRES荧光素酶、pMIG、MDH1-PGK-GFP_2.0、TtRMPVIR、pMSCV-IRES-mCherry FP、pRetroX GFP T2A Cre、pRXTN、pLncEXP和pLXIN-Luc。
在其他方面,本文提供了包含本发明的多核苷酸或载体的细胞。在一些实施方案中,本发明涉及细胞,例如体外细胞,其包含编码包含本文所述的TCD的CAR或TCR的多核苷酸。在其他实施方案中,本发明涉及细胞,例如体外细胞,其包含由包含本文所述的TCD的CAR或TCR编码的多肽。
对于本发明的多核苷酸、载体或多肽,任何细胞可以用作宿主细胞。在一些实施方案中,细胞可以为原核细胞、真菌细胞、酵母细胞或高等真核细胞例如哺乳动物细胞。适合的原核细胞包括但不限于,真细菌,例如革兰氏阴性或革兰氏阳性生物体,例如,肠杆菌科细菌(Enterobactehaceae)例如
埃希氏菌(Escherichia),例如大肠杆菌(E.coli);肠杆菌(Enterobacter);欧文氏菌(Erwinia);克雷伯氏菌(Klebsiella);变形杆菌(Proteus);沙门氏菌(Salmonella),例如鼠伤寒沙门氏菌(Salmonella typhimurium);沙雷氏菌(Serratia),例如褪色沙雷氏菌(Serratia marcescans)和志贺氏菌(Shigella);芽孢杆菌(Bacilli)例如枯草芽孢杆菌(B.subtilis)和地衣芽孢杆菌(B.licheniformis);假单胞菌(Pseudomonas)例如铜绿假单胞菌(P.aeruginosa);和链霉菌(Streptomyces)。在一些实施方案中,细胞为人细胞。在一些实施方案中,细胞为免疫细胞。在一些实施方案中,免疫细胞选自由以下各项组成的组:T细胞、B细胞、肿瘤浸润淋巴细胞(TIL)、TCR表达细胞、自然杀伤(NK)细胞、树突状细胞、粒细胞、先天淋巴样细胞、巨核细胞、单核细胞、巨噬细胞、血小板、胸腺细胞和髓样细胞。在一个实施方案中,免疫细胞为T细胞。在另一个实施方案中,免疫细胞为NK细胞。在某些实施方案中,T细胞为肿瘤浸润淋巴细胞(TIL)、自体T细胞、工程化自体T细胞(eACTTM)、同种异体T细胞、异源T细胞,或它们的任何组合。
可以通过本领域已知的任何来源获得本发明的细胞。例如,T细胞可以在体外从造血干细胞群分化,或者可以从受试者获得T细胞。T细胞可以从例如外周血单核细胞、骨髓、淋巴结组织、脐带血、胸腺组织、来自感染部位的组织、腹水、胸腔积液、脾组织以及肿瘤获得。此外,T细胞可以源自本领域中可获得的一个或多个T细胞系。T细胞也可以使用本领域技术人员已知的任何数目的技术(例如FICOLLTM分离和/或单采术(apheresis))从受试者收集的血液单位取得。在某些实施方案中,通过单采术收集的细胞经清洗以去除血浆部分,并且放置于适当的缓冲液或介质中以进行后续处理。在一些实施方案中,用PBS清洗细胞。如应当领会的,可以例如通过使用半自动无逆流离心机(例如CobeTM 2991细胞处理器,BaxterCytoMateTM等)来使用清洗步骤。在一些实施方案中,将经清洗的细胞重悬于一种或多种生物相容性缓冲液,或含有或不含有缓冲液的其他盐溶液中。在某些实施方案中,除去单采样品中不需要的成分。分离用于T细胞疗法的T细胞的另外的方法公开于美国专利公开号2013/0287748,其通过引用整体并入本文。
在某些实施方案中,通过溶解红细胞和消耗单核细胞(例如经由PERCOLLTM梯度,通过使用离心来分离)从PBMC分离T细胞。在一些实施方案中,T细胞的特定亚群,例如CD4+、CD8+、CD28+、CD45RA+和CD45RO+T细胞可以通过本领域中已知的正或负选择技术进一步分离。例如,通过负选择进行的T细胞群富集可以使用针对经负选择的细胞所特有的表面标志物的抗体组合来完成。在一些实施方案中,可以使用细胞分选和/或经由负磁性免疫黏附或流式细胞术(其使用针对存在于经负选择的细胞上的细胞表面标志物的单克隆抗体混合物)进行选择。例如,为了通过负选择来富集CD4+细胞,单克隆抗体混合物通常包括针对CD8、CD11b、CD14、CD16、CD20和HLA-DR的抗体。在某些实施方案中,使用流式细胞术和细胞分选来分离用于本发明中的感兴趣的细胞群。
在一些实施方案中,PBMC直接用于使用如本文所述的方法的免疫细胞的遗传修饰(例如CAR或TCR)。在某些实施方案中,分离PBMC后,可以进一步分离出T淋巴细胞,并在遗传修饰和/或扩增前或后将细胞毒性和辅助性T淋巴细胞两者分选成初始T细胞、记忆T细胞和效应T细胞亚群。
在一些实施方案中,通过鉴别与CD8+细胞的初始细胞、中央记忆细胞和效应细胞类型中每种相关联的细胞表面抗原来将CD8+细胞进一步分选成初始细胞、中央记忆细胞及效应细胞。在一些实施方案中,中央记忆T细胞的表型标志物的表达包括CCR7、CD3、CD28、CD45RO、CD62L和CD127并且为颗粒酶B阴性。在一些实施方案中,中央记忆T细胞为CD8+、CD45RO+和CD62L+T细胞。在一些实施方案中,效应T细胞为CCR7、CD28、CD62L和CD127阴性并且为颗粒酶B和穿孔蛋白阳性。在某些实施方案中,将CD4+T细胞进一步分选成亚群。例如,可以通过鉴别具有细胞表面抗原的细胞群将CD4+T辅助性细胞分选为初始细胞、中央记忆细胞和效应细胞。
在一些实施方案中,免疫细胞例如T细胞在分离后使用已知的方法进行遗传修饰,或者免疫细胞在经遗传修饰前在体外活化和扩增(或者,在祖细胞的情况下分化)。在另一个实施方案中,免疫细胞例如T细胞以本文所述的嵌合抗原受体进行遗传修饰(例如用包含一个或多个编码CAR的核苷酸序列的病毒载体转导),并然后在体外活化和/或扩增。用于活化和扩增T细胞的方法为本领域所已知并描述于例如美国专利号6,905,874;6,867,041;和6,797,514;以及PCT公开号WO 2012/079000,其内容通过引用整体并入本文。一般而言,此类方法包括将PBMC或分离的T细胞在具有适当的细胞因子(例如IL-2)的培养基中与刺激剂和共刺激剂(例如抗CD3和抗CD28抗体,通常黏附在珠或其他表面)接触。黏附在相同珠上的抗CD3和抗CD28抗体充当“替代”抗原呈递细胞(APC)。一种实例为系统,用于生理活化人T细胞的CD3/CD28活化剂/刺激剂系统。在其他实施方案中,使用例如美国专利号6,040,177和5,827,642以及PCT公开号WO 2012/129514(其内容通过引用整体并入本文)中描述的方法,以饲养细胞以及适当的抗体和细胞因子活化并刺激T细胞以进行增殖。
在某些实施方案中,从供体受试者获得T细胞。在一些实施方案中,供体受试者为患有癌症或肿瘤的人类患者。在其他实施方案中,供体受试者为未患有癌症或肿瘤的人类患者。
本发明的其他方面涉及包含本文所述的多核苷酸、本文所述的载体、本文所述的多肽或本文所述的体外细胞的组合物。在一些实施方案中,组合物包含药学上可接受的载体、稀释剂、增溶剂、乳化剂、防腐剂和/或佐剂。在一些实施方案中,组合物包含赋形剂。在一个实施方案中,组合物包含编码包含本文所述的截短铰链结构域(“THD”)的CAR或TCR的多核苷酸。在另一个实施方案中,组合物包含含有由本发明的多核苷酸编码的TCD的CAR或TCR。在另一个实施方案中,组合物包含含有CAR或TCR(其包含本文所述的TCD)的T细胞。
在其他实施方案中,组合物经选择以用于肠胃外递送、用于吸入或用于通过消化道递送,例如口服。制备此类药学上可接受的组合物在本领域技术人员的能力内。在某些实施方案中,缓冲液用于将该组合物维持在生理pH或稍低的pH,通常在约5至约8的pH范围内。在某些实施方案中,当考虑肠胃外施用时,组合物为无热原、肠胃外可接受的水溶液形式,其包含在药学上可接受的媒介物中的具有或不具有另外的治疗剂的本文所述的组合物。在某些实施方案中,用于肠胃外注射的媒介物为无菌蒸馏水,其中将本文所述的组合物(具有或不具有至少一种另外的治疗剂)配制成经适当保存的无菌的等张溶液。在某些实施方案中,制备牵涉具有提供产品受控或持续释放的聚合化合物(例如聚乳酸或聚乙醇酸)、珠或脂质体的所需分子的制剂,然后该制剂经由贮存注射(depot injection)来递送。在某些实施方案中,使用可植入的药物递送装置来导入所需分子。
III.本发明的方法
本发明的另一方面涉及制造表达CAR或TCR的细胞的方法,其包含在适合的条件下用本文所公开的多核苷酸转导细胞。在一些实施方案中,如本文所公开的,方法包含用编码CAR或TCR的多核苷酸转导细胞。在一些实施方案中,方法包含用包含编码CAR或TCR的多核苷酸的载体转导细胞。
本发明的另一方面涉及诱导针对肿瘤的免疫的方法,其包含对受试者施用有效量的细胞,该细胞包含本文所述的多核苷酸、本文所述的载体或本文所述的CAR或TCR。在一个实施方案中,方法包含对受试者施用有效量的细胞,该细胞包含编码本文所公开的CAR或TCR的多核苷酸。在另一个实施方案中,方法包含对受试者施用有效量的包含载体的细胞,该载体包含编码本文所公开的CAR或TCR的多核苷酸。在另一个实施方案中,方法包含对受试者施用有效量的细胞,该细胞包含由本文所公开的多核苷酸编码的CAR或TCR。
本发明的另一方面涉及诱导受试者中免疫应答的方法,其包含施用有效量的本申请的经工程化改造的免疫细胞。在一些实施方案中,免疫应答为T细胞介导的免疫应答。在一些实施方案中,T细胞介导的免疫应答针对一种或多种靶细胞。在一些实施方案中,经工程化改造的免疫细胞包含CAR或TCR,其中CAR或TCR包含本公开中所述的THD。在一些实施方案中,靶细胞为肿瘤细胞。
本发明的另一方面涉及用于治疗或预防恶性肿瘤的方法,所述方法包含对有此需要的受试者施用有效量的至少一种免疫细胞,其中免疫细胞包含至少一种CAR或TCR,并且其中该CAR或TCR包含本文所述的THD。
本发明的另一方面涉及治疗有此需要的受试者中癌症的方法,其包含对受试者施用本文所公开的多核苷酸、载体、CAR或TCR、细胞或组合物。在一个实施方案中,方法包含施用编码CAR或TCR的多核苷酸。在另一个实施方案中,方法包含施用包含编码CAR或TCR的多核苷酸的载体。在另一个实施方案中,方法包含施用由本文所公开的多核苷酸编码的CAR或TCR。在另一个实施方案中,方法包含施用包含编码CAR或TCR的多核苷酸或包含编码CAR或TCR的多核苷酸的载体的细胞。
在一些实施方案中,治疗有此需要的受试者中癌症的方法包含T细胞疗法。在一个实施方案中,本发明的T细胞疗法为工程化自体细胞疗法(eACTTM)。根据该实施方案,方法可以包括从患者收集血细胞。然后,分离的血细胞(例如T细胞)可以经工程化改造以表达本发明的CAR或TCR。在一个具体的实施方案中,将CART细胞或TCRT细胞施用于患者。在一些实施方案中,CART细胞或TCRT细胞治疗患者中的肿瘤或癌症。在一个实施方案中,CART细胞或TCRT细胞缩小肿瘤或癌症的尺寸。
在一些实施方案中,从患者获得用于T细胞疗法中的供体T细胞(例如用于自体T细胞疗法)。在其他实施方案中,从非患者的受试者获得用于T细胞疗法中的供体T细胞。
T细胞可以以治疗有效量施用。例如,T细胞的治疗有效量可以为至少约104个细胞、至少约105个细胞、至少约106个细胞、至少约107个细胞、至少约108个细胞、至少约109个细胞或至少约1010个细胞。在另一个实施方案中,T细胞的治疗有效量为约104个细胞、约105个细胞、约106个细胞、约107个细胞或约108个细胞。在一个具体的实施方案中,CART细胞或TCRT细胞的治疗有效量为约2X 106个细胞/kg、约3X 106个细胞/kg、约4X 106个细胞/kg、约5X 106个细胞/kg、约6X 106个细胞/kg、约7X 106个细胞/kg、约8X 106个细胞/kg、约9X 106个细胞/kg、约1X 107个细胞/kg、约2X 107个细胞/kg、约3X 107个细胞/kg、约4X 107个细胞/kg、约5X 107个细胞/kg、约6X 107个细胞/kg、约7X 107个细胞/kg、约8X 107个细胞/kg、或约9X 107个细胞/kg。
IV.癌症治疗
本发明的方法可以用于治疗受试者中的癌症、缩小肿瘤尺寸、杀死肿瘤细胞、防止肿瘤细胞增殖、防止肿瘤生长、从患者消除肿瘤、防止肿瘤复发、防止肿瘤转移、诱导患者缓解或它们的任何组合。在某些实施方案中,方法诱导完整响应。在其他实施方案中,方法引起部分响应。
可以治疗的癌症包括未血管化、基本上尚未血管化或血管化的肿瘤。癌症也可以包括实体瘤或非实体瘤。在一些实施方案中,癌症为血液学癌症。在一些实施方案中,癌症为白细胞的癌症。在其他实施方案中,癌症为浆细胞的癌症。在一些实施方案中,癌症为白血病、淋巴瘤或骨髓瘤。在某些实施方案中,癌症为急性淋巴母细胞白血病(ALL)(包括非T细胞ALL)、急性淋巴细胞白血病(ALL)和噬血细胞性淋巴组织细胞增生症(HLH)、B细胞幼淋巴细胞白血病、B细胞急性淋巴细胞白血病(“BALL”)、母细胞性浆细胞样树突状细胞肿瘤、伯基特淋巴瘤、慢性淋巴细胞白血病(CLL)、慢性髓细胞性白血病(CML)、慢性髓样白血病(CML)、慢性或急性肉芽肿病、慢性或急性白血病、弥漫性大B细胞淋巴瘤、弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤、滤泡性淋巴瘤(FL)、毛细胞白血病、噬血细胞综合征(巨噬细胞活化综合征(MAS)、霍奇金病、大细胞肉芽肿、白细胞黏附缺陷、恶性淋巴细胞增生性疾病、MALT淋巴瘤、套细胞淋巴瘤、边缘区淋巴瘤、意义不明的单克隆丙种球蛋白病(MGUS)、多发性骨髓瘤、骨髓增生异常和骨髓增生异常综合征(MDS)、髓样疾病包括但不限于急性髓样白血病(AML)、非霍奇金淋巴瘤(NHL)、浆细胞增生性疾病(例如无症状性骨髓瘤(冒烟型多发性骨髓瘤或惰性骨髓瘤)、浆母细胞性淋巴瘤、浆细胞样树突状细胞肿瘤、浆细胞瘤(例如浆细胞恶液质;单发性骨髓瘤;单发性浆细胞瘤;髓外浆细胞瘤;和多发性浆细胞瘤)、POEMS综合征(克罗-深濑综合征;Takatsuki病;PEP综合征)、原发性纵隔大B细胞淋巴瘤(PMBC)、小细胞或大细胞滤泡性淋巴瘤、脾边缘区淋巴瘤(SMZL)、系统性淀粉样蛋白轻链淀粉样变、T细胞急性淋巴细胞白血病(“TALL”)、T细胞淋巴瘤、转化滤泡性淋巴瘤或瓦氏巨球蛋白血症,或它们的组合。
在一个实施方案中,癌症为骨髓瘤。在一个具体的实施方案中,癌症为多发性骨髓瘤。在另一个实施方案中,癌症为白血病。在一个实施方案中,癌症为急性髓样白血病。
在一些实施方案中,方法进一步包含施用化疗剂。在某些实施方案中,选择的化疗剂是淋巴消减(预调理)化疗剂。有益的预调理治疗方案以及相关的有益生物标志物描述于美国临时专利申请62/262,143和62/167,750,其通过引用整体并入本文。这些描述了例如调理需要T细胞疗法的患者的方法,包含对患者施用规定的有益剂量的环磷酰胺(200mg/m2/天-2000mg/m2/天)和规定剂量的氟达拉滨(20mg/m2/天-900mg/m2/天)。一种此类剂量方案牵涉治疗患者,包含每天对患者施用约500mg/m2/天的环磷酰胺和约60mg/m2/天的氟达拉滨,持续3天,然后对患者施用治疗有效量的工程化T细胞。
在其他实施方案中,抗原结合分子,转导的(或以其他方式工程化的)细胞(例如CAR或TCR)和化疗剂各自以有效治疗受试者的疾病或状况的量施用。
在某些实施方案中,包含本文所公开的表达CAR和/或TCR的免疫效应细胞的组合物可以与任何数目的化疗剂联合施用。化疗剂的实例包括烷化剂类(alkylating agents),诸如塞替派(thiotepa)和环磷酰胺(cyclophosphamide)(CYTOXANTM);磺酸烷基酯类(alkylsulfonates),诸如白消安(busulfan)、英丙舒凡(improsulfan)和哌泊舒凡(piposulfan);氮丙啶类(aziridines),诸如苯佐替派(benzodepa)、卡波醌(carboquone)、美妥替派(meturedepa)和乌瑞替派(uredepa);乙撑亚胺类(ethylenimines)和甲基蜜胺类(methylamelamines),包括六甲蜜胺(altretamine)、三乙撑蜜胺(triethylenemelamine)、三乙撑磷酰胺(trietylenephosphoramide)、三乙撑硫代磷酰胺(triethylenethiophosphaoramide)和三羟甲蜜胺(trimethylolomelamine resume);氮芥类(nitrogen mustards),诸如苯丁酸氮芥(chlorambucil)、萘氮芥(chlornaphazine)、胆磷酰胺(cholophosphamide)、雌莫司汀(estramustine)、异环磷酰胺(ifosfamide)、双氯乙基甲胺(mechlorethamine)、盐酸氧氮芥(mechlorethamine oxide hydrochloride)、美法仑(melphalan)、新氮芥(novembichin)、苯芥胆甾醇(phenesterine)、泼尼莫司汀(prednimustine)、曲磷胺(trofosfamide)、尿嘧啶氮芥(uracil mustard);亚硝脲类(nitrosoureas),诸如卡莫司汀(carmustine)、氯脲菌素(chlorozotocin)、福莫司汀(fotemustine)、洛莫司汀(lomustine)、尼莫司汀(nimustine)、雷莫司汀(ranimustine);抗生素类,诸如阿克拉霉素(aclacinomycin)、放线菌素(actinomycin)、氨茴霉素(anthramycin)、偶氮丝氨酸(azaserine)、博来霉素(bleomycin)、放线菌素C(cactinomycin)、加利车霉素(calicheamicin)、carabicin、洋红霉素(carminomycin)、嗜癌霉素(carzinophilin)、色霉素(chromomycin)、放线菌素D(dactinomycin)、柔红霉素(daunorubicin)、地托比星(detorubicin)、6-二氮-5-氧-L-正亮氨酸、多柔比星(doxorubicin)、表柔比星(epirubicin)、依索比星(esorubicin)、伊达比星(idarubicin)、麻西罗霉素(marcellomycin)、丝裂霉素类(mitomycins)、霉酚酸(mycophenolic acid)、诺拉霉素(nogalamycin)、橄榄霉素(olivomycin)、培洛霉素(peplomycin)、泊非霉素(potfiromycin)、嘌呤霉素(puromycin)、三铁阿霉素(quelamycin)、罗多比星(rodorubicin)、链黑菌素(streptonigrin)、链佐星(streptozocin)、杀结核菌素(tubercidin)、乌苯美司(ubenimex)、净司他丁(zinostatin)、佐柔比星(zorubicin);抗代谢物类,诸如甲氨蝶呤、和5-氟尿嘧啶(5-FU);叶酸类似物,诸如二甲叶酸(denopterin)、甲氨蝶呤、蝶酰三谷氨酸(pteropterin)、三甲曲沙(trimetrexate);嘌呤类似物,诸如氟达拉滨(fludarabine)、6-巯基嘌呤(mercaptopurine)、硫咪嘌呤(thiamiprine)、硫鸟嘌呤(thioguanine);嘧啶类似物,诸如安西他滨(ancitabine)、阿扎胞苷(azacitidine)、6-氮尿苷、卡莫氟(carmofur)、阿糖胞苷(cytarabine)、双脱氧尿苷(dideoxyuridine)、去氧氟尿苷(doxifluridine)、依诺他滨(enocitabine)、氟尿苷(floxuridine)、5-FU;雄激素类,诸如卡鲁睾酮(calusterone)、丙酸屈他雄酮(dromostanolone propionate)、表硫雄醇(epitiostanol)、美雄烷(mepitiostane)、睾内酯(testolactone);抗肾上腺类,诸如氨鲁米特(aminoglutethimide)、米托坦(mitotane)、曲洛司坦(trilostane);叶酸补充剂,诸如亚叶酸(folinic acid);醋葡醛内酯(aceglatone);醛磷酰胺糖苷(aldophosphamideglycoside);氨基乙酰丙酸(aminolevulinic acid);安吖啶(amsacrine);曲布赛(bestrabucil);比生群(bisantrene);依达曲沙(edatraxate);地磷酰胺(defosfamide);地美可辛(demecolcine);地吖醌(diaziquone);elfornithine;依利醋铵(elliptiniumacetate);依托格鲁(etoglucid);硝酸镓;羟脲(hydroxyurea);香菇多糖(lentinan);氯尼达明(lonidamine);米托胍腙(mitoguazone);米托蒽醌(mitoxantrone);莫哌达醇(mopidamol);二胺硝吖啶(nitracrine);鬼臼酸(podophyllinic acid);蛋氨氮芥(phenamet);吡柔比星(pirarubicin);洛索蒽醌(losoxantrone);2-乙基酰肼(ethylhydrazide);丙卡巴肼(procarbazine);雷佐生(razoxane);西索菲兰(sizofiran);螺旋锗(spirogermanium);细交链孢菌酮酸(tenuazonic acid);三亚胺醌(triaziquone);2,2′,2″-三氯三乙胺;乌拉坦(urethan);长春地辛(vindesine);达卡巴嗪(dacarbazine);甘露醇氮芥(mannomustine);二溴甘露醇(mitobronitol);二溴卫矛醇(mitolactol);哌泊溴烷(pipobroman);加西托辛(gacytosine);阿糖胞苷(arabinoside)(“Ara-C”);环磷酰胺;塞替派(thiotepa);类紫杉醇(taxoids),例如帕利他塞(paclitaxel)(TAXOLTM,Bristol-Myers Squibb)和多西他塞(doxetaxel)(Rhone-Poulenc Rorer);苯丁酸氮芥(chlorambucil);吉西他滨;6-硫鸟嘌呤(thioguanine);巯基嘌呤(mercaptopurine);甲氨蝶呤(methotrexate);铂类似物,诸如顺铂(cisplatin)和卡铂(carboplatin);长春碱(vinblastine);铂;依托泊苷(etoposide)(VP-16);异环磷酰胺(ifosfamide);丝裂霉素C;米托蒽醌(mitoxantrone);长春新碱;长春瑞滨;诺维本(navelbine);能灭瘤(novantrone);替尼泊苷(teniposide);道诺霉素(daunomycin);氨基蝶呤(aminopterin);xeloda;伊本膦酸盐(ibandronate);CPT-11;拓扑异构酶抑制剂RFS2000;二氟甲基鸟氨酸(DMFO);维A酸(retinoic acid)衍生物,如TargretinTM(贝沙罗汀(bexarotene))、PanretinTM、(阿利维A酸(alitretinoin));ONTAKTM(denileukindiftitox);埃斯培拉霉素(esperamicin);卡培他滨(capecitabine);和上述任何物质的药学上可接受的盐、酸或衍生物。在一些实施方案中,可以与抗激素剂联合施用包含CAR和/或TCR表达性免疫效应细胞的组合物,所述抗激素剂作用为调节或抑制激素对肿瘤的作用,诸如抗雌激素,包括例如他莫昔芬(tamoxifen)、雷洛昔芬(raloxifene)、芳香酶抑制性4(5)-咪唑、4-羟基他莫昔芬、曲沃昔芬(trioxifene)、奇沃昔芬(keoxifene)、LY117018、奥那司酮(onapristone)和托瑞米芬(toremifene)(Fareston);和抗雄激素诸如氟他胺(flutamide)、尼鲁米特(nilutamide)、比卡鲁胺(bicalutamide)、亮丙瑞林(leuprolide)、和戈舍瑞林(goserelin);和上述任何物质的药学上可接受的盐、酸或衍生物。在适当的情况下也施用化疗剂的组合,包括但不限于CHOP,即环磷酰胺多柔比星(羟基多柔比星)、长春新碱和泼尼松。
在一些实施方案中,在施用工程化细胞或核酸同时或之后一周内施用化疗剂。在其他实施方案中,在施用工程化细胞或核酸后1至4周或1周至1个月,1周至2个月,1周至3个月,1周至6个月,1周至9个月或1周至12个月施用化疗剂。在一些实施方案中,在施用细胞或核酸之前至少1个月施用化疗剂。在一些实施方案中,该方法还包含施用两种或更多种化疗剂。
多种另外的治疗剂可以与本文所述的组合物联合使用。例如,潜在有用的另外的治疗剂包括PD-1抑制剂,例如纳武单抗(nivolumab)派姆单抗(pembrolizumab)派姆单抗、阿巴伏单抗(pidilizumab)(CureTech)和阿特珠单抗(Atezolizumab)(Roche)。
适合于与本发明组合使用的另外的治疗剂包括但不限于伊布替尼(ibrutinib)奥法木单抗(ofatumumab)利妥昔单抗(rituximab)贝伐单抗(bevacizumab)曲妥珠单抗(trastuzumab)trastuzumab emtansine伊马替尼(imatinib)西妥昔单抗(cetuximab)帕尼单抗(panitumumab)卡妥索单抗(Catumaxomab)、替伊莫单抗(ibritumomab)、奥法木单抗、托西莫单抗(tositumomab)、本妥昔单抗(brentuximab)、阿仑单抗(alemtuzumab)、吉妥珠单抗(gemtuzumab)、厄洛替尼(erlotinib)、吉非替尼(gefitinib)、凡德他尼(vandetanib)、阿法替尼afatinib)、拉帕替尼(lapatinib)、来那替尼(neratinib)、阿昔替尼(axitinib)、马赛替尼(masitinib)、帕唑帕尼(pazopanib)、舒尼替尼(sunitinib)、索拉非尼(sorafenib)、toceranib、来他替尼(lestaurtinib)、阿昔替尼(axitinib)、西地尼布(cediranib)、乐伐替尼(lenvatinib)、尼达尼布(nintedanib)、帕唑帕尼(pazopanib)、瑞格非尼(regorafenib)、司马沙尼(semaxanib)、索拉非尼(sorafenib)、舒尼替尼(sunitinib)、替瓦沙尼(tivozanib)、托西雷尼(toceranib)、凡德他尼、恩曲替尼(entrectinib)、卡博替尼(cabozantinib)、伊马替尼(imatinib)、达沙替尼(dasatinib)、尼洛替尼(nilotinib)、帕纳替尼(ponatinib)、雷多替尼(radotinib)、博舒替尼(bosutinib)、来他替尼(lestaurtinib)、鲁索替尼(ruxolitinib)、帕利替尼(pacritinib)、考比替尼(cobimetinib)、司美替尼(selumetinib)、曲美替尼(trametinib)、必尼美替尼(binimetinib)、阿雷替尼(alectinib)、色瑞替尼(ceritinib)、克唑替尼(crizotinib)、阿柏西普(aflibercept)、阿迪波太(adipotide)、地尼白介素(denileukindiftitox)、mTOR抑制剂诸如依维莫司(Everolimus)和西罗莫司(Temsirolimus)、hedgehog抑制剂诸如索尼得吉(sonidegib)和维莫得告(vismodegib)、CDK抑制剂诸如CDK抑制剂(帕博西尼(palbociclib))。
在另外的实施方案中,与消炎剂一起施用包含含有CAR和/或TCR的免疫细胞的组合物。消炎剂或药物可以包括但不限于类固醇和糖皮质激素(包括倍他米松(betamethasone)、布地奈德(budesonide)、地塞米松(dexamethasone)、乙酸氢化可的松、氢化可的松、氢化可的松、甲泼尼龙(methylprednisolone)、泼尼松龙(prednisolone)、泼尼松(prednisone)、曲安西龙(triamcinolone))、非类固醇类消炎药(NSAIDS),包括阿司匹林(aspirin)、布洛芬(ibuprofen)、萘普生(naproxen)、甲氨蝶呤、柳氮磺胺吡啶、来氟米特(leflunomide)、抗TNF药物、环磷酰胺和麦考酚酯(mycophenolate)。例示性的NSAID包括布洛芬、萘普生、萘普生钠、Cox-2抑制剂和唾液酸化物(sialylate)。例示性镇痛剂包括扑热息痛(acetaminophen)、羟考酮(oxycodone)、曲马多或盐酸丙氧芬(tramadol ofproporxyphene hydrochloride)。例示性糖皮质激素包括可的松、地塞米松、氢化可的松、甲泼尼龙、泼尼松龙或泼尼松。例示性生物反应调节剂包括针对细胞表面标志物(例如CD4,CD5等)的分子、细胞因子抑制剂如TNF拮抗剂,(例如依那西普(etanercept)阿达木单抗(adalimumab)和英夫利昔单抗(infliximab)生物反应调节剂包括单克隆抗体以及重组形式的分子。例示性的DMARD包括硫唑嘌呤(azathioprine)、环磷酰胺、环孢菌素、甲氨蝶呤、青霉胺、来氟米特、柳氮磺胺吡啶、羟氯喹、Gold(口服(金诺芬(auranofin))和肌内)和米诺环素(minocycline)。
在某些实施方案中,与细胞因子联合施用本文所述的组合物。如本文所用,“细胞因子”意指由一种细胞群释放的、作为细胞间介质对另一种细胞起作用的蛋白质。细胞因子的实例是淋巴因子、单核因子和传统的多肽激素。细胞因子中包括生长激素,如人生长激素,N-甲硫氨酰人生长激素和牛生长激素;甲状旁腺激素;甲状腺素;胰岛素;胰岛素原;松弛素;松弛素原;糖蛋白激素,如促卵泡激素(FSH)、促甲状腺激素(TSH)和黄体生成素(LH);肝生长因子(HGF);成纤维细胞生长因子(FGF);催乳素;胎盘催乳激素;缪勒管抑制物质(mullerian-inhibiting substance);小鼠促性腺激素相关肽;抑制素;激活素;血管内皮生长因子;整合素;血小板生成素(TPO);神经生长因子(NGF)如NGF-beta;血小板生长因子;转化生长因子(TGF)如TGF-alpha和TGF-beta;胰岛素样生长因子-I和-II;促红细胞生成素(EPO);骨诱导因子;干扰素如干扰素-alpha,beta和-gamma;集落刺激因子(CSF),如巨噬细胞-CSF(M-CSF);粒细胞-巨噬细胞-CSF(GM-CSF);和粒细胞-CSF(G-CSF);白细胞介素(IL),如IL-1、IL-1α、IL-2、IL-3、IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL-10、IL-11、IL-12;IL-15,肿瘤坏死因子如TNF-alpha或TNF-beta;和其他多肽因子,包括LIF和kit配体(KL)。如本文所用,术语细胞因子包括来自天然来源或来自重组细胞培养物的蛋白质,以及天然序列细胞因子的生物活性等同物。
本说明书中所提及的所有出版物、专利及专利申请以引用方式并入本文,其程度如同个别出版物、专利或专利申请各自被具体且单独地指明以引用方式并入本发明中。然而,本文的参考文献的引用不应被解释为承认该参考文献为本发明的现有技术。任何以引用方式被并入的参考文献中所提供的任何定义或术语与本文所提供的术语和讨论不同时,以本发明的术语和定义为准。
实施例
实施例1
通过用EcoRI和BamHI(NEB)过夜消化10μg DNA,使编码T7启动子、CAR构建体和beta珠蛋白稳定序列的质粒线性化。然后将DNA用蛋白酶K(Thermo Fisher,600U/ml)于50℃消化2小时,用苯酚/氯仿纯化,并通过添加乙酸钠和两倍体积的乙醇沉淀。然后将沉淀干燥,重悬于不含RNA酶/DNA酶的水中并使用NanoDrop定量。然后按照制造商的说明使用mMESSAGE mMACHINE T7Ultra(Thermo Fisher)将1μg的线性DNA用于体外转录。进一步按照制造商的说明使用MEGAClear Kit(Thermo Fisher)纯化RNA并使用NanoDrop定量。使用琼脂糖凝胶上的迁移率评估mRNA完整性。根据制造商的说明书,使用ficoll-paque密度离心从健康的供体leukopak(Hemacare)中分离PBMC。使用在R10培养基中的OKT3(50ng/ml,Miltenyi Biotec)+IL-2(300IU/ml, Therapeutics和Diagnostics)刺激PBMC。刺激后7天,将T细胞在Opti-MEM培养基(Thermo FisherScientific)中清洗两次,并在Opti-MEM培养基中以2.5x107个细胞/ml的终浓度重悬。每次电穿孔使用10μg mRNA。使用Gemini X2系统(Harvard Apparatus BTX)实施细胞的电穿孔,在2mm比色皿(Harvard Apparatus BTX)中递送单个400V脉冲0.5ms。立即将细胞转移到R10+IL-2培养基中并使其恢复6小时。为了检测CAR表达,将T细胞用染色缓冲液(BDPharmingen)中的FLT-=3-HIS(Sino Biological Inc.)或生物素化的蛋白质L(ThermoScientific)于4℃染色30分钟。然后清洗细胞并用染色缓冲液中的抗HIS-PE(MiltenyiBiotec)或PE链霉抗生物素蛋白(BD Pharmingen)于4℃染色30分钟。然后清洗细胞并在数据采集之前将其重悬于含有碘化丙啶(BD Pharmingen)的染色缓冲液中。在经电穿孔的T细胞中FLT3CAR的表达显示于图3中。
用编码抗FLT3 CAR的质粒电穿孔T细胞,所述FLT3 CAR包含10E3、2E7、8B5、4E9或11F11抗FLT3结合分子以及选自全长铰链结构域(完整铰链结构域或“CHD”)或截短铰链结构域(“THD”)的铰链结构域。然后将经电穿孔的抗FLT3CAR T细胞与Namalwa(FLT3阴性)、EoL1(FLT3阳性)、HL60(FLT3阳性)或MV4;11(FLT3阳性)靶细胞以1∶1 E∶T比率在R10培养基中共培养。共培养后16小时,通过Lumihex(EMD Millipore)分析来自Namalwa(图4A-4F)、EoL1(图4G-4L)、HL60(图4M-4R)和MV4;11(图4S-4X)的上清液的IFNγ(图4A、4B、4G、4H、4M、4N、4S和4T)、IL-2(图4C、4D、4I、4J、4O、4P、4U和4V)和TNFα(图4E、4F、4K、4L、4Q、4R、4W和4X)的产量。
通过CD3阴性细胞的碘化丙啶(PI)摄取的流式细胞术分析来评估靶细胞生存力。共培养后16小时,将经电穿孔的抗FLT3CART细胞与Namalwa(图5A-5B)、EoL1(图5C-5D)、HL60(图5E-5F)和MV4;11(图5G-5H)靶细胞共培养。
实施例2
将含有不同的CAR构建体的第三代慢病毒转移载体连同ViraPower慢病毒包装混合物(Life Technologies)一起使用以生成该慢病毒上清液。简言之,通过将15μg的DNA和22.5μl的聚乙烯亚胺(polyethileneimine)(Polysciences,1mg/ml)在600μl的OptiMEM培养基中混合以生成转染混合物。将混合物于室温温育5分钟。同时,以胰蛋白酶处理293T细胞(ATCC),计数,并将总计10x106个细胞与转染混合物一起铺在T75烧瓶中。转染三天后,收集上清液并通过0.45μm过滤器过滤,再储存于-80℃直至使用。根据制造商的说明,使用ficoll-paque密度离心从健康的供体leukopak(Hemacare)分离PBMC。使用在R10培养基中的OKT3(50ng/ml,Miltenyi Biotec)+IL-2(300IU/ml, Therapeutics and Diagnostics)刺激PBMC。刺激后48小时,使用慢病毒以MOI=10转导细胞。在用于活性测定中之前将细胞维持在0.5-2.0x 106个细胞/ml。为了检测CAR表达,将T细胞用染色缓冲液(BD Pharmingen)中的FLT-3-HIS(Sino BiologicalInc.)或生物素化的蛋白质L(Thermo Scientific)于4℃染色30分钟。然后清洗细胞并用染色缓冲液中的抗HIS-PE(Miltenyi Biotec)或PE链霉抗生物素蛋白(BD Pharmingen)于4℃染色30分钟。然后清洗细胞并在数据采集之前将其重悬于含有碘化丙啶(BD Pharmingen)的染色缓冲液中。在来自两个健康供体的T细胞中FLT3CAR的表达显示于图6A-6B中。
用编码抗FLT3CART细胞的慢病毒转导来自两个健康供体的T细胞,所述FLT3CAR包含10E3、8B5或11F11结合分子以及选自完整铰链结构域(“CHD”)、截短铰链结构域(“THD”)和CD8铰链结构域的铰链结构域。将经转导的T细胞与靶细胞以1∶1 E∶T比率在R10培养基中共培养。共培养后16小时,通过Luminex(EMD Millipore)分析上清液的IFNγ(图7A-7B)、TNFα(图7C-7D)和IL-2(图7E-7F)的产生。
通过CD3阴性细胞的碘化丙啶(PI)摄取的流式细胞术分析来评估靶细胞生存力。测量与Namalwa(图8A)、EoL1(图8B)、MV4;11(图8C)和HL60(图8D)靶细胞共培养的经慢病毒转导的CART细胞(来自两个健康供体)的平均细胞溶解活性。
为了评估响应表达FLT3的靶细胞的CART细胞增殖,在与靶细胞以1∶1 E∶T比率在R10培养基中共培养前用CFSE标记T细胞。五天后,通过CFSE稀释的流式细胞术分析来评估T细胞增殖。FLT3 CAR T细胞的增殖显示于图9A-9B中。
实施例3
为了检测体内抗白血病活性,生成FLT3 CART细胞以用于人AML的异种模型。用于人AML的异种模型的各种效应系的CAR表达显示于图10A-10D中。将荧光素酶标记的MV4;11细胞(2x 106个细胞/动物)静脉内注射到5至6周龄的雌性NSG小鼠中。6天后,静脉内注射200μl PBS中的6x 106个T细胞(~50%CAR+),使用生物发光成像每周测量动物的肿瘤负荷(图10E-10G)。通过注射对照(模拟品)或表达10E3-CHD(图10H)、10E3-THD(图10I)或8B5-THD(图10J)的CART细胞实施存活分析。
实施例4
用编码抗CLL-1 CAR构建体24C8_HL-CHD CAR(包含共刺激蛋白质的完整铰链结构域)和24C8_HL-THD CAR(包含共刺激蛋白质的截短铰链结构域)的质粒电穿孔T细胞。经电穿孔的T细胞的抗CLL-1表达显示于图11A-11D。然后在mRNA电穿孔6小时后将抗CLL-1 CART细胞与靶Namalwa(ATCC;CLL-1阴性)、U937(ATCC;CLL-1阳性)、HL-60(ATCC;CLL-1阳性)、EoL-1(Sigma;CLL-1阳性)、KG1a(ATCC;CLL-1阳性)和MV4;11(ATCC;CLL-1阳性)细胞以1∶1E∶T比率在R10培养基中培养。共培养后16小时,根据制造商的说明,通过Luminex(EMDMillipore)分析上清液的IL-2(图12A)、IFNγ(图12B)和TNFα(图12C)的产量。
通过碘化丙啶(PI)摄取的流式细胞术分析来评估靶细胞生存力。将经电穿孔的抗CLL-1 CAR T细胞与Namalwa(图13A)、MV4;11(图13B)、EoL-1(图13C)、HL-60(图13D)或U937(图13E)靶细胞共培养16小时。正如所料,相对于对照,与抗CLL-1 CART细胞共培养的Namalwa细胞显示靶细胞生存力几乎没有变化(图13A)。然而,相对于对照,在与24C8_HL-CHD和24C8_HL-THDT细胞共培养的MV;411细胞中观察到增加的细胞溶解活性,其中在24C8_HL-THDT细胞共培养中观察到更大的靶细胞细胞溶解活性(图13B)。此外,相对于对照,在与24C8_HL-CHD和24C8_HL-THDT细胞共培养的EoL-1细胞中观察到增加的细胞溶解活性(图13C)。相对于对照,在与24C8_HL-CHD和24C8_HL-THDT细胞共培养的HL-60细胞中观察到增加的细胞溶解活性(图13D)。相对于对照,在与24C8_HL-CHD和24C8_HL-THD T细胞共培养的U937细胞中观察到增加的细胞溶解活性,其中在24C8_HL-THDT细胞共培养中观察到更大的靶细胞细胞溶解活性(图13E)。
实施例5
在T细胞刺激12天后,将用包含抗CLL-1 CAR构建体(具有共刺激蛋白质的截短铰链结构域(“THD”),10E3_THD或24C1_LH_THD)的慢病毒载体转导的T细胞与Namalwa、U937、HL-60、EoL-1、KG1a和MV4;11靶细胞以1∶1 E∶T比率在R10培养基中共培养。共培养后16小时,根据制造商的说明,如图所示,通过Luminex(EMD Millipore)分析上清液的效应10E3_THD CAR T细胞和24C1_LH_THD CART细胞与靶Namalwa、HL-60或MVA;11细胞的共培养物中细胞因子IFNγ(图14A)、IL-2(图14B)和TNFα(图14C)的产生。
通过碘化丙啶(PI)摄取的流式细胞术分析来评估靶细胞生存力。将经转导的效应24C1_LH_THD CART细胞与Namalwa、U937、HL-60、EoL-1、KG1a或MV4;11靶细胞共培养16小时或40小时。与模拟品对照相比,Namalwa靶细胞与经转导的C1_24C1_LH_THD CART细胞的共培养物在16小时和40小时对活的Namalwa靶细胞的百分比没有影响(图15A)。然而,与模拟品对照相比,与MV4;11(图15B)或HL-60(图15C)靶细胞共培养的C1_24C1_LH_THD CART细胞在16小时和40小时两者都导致较低百分比的活的靶细胞。
实施例6
在T细胞刺激12天后,将用包含共刺激蛋白质的截短铰链结构域(“THD”)的抗BCMACAR构建体转导的CART细胞与靶细胞以1∶1效应细胞比靶细胞(E∶T)的比率在R10培养基中培养。经测试的细胞系包括EoL-1(Sigma;BCMA阴性)、NCI-H929(Molecular Imaging;BCMA阳性)和MM1S(Molecular Imaging;BCMA阳性)。共培养后16小时,根据制造商的说明,通过Luminex(EMD Millipore)分析上清液的细胞因子IFNγ(图16A-16B)、TNFα(图16C-16D)和IL-2(图16E-16F)的产生。对于在两个供体(图16A-16B)中测试的每种抗BCMA CART细胞,在NCI-H929和MM1S靶细胞共培养物的上清液中观察到IFNγ(图16A-16B)、TNFα(图16C-16D)和IL-2(图16E-16F);然而,对于IR阴性对照T细胞(图16A),仅在EoL-1靶细胞共培养物的上清液中观察到高于背景的IFNγ(图16A-16B)、TNFα(图16C-16D)和IL-2(图16E-16F)。
通过CD3阴性细胞的碘化丙啶(PI)摄取的流式细胞术分析来评估靶细胞生存力。将抗BCMA CART细胞与EoL1(图17A-17B)、NCI-H929(图17C-17D)或MM1S(图17E-17F)靶细胞共培养16小时、40小时、64小时、88小时或112小时。在抗BCMA CART细胞的任何时间段,在EoL-1共培养物中观察到很少的细胞溶解活性(图17A-17B)。然而,抗BCMA CART细胞与NCI-H929或MM1S靶细胞的共培养导致对于每种抗BCMA CART细胞测量的每个时间点的活的靶细胞的百分比降低。
为了检测增殖,在与EoL-1、NCI-H929或MM1S靶细胞以1∶1 E∶T比率在R10培养基中共培养之前,用羧基荧光素琥珀酰亚胺酯(CFSE)标记抗BCMA CART细胞。五天后,通过CFSE稀释的流式细胞术分析来评估T细胞增殖(图18A-18B)。
实施例7
增强的稳定性是蛋白质的期望性质。这通常通过在各种条件下测定蛋白质的解链温度来评估。具有较高解链温度的蛋白质通常稳定较长时间。当CAR具有更高的热稳定性时,其可以在细胞的表面上较长时间地具有功能活性。
使用Bio-Rad C1000热循环仪,CFx96实时系统测量具有较长铰链结构域,即完整铰链结构域(“CHD”)的CAR细胞外结构域(ECD)的热稳定性和具有截短铰链结构域(“THD”)的CAR ECD的热稳定性。使用荧光染料SYPRO Orange(Invitrogen)监测蛋白质的解折叠,该荧光染料与疏水氨基酸结合,随着蛋白质解折叠,疏水氨基酸变为溶剂暴露。设定温度梯度为25℃至95℃,增量为1℃/1分钟。每个样品含有10μM重组CAR ECD蛋白质和5X SYPROOrange(Molecular ProbesTM SYPROTM Orange蛋白质凝胶染色(DMSO中5,000X浓缩液))。在含有或不含有50mM NaCl的PBS中实施测定。
如图19A和图19B中所示,具有THD的CAR的ECD与具有CHD(例如包括IEVMYPPPY(SEQID NO:250)基序)的CAR的ECD相比,显示增强的热稳定性。在该实施例中描述的这些方法是用于测试编码CAR的mRNA和CAR本身的稳定性的有用方法,因为一旦用编码CAR的mRNA转导T细胞,经转导的T细胞将表达CAR而单个mRNA或蛋白质的稳定性将不易评估。
序列表
<110> 凯德药业股份有限公司
<120> 嵌合抗原和T细胞受体及使用的方法
<130> K-1031.02
<150> US 62/317,258
<151> 2016-04-01
<160> 251
<170> PatentIn version 3.5
<210> 1
<211> 220
<212> PRT
<213> 人
<400> 1
Met Leu Arg Leu Leu Leu Ala Leu Asn Leu Phe Pro Ser Ile Gln Val
1 5 10 15
Thr Gly Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr
20 25 30
Asp Asn Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser
35 40 45
Arg Glu Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu
50 55 60
Val Cys Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser
65 70 75 80
Lys Thr Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr
85 90 95
Phe Tyr Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys
100 105 110
Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser
115 120 125
Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
130 135 140
Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
145 150 155 160
Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
165 170 175
Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
180 185 190
Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
195 200 205
Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser
210 215 220
<210> 2
<211> 90
<212> DNA
<213> 人工序列
<220>
<223> 铰链结构域
<400> 2
cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60
tcacccttgt tccctggtcc atccaagcca 90
<210> 3
<211> 30
<212> PRT
<213> 人工序列
<220>
<223> 铰链结构域
<400> 3
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
1 5 10 15
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro
20 25 30
<210> 4
<211> 81
<212> DNA
<213> 人工序列
<220>
<223> TM结构域
<400> 4
ttctgggtgt tggtcgtagt gggtggagtc ctcgcttgtt actctctgct cgtcaccgtg 60
gcttttataa tcttctgggt t 81
<210> 5
<211> 27
<212> PRT
<213> 人工序列
<220>
<223> TM结构域
<400> 5
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
1 5 10 15
Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
20 25
<210> 6
<211> 123
<212> DNA
<213> 人工序列
<220>
<223> 信号传导/共刺激结构域
<400> 6
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 60
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 120
agc 123
<210> 7
<211> 41
<212> PRT
<213> 人工序列
<220>
<223> 信号传导/共刺激结构域
<400> 7
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40
<210> 8
<211> 336
<212> DNA
<213> 人工序列
<220>
<223> CD3z活化结构域
<400> 8
agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg 60
tataacgagc tcaacctggg acgcagggaa gagtatgacg ttttggacaa gcgcagagga 120
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat 180
gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg 240
agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact 300
tatgacgctc tccacatgca agccctgcca cctagg 336
<210> 9
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> CD3z活化结构域
<400> 9
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 10
<211> 63
<212> DNA
<213> 人工序列
<220>
<223> 信号(前导)肽
<400> 10
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccg 63
<210> 11
<211> 21
<212> PRT
<213> 人工序列
<220>
<223> 信号(前导)肽
<400> 11
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro
20
<210> 12
<211> 18
<212> PRT
<213> 人工序列
<220>
<223> 接头
<400> 12
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
1 5 10 15
Lys Gly
<210> 13
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 13
Gly Phe Thr Phe Ser Ser Tyr
1 5
<210> 14
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 14
Phe Thr Phe Ser Ser Tyr
1 5
<210> 15
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 15
Gly Tyr Thr Phe Thr Ser Tyr
1 5
<210> 16
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 16
Gly Gly Ser Ile Ser Ser Ser Ser Tyr
1 5
<210> 17
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 17
Gly Phe Thr Phe Ser Ser Tyr
1 5
<210> 18
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 18
Gly Phe Thr Phe Ser Ser Tyr Gly Met His
1 5 10
<210> 19
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 19
Gly Gly Thr Phe Ser Ser Tyr
1 5
<210> 20
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 20
Gly Phe Thr Phe Ser Ser Tyr
1 5
<210> 21
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 21
Ser Gly Ser Gly Gly Ser
1 5
<210> 22
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 22
Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 23
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 23
Asn Pro Gly Gly Gly Ser
1 5
<210> 24
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 24
Ser Tyr Ser Gly Ser
1 5
<210> 25
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 25
Ser Ser Ser Ser Ser Thr
1 5
<210> 26
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 26
Ser Tyr Asp Gly Ser Asn
1 5
<210> 27
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 27
Ile Pro Ile Phe Gly Thr
1 5
<210> 28
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 28
Ser Tyr Asp Gly Ser Asn
1 5
<210> 29
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 29
Ala Glu Met Gly Ala Val Phe Asp Ile
1 5
<210> 30
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 30
Asp Gly Thr Tyr Leu Gly Gly Leu Trp Tyr Phe Asp Leu
1 5 10
<210> 31
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 31
Glu Ser Trp Pro Met Asp Val
1 5
<210> 32
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 32
Gly Arg Gly Tyr Ala Thr Ser Leu Ala Phe Asp Ile
1 5 10
<210> 33
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 33
Gly Ser Gln Glu His Leu Ile Phe Asp Tyr
1 5 10
<210> 34
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 34
Thr Asp Phe Trp Ser Gly Ser Pro Pro Gly Leu Asp Tyr
1 5 10
<210> 35
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 35
Thr Pro Glu Tyr Ser Ser Ser Ile Trp His Tyr Tyr Tyr Gly Met Asp
1 5 10 15
Val
<210> 36
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 36
Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly Met Asp Val
1 5 10
<210> 37
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 37
Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala
1 5 10
<210> 38
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 38
Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp
1 5 10 15
<210> 39
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 39
Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10
<210> 40
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 40
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 41
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 41
Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala
1 5 10
<210> 42
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 42
Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala
1 5 10
<210> 43
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 43
Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu
1 5 10 15
Ala
<210> 44
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 44
Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10
<210> 45
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 45
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 46
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 46
Leu Gly Ser Asn Arg Ala Ser
1 5
<210> 47
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 47
Gly Ala Ser Thr Arg Ala Thr
1 5
<210> 48
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 48
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 49
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 49
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 50
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 50
Gly Ala Ser Ser Leu Gln Ser
1 5
<210> 51
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 51
Trp Ala Ser Thr Arg Glu Ser
1 5
<210> 52
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 52
Ser Ala Ser Thr Arg Ala Thr
1 5
<210> 53
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 53
Gln Gln Arg Ile Ser Trp Pro Phe Thr
1 5
<210> 54
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 54
Met Gln Gly Leu Gly Leu Pro Leu Thr
1 5
<210> 55
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 55
Gln Gln Tyr Ala Ala Tyr Pro Thr
1 5
<210> 56
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 56
Gln Gln Arg His Val Trp Pro Pro Thr
1 5
<210> 57
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 57
Gln Gln Arg Phe Tyr Tyr Pro Trp Thr
1 5
<210> 58
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 58
Gln Gln Ile Tyr Thr Phe Pro Phe Thr
1 5
<210> 59
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 59
Gln Gln Phe Ala His Thr Pro Phe Thr
1 5
<210> 60
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 60
Gln Gln His His Val Trp Pro Leu Thr
1 5
<210> 61
<211> 354
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 61
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggcggtgt actactgcgc aagagccgag 300
atgggagccg tattcgacat atggggtcag ggtacaatgg tcaccgtctc ctca 354
<210> 62
<211> 366
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 62
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagtt atatcgtatg atggaagtaa taaatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggcggtgt actactgcgc cagagacggt 300
acttatctag gtggtctctg gtacttcgac ttatggggga gaggtacctt ggtcaccgtc 360
tcctca 366
<210> 63
<211> 348
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 63
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt 60
tcctgcaagg catctggata caccttcacc agctactata tgcactgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggaata atcaaccctg gtggtggtag cacaagctac 180
gcacagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac 240
atggagctga gcagcctgag atctgaggac acggcggtgt actactgcgc cagagagagt 300
tggccaatgg acgtatgggg ccagggaaca actgtcaccg tctcctca 348
<210> 64
<211> 366
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 64
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc agtagtagtt actactgggg ctggatccgc 120
cagcccccag ggaaggggct ggagtggatt gggagtatct cctatagtgg gagcacctac 180
tacaacccgt ccctcaagag tcgagtcacc atatccgtag acacgtccaa gaaccagttc 240
tccctgaagc tgagttctgt gaccgccgca gacacggcgg tgtactactg cgccagaggc 300
aggggatatg caaccagctt agccttcgat atctggggtc agggtacaat ggtcaccgtc 360
tcctca 366
<210> 65
<211> 357
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 65
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatagca tgaactgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtttcaacc attagtagta gtagtagtac catatactac 180
gcagactctg tgaagggccg attcaccatc tccagagaca atgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agctgaggac acggcggtgt actactgcgc cagaggttct 300
caggagcacc tgattttcga ttattgggga cagggtacat tggtcaccgt ctcctca 357
<210> 66
<211> 366
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 66
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagtt atatcgtatg atggaagtaa taaatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggcggtgt actactgcgc cagaactgac 300
ttctggagcg gatcccctcc aggcttagat tactggggac agggtacatt ggtcaccgtc 360
tcctca 366
<210> 67
<211> 378
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 67
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac 180
gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggcggtgt actactgcgc cagaactcct 300
gaatactcct ccagcatatg gcactattac tacggcatgg acgtatgggg ccagggaaca 360
actgtcaccg tctcctca 378
<210> 68
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 68
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagtt atatcgtatg atggaagtaa taaatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggcggtgt actactgcgt caaggggccg 300
ttgcaggagc cgccatacga ttatggaatg gacgtatggg gccagggaac aactgtcacc 360
gtctcctca 369
<210> 69
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 69
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc aggtacttag cctggtacca acagaaacct 120
ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc 180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct 240
gaagattttg cagtttatta ctgtcagcag agaatctcct ggcctttcac ttttggcgga 300
gggaccaagg ttgagatcaa a 321
<210> 70
<211> 336
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 70
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcagggact cggcctccct 300
ctcacttttg gcggagggac caaggttgag atcaaa 336
<210> 71
<211> 318
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 71
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tacgccgcct accctacttt tggcggaggg 300
accaaggttg agatcaaa 318
<210> 72
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 72
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agctacttag cctggtacca acagaaacct 120
ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc 180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct 240
gaagattttg cagtttatta ctgtcagcag agacacgtct ggcctcctac ttttggcgga 300
gggaccaagg ttgagatcaa a 321
<210> 73
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 73
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc aggtacttag cctggtacca acagaaacct 120
ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc 180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct 240
gaagattttg cagtttatta ctgtcagcag agattctact acccttggac ttttggcgga 300
gggaccaagg ttgagatcaa a 321
<210> 74
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 74
gacatccagt tgacccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc 60
atcacttgtc gggcgagtca gggtattagc agctggttag cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctatggt gcatccagtt tgcaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcagcag atatacacct tccctttcac ttttggcgga 300
gggaccaagg ttgagatcaa a 321
<210> 75
<211> 339
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 75
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcca gagtgtttta tacagctcca acaataagaa ctacttagct 120
tggtaccagc agaaaccagg acagcctcct aagctgctca tttactgggc atctacccgg 180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240
atcagcagcc tgcaggctga agatgtggca gtttattact gtcagcagtt cgcccacact 300
cctttcactt ttggcggagg gaccaaggtt gagatcaaa 339
<210> 76
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 76
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatagc gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag caccacgtct ggcctctcac ttttggcgga 300
gggaccaagg ttgagatcaa a 321
<210> 77
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> VH蛋白质
<400> 77
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Glu Met Gly Ala Val Phe Asp Ile Trp Gly Gln Gly Thr
100 105 110
Met Val Thr Val Ser Ser
115
<210> 78
<211> 122
<212> PRT
<213> 人工序列
<220>
<223> VH蛋白质
<400> 78
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Thr Tyr Leu Gly Gly Leu Trp Tyr Phe Asp Leu Trp
100 105 110
Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 79
<211> 116
<212> PRT
<213> 人工序列
<220>
<223> VH蛋白质
<400> 79
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Asn Pro Gly Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ser Trp Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val
100 105 110
Thr Val Ser Ser
115
<210> 80
<211> 122
<212> PRT
<213> 人工序列
<220>
<223> VH蛋白质
<400> 80
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Arg Gly Tyr Ala Thr Ser Leu Ala Phe Asp Ile Trp
100 105 110
Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120
<210> 81
<211> 119
<212> PRT
<213> 人工序列
<220>
<223> VH蛋白质
<400> 81
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Ser Gln Glu His Leu Ile Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 82
<211> 122
<212> PRT
<213> 人工序列
<220>
<223> VH蛋白质
<400> 82
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Thr Asp Phe Trp Ser Gly Ser Pro Pro Gly Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 83
<211> 126
<212> PRT
<213> 人工序列
<220>
<223> VH蛋白质
<400> 83
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Thr Pro Glu Tyr Ser Ser Ser Ile Trp His Tyr Tyr Tyr Gly
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 84
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> VH蛋白质
<400> 84
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 85
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> VL蛋白质
<400> 85
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ile Ser Trp Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 86
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> VL蛋白质
<400> 86
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Leu Gly Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 87
<211> 106
<212> PRT
<213> 人工序列
<220>
<223> VL蛋白质
<400> 87
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ala Ala Tyr Pro Thr
85 90 95
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 88
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> VL蛋白质
<400> 88
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg His Val Trp Pro Pro
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 89
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> VL蛋白质
<400> 89
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Phe Tyr Tyr Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 90
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> VL蛋白质
<400> 90
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile Tyr Thr Phe Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 91
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> VL蛋白质
<400> 91
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
20 25 30
Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Phe Ala His Thr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
100 105 110
Lys
<210> 92
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> VL蛋白质
<400> 92
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His His Val Trp Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 93
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 93
Gly Gly Ser Ile Ser Ser Tyr
1 5
<210> 94
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 94
Gly Gly Ser Ile Ser Ser Gly Gly Phe
1 5
<210> 95
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 95
Gly Tyr Thr Leu Thr Glu Leu
1 5
<210> 96
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VH CDR1
<400> 96
Gly Phe Thr Phe Ser Ser Tyr
1 5
<210> 97
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 97
Tyr Tyr Ser Gly Ser
1 5
<210> 98
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 98
His His Ser Gly Ser
1 5
<210> 99
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 99
Asp Pro Glu Asp Gly Glu
1 5
<210> 100
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VH CDR2
<400> 100
Ser Tyr Asp Gly Ser Asp
1 5
<210> 101
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 101
Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr
1 5 10
<210> 102
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 102
Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr
1 5 10
<210> 103
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 103
Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr
1 5 10
<210> 104
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> VH CDR3
<400> 104
Glu Arg Tyr Ser Gly Arg Asp Tyr
1 5
<210> 105
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 105
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
1 5 10
<210> 106
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 106
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
1 5 10
<210> 107
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 107
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 108
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VL CDR1
<400> 108
Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr
1 5 10
<210> 109
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 109
Asp Ala Ser Asn Leu Glu Thr
1 5
<210> 110
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 110
Asp Ala Ser Asn Leu Glu Thr
1 5
<210> 111
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 111
Gly Ala Ser Ser Leu Lys Ser
1 5
<210> 112
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VL CDR2
<400> 112
Gly Ala Ser Thr Arg Ala Thr
1 5
<210> 113
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 113
Gln Gln Tyr Gly Asn Leu Pro Phe Thr
1 5
<210> 114
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 114
Gln Gln Tyr Gly Asn Leu Pro Phe Thr
1 5
<210> 115
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 115
Gln Gln Ser Tyr Ser Thr Pro Ile Thr
1 5
<210> 116
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VL CDR3
<400> 116
Gln Gln Tyr Asp Thr Trp Pro Phe Thr
1 5
<210> 117
<211> 366
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 117
caggtgcagc tgcaggaatc cggaccgggg ctggtgaagc ccagcgagac tctgagtctc 60
acgtgtacag tttctggagg tagcattagc tcctactatt ggtcatggat aaggcagccc 120
cccgggaagg gattggaatg gatcggctat atttactaca gtgggagcac caattacaac 180
ccctcactga agtctagagt tacaatcagc gttgacacct caaagaatca gttcagtttg 240
aaattgtcta gcgtcacagc agctgataca gccgtctatt attgtgtttc tctggtctat 300
tgcggtgggg attgttacag tggctttgac tattgggggc agggtactct ggttacagtt 360
tcttcc 366
<210> 118
<211> 372
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 118
caggtacagc tgcaggaatc tgggcccgga cttgtcaagc caagtcagac actttctctt 60
acatgtaccg tgagcggcgg aagtataagc agtggaggct tttactggtc ttggatacgg 120
cagcacccag gcaaaggctt ggagtggatt ggatacattc atcattcagg atctacacac 180
tataatccat cccttaagtc ccgggtcacc attagcattg atacgtctaa gaatctgttc 240
agtctcaggc tgtcctccgt cactgctgcc gacacagccg tgtactactg cgcctccttg 300
gtttactgcg gaggcgactg ttatagcggc tttgattatt gggggcaggg gaccctcgta 360
accgtgagct ct 372
<210> 119
<211> 363
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 119
caggtccaac tggtgcagtc cggagccgaa gtcaagaaac caggtgcctc cgttaaagtg 60
agttgcaaag tctctggata cactctgacc gagctctcta tgcactgggt ccggcaggcc 120
cccggcaagg gattggaatg gatgggcggg ttcgatcctg aggacggaga gactatctac 180
gctcaaaaat tccagggacg agtgactgtg accgaagaca ctagtaccga cactgcctac 240
atggaacttt cctctctgcg atcagaagat accgcagtgt actactgtgc tactgaatct 300
aggggcattg gatggcccta cttcgattac tggggtcagg gaactctggt gactgtctcc 360
agc 363
<210> 120
<211> 351
<212> DNA
<213> 人工序列
<220>
<223> VH DNA
<400> 120
caggtccagt tggtcgaaag tggcggtggt gtagtgcagc cgggccgcag tttgaggctt 60
tcctgtgcgg cttcaggctt tactttttcc agctatggaa tgcactgggt gcggcaggcc 120
cccggcaaag gacttgagtg ggtggccgtc atttcttatg acggatcaga taagtactac 180
gtggacagcg tcaagggcag attcaccatc tctagggaca acagtaaaaa tagactctac 240
ctccagatga atagcctcag agctgaagac acggccgtct actattgtgc tcgggagcgg 300
tatagtggca gagactactg ggggcagggc acactcgtta cagtgagtag c 351
<210> 121
<211> 324
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 121
gacatccagt tgacacagag cccgagttcc ttgtccgcct ccgtcgggga tagagtgtca 60
tttacctgtc aggcctctca ggatattaat aactttctga attggtatca gcaaaagccc 120
ggaaaggcac ccaagctgtt gatttacgac gccagtaacc tggagacagg cgtgccctcc 180
cggtttagtg gtagcggaag cggtacggat tttaccttta ctatcagctc tctccaaccc 240
gaagacattg caacctacta ttgtcaacaa tatggaaacc tgccttttac atttggcggc 300
ggcaccaagg tggagattaa gcgg 324
<210> 122
<211> 324
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 122
gatatccagc tcactcaaag cccctctagt ctctctgcct cagtggggga tcgggtcagt 60
tttacttgtc aagcttcaca ggatatcaac aacttcctta attggtatca gcagaagcca 120
ggaaaagcac ccaagctgct catctatgat gcctcaaatt tggagacggg tgttcccagt 180
cgattctctg ggtcagggtc cgggaccgac tttacgttta cgatctcctc tctgcagccc 240
gaagacatcg ccacatacta ttgtcaacag tacggcaact tgcctttcac atttgggggc 300
gggactaagg ttgaaatcaa gagg 324
<210> 123
<211> 324
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 123
gatattcaga tgactcaatc tccttcttct ctgtccgctt ccgtgggcga tagagtgacc 60
attacttgta gggcgtccca gtcaatctcc agttatttga attggtatca gcagaagccc 120
gggaaagcac ctaagctgtt gatcagcggg gcttctagcc tgaagagtgg ggtaccttca 180
cggttcagcg gaagcggaag cggaaccgat ttcaccctga ctatcagcag cctgccacct 240
gaggactttg caacttacta ctgccaacag tcatacagca ctccgatcac tttcggccag 300
ggcacccggc tcgaaatcaa gcgc 324
<210> 124
<211> 324
<212> DNA
<213> 人工序列
<220>
<223> VL DNA
<400> 124
gagattgtta tgacccagag tcctgcgacc ctctcagtca gccccgggga gcgcgcaact 60
ttgtcttgca gagctagtca gtccgtgtcc tctcttctga catggtacca gcaaaagccc 120
gggcaggctc cgcgcctttt gatctttggg gcttcaacaa gagccactgg gattcccgca 180
cgattctctg gctccgggag cggtactggt ttcaccctga cgattagcag tctccagagc 240
gaggacttcg ccgtatacta ctgccagcag tacgatacgt ggccattcac ttttggacca 300
gggactaaag tggattttaa gcgc 324
<210> 125
<211> 122
<212> PRT
<213> 人工序列
<220>
<223> VH AA
<400> 125
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 126
<211> 124
<212> PRT
<213> 人工序列
<220>
<223> VH AA
<400> 126
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 127
<211> 121
<212> PRT
<213> 人工序列
<220>
<223> VH AA
<400> 127
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 128
<211> 117
<212> PRT
<213> 人工序列
<220>
<223> VH AA
<400> 128
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
<210> 129
<211> 108
<212> PRT
<213> 人工序列
<220>
<223> VL AA
<400> 129
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 130
<211> 108
<212> PRT
<213> 人工序列
<220>
<223> VL AA
<400> 130
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 131
<211> 108
<212> PRT
<213> 人工序列
<220>
<223> VL AA
<400> 131
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Ser Gly Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
100 105
<210> 132
<211> 108
<212> PRT
<213> 人工序列
<220>
<223> VL AA
<400> 132
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
100 105
<210> 133
<211> 1437
<212> DNA
<213> 人工序列
<220>
<223> FS-21495CARDNAHxL
<400> 133
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaggtgc agctgttgga gtctggggga ggcttggtac agcctggggg gtccctgaga 120
ctctcctgtg cagcctctgg attcaccttt agcagctatg ccatgagctg ggtccgccag 180
gctccaggga aggggctgga gtgggtctca gctattagtg gtagtggtgg tagcacatac 240
tacgcagact ccgtgaaggg ccggttcacc atctccagag acaattccaa gaacacgctg 300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgcaagagcc 360
gagatgggag ccgtattcga catatggggt cagggtacaa tggtcaccgt ctcctcaggg 420
tctacatccg gctccgggaa gcccggaagt ggcgaaggta gtacaaaggg ggaaattgtg 480
ttgacacagt ctccagccac cctgtctttg tctccagggg aaagagccac cctctcctgc 540
agggccagtc agagtgttag caggtactta gcctggtacc aacagaaacc tggccaggct 600
cccaggctcc tcatctatga tgcatccaac agggccactg gcatcccagc caggttcagt 660
ggcagtgggt ctgggacaga cttcactctc accatcagca gcctagagcc tgaagatttt 720
gcagtttatt actgtcagca gagaatctcc tggcctttca cttttggcgg agggaccaag 780
gttgagatca aacgggccgc tgcccttgat aatgaaaagt caaacggaac aatcattcac 840
gtgaagggca agcacctctg tccgtcaccc ttgttccctg gtccatccaa gccattctgg 900
gtgttggtcg tagtgggtgg agtcctcgct tgttactctc tgctcgtcac cgtggctttt 960
ataatcttct gggttagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1080
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag 1140
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt 1200
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc 1260
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata 1320
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1380
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc taggtaa 1437
<210> 134
<211> 478
<212> PRT
<213> 人工序列
<220>
<223> FS-21495CARHxL
<400> 134
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr
65 70 75 80
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Ala Glu Met Gly Ala Val Phe Asp Ile
115 120 125
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Ser Thr Ser Gly
130 135 140
Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val
145 150 155 160
Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala
165 170 175
Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala
195 200 205
Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe
225 230 235 240
Ala Val Tyr Tyr Cys Gln Gln Arg Ile Ser Trp Pro Phe Thr Phe Gly
245 250 255
Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu
260 265 270
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
275 280 285
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
290 295 300
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
305 310 315 320
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
325 330 335
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
340 345 350
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
355 360 365
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
370 375 380
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
385 390 395 400
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
405 410 415
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
420 425 430
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
435 440 445
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
450 455 460
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 135
<211> 1437
<212> DNA
<213> 人工序列
<220>
<223> FS-21495CARDNALxH
<400> 135
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaaattg tgttgacaca gtctccagcc accctgtctt tgtctccagg ggaaagagcc 120
accctctcct gcagggccag tcagagtgtt agcaggtact tagcctggta ccaacagaaa 180
cctggccagg ctcccaggct cctcatctat gatgcatcca acagggccac tggcatccca 240
gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctagag 300
cctgaagatt ttgcagttta ttactgtcag cagagaatct cctggccttt cacttttggc 360
ggagggacca aggttgagat caaacggggg tctacatccg gctccgggaa gcccggaagt 420
ggcgaaggta gtacaaaggg ggaggtgcag ctgttggagt ctgggggagg cttggtacag 480
cctggggggt ccctgagact ctcctgtgca gcctctggat tcacctttag cagctatgcc 540
atgagctggg tccgccaggc tccagggaag gggctggagt gggtctcagc tattagtggt 600
agtggtggta gcacatacta cgcagactcc gtgaagggcc ggttcaccat ctccagagac 660
aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga cacggcggtg 720
tactactgcg caagagccga gatgggagcc gtattcgaca tatggggtca gggtacaatg 780
gtcaccgtct cctcagccgc tgcccttgat aatgaaaagt caaacggaac aatcattcac 840
gtgaagggca agcacctctg tccgtcaccc ttgttccctg gtccatccaa gccattctgg 900
gtgttggtcg tagtgggtgg agtcctcgct tgttactctc tgctcgtcac cgtggctttt 960
ataatcttct gggttagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1080
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag 1140
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt 1200
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc 1260
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata 1320
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1380
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc taggtaa 1437
<210> 136
<211> 478
<212> PRT
<213> 人工序列
<220>
<223> FS-21495CARLxH
<400> 136
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg
100 105 110
Ile Ser Trp Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140
Thr Lys Gly Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
145 150 155 160
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
165 170 175
Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
180 185 190
Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala
195 200 205
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
210 215 220
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
225 230 235 240
Tyr Tyr Cys Ala Arg Ala Glu Met Gly Ala Val Phe Asp Ile Trp Gly
245 250 255
Gln Gly Thr Met Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu
260 265 270
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
275 280 285
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
290 295 300
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
305 310 315 320
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
325 330 335
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
340 345 350
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
355 360 365
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
370 375 380
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
385 390 395 400
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
405 410 415
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
420 425 430
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
435 440 445
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
450 455 460
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 137
<211> 1464
<212> DNA
<213> 人工序列
<220>
<223> PC-21497CARDNAHxL
<400> 137
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgga gtctggggga ggcgtggtcc agcctgggag gtccctgaga 120
ctctcctgtg cagcgtctgg attcaccttc agtagctatg gcatgcactg ggtccgccag 180
gctccaggca aggggctgga gtgggtggca gttatatcgt atgatggaag taataaatac 240
tatgcagact ccgtgaaggg ccgattcacc atctccagag acaattccaa gaacacgctg 300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgccagagac 360
ggtacttatc taggtggtct ctggtacttc gacttatggg ggagaggtac cttggtcacc 420
gtctcctcag ggtctacatc cggctccggg aagcccggaa gtggcgaagg tagtacaaag 480
ggggatattg tgatgactca gtctccactc tccctgcccg tcacccctgg agagccggcc 540
tccatctcct gcaggtctag tcagagcctc ctgcatagta atggatacaa ctatttggat 600
tggtacctgc agaagccagg gcagtctcca cagctcctga tctatttggg ttctaatcgg 660
gcctccgggg tccctgacag gttcagtggc agtggatcag gcacagattt tacactgaaa 720
atcagcagag tggaggctga ggatgttggg gtttattact gcatgcaggg actcggcctc 780
cctctcactt ttggcggagg gaccaaggtt gagatcaaac gggccgctgc ccttgataat 840
gaaaagtcaa acggaacaat cattcacgtg aagggcaagc acctctgtcc gtcacccttg 900
ttccctggtc catccaagcc attctgggtg ttggtcgtag tgggtggagt cctcgcttgt 960
tactctctgc tcgtcaccgt ggcttttata atcttctggg ttagatccaa aagaagccgc 1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1140
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1200
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1260
ggtggcaaac caagacgaaa aaacccccag gagggtctct ataatgagct gcagaaggat 1320
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1380
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1440
atgcaagccc tgccacctag gtaa 1464
<210> 138
<211> 487
<212> PRT
<213> 人工序列
<220>
<223> PC-21497CARHxL
<400> 138
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr
65 70 75 80
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Asp Gly Thr Tyr Leu Gly Gly Leu Trp
115 120 125
Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
145 150 155 160
Gly Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro
165 170 175
Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His
180 185 190
Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
195 200 205
Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val
210 215 220
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
225 230 235 240
Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln
245 250 255
Gly Leu Gly Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
260 265 270
Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile
275 280 285
His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
290 295 300
Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320
Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335
Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350
Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365
Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
370 375 380
Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415
Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445
Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480
Met Gln Ala Leu Pro Pro Arg
485
<210> 139
<211> 1464
<212> DNA
<213> 人工序列
<220>
<223> PC-21497CARDNALxH
<400> 139
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggatattg tgatgactca gtctccactc tccctgcccg tcacccctgg agagccggcc 120
tccatctcct gcaggtctag tcagagcctc ctgcatagta atggatacaa ctatttggat 180
tggtacctgc agaagccagg gcagtctcca cagctcctga tctatttggg ttctaatcgg 240
gcctccgggg tccctgacag gttcagtggc agtggatcag gcacagattt tacactgaaa 300
atcagcagag tggaggctga ggatgttggg gtttattact gcatgcaggg actcggcctc 360
cctctcactt ttggcggagg gaccaaggtt gagatcaaac gggggtctac atccggctcc 420
gggaagcccg gaagtggcga aggtagtaca aaggggcagg tgcagctggt ggagtctggg 480
ggaggcgtgg tccagcctgg gaggtccctg agactctcct gtgcagcgtc tggattcacc 540
ttcagtagct atggcatgca ctgggtccgc caggctccag gcaaggggct ggagtgggtg 600
gcagttatat cgtatgatgg aagtaataaa tactatgcag actccgtgaa gggccgattc 660
accatctcca gagacaattc caagaacacg ctgtatctgc aaatgaacag cctgagagcc 720
gaggacacgg cggtgtacta ctgcgccaga gacggtactt atctaggtgg tctctggtac 780
ttcgacttat gggggagagg taccttggtc accgtctcct cagccgctgc ccttgataat 840
gaaaagtcaa acggaacaat cattcacgtg aagggcaagc acctctgtcc gtcacccttg 900
ttccctggtc catccaagcc attctgggtg ttggtcgtag tgggtggagt cctcgcttgt 960
tactctctgc tcgtcaccgt ggcttttata atcttctggg ttagatccaa aagaagccgc 1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1140
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1200
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1260
ggtggcaaac caagacgaaa aaacccccag gagggtctct ataatgagct gcagaaggat 1320
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1380
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1440
atgcaagccc tgccacctag gtaa 1464
<210> 140
<211> 487
<212> PRT
<213> 人工序列
<220>
<223> PC-21497CARHxL
<400> 140
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu
20 25 30
Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln
35 40 45
Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln
50 55 60
Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg
65 70 75 80
Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
85 90 95
Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr
100 105 110
Tyr Cys Met Gln Gly Leu Gly Leu Pro Leu Thr Phe Gly Gly Gly Thr
115 120 125
Lys Val Glu Ile Lys Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly
130 135 140
Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Gln Leu Val Glu Ser Gly
145 150 155 160
Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala
165 170 175
Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala
180 185 190
Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser
195 200 205
Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
210 215 220
Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala
225 230 235 240
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Thr Tyr Leu Gly
245 250 255
Gly Leu Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val
260 265 270
Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile
275 280 285
His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
290 295 300
Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320
Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335
Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350
Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365
Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
370 375 380
Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415
Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445
Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480
Met Gln Ala Leu Pro Pro Arg
485
<210> 141
<211> 1428
<212> DNA
<213> 人工序列
<220>
<223> AJ-21508CARDNAHxL
<400> 141
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgca gtctggggct gaggtgaaga agcctggggc ctcagtgaag 120
gtttcctgca aggcatctgg atacaccttc accagctact atatgcactg ggtgcgacag 180
gcccctggac aagggcttga gtggatggga ataatcaacc ctggtggtgg tagcacaagc 240
tacgcacaga agttccaggg cagagtcacc atgaccaggg acacgtccac gagcacagtc 300
tacatggagc tgagcagcct gagatctgag gacacggcgg tgtactactg cgccagagag 360
agttggccaa tggacgtatg gggccaggga acaactgtca ccgtctcctc agggtctaca 420
tccggctccg ggaagcccgg aagtggcgaa ggtagtacaa agggggaaat agtgatgacg 480
cagtctccag ccaccctgtc tgtgtctcca ggggaaagag ccaccctctc ctgcagggcc 540
agtcagagtg ttagcagcaa cttagcctgg taccagcaga aacctggcca ggctcccagg 600
ctcctcatct atggtgcatc caccagggcc actggtatcc cagccaggtt cagtggcagt 660
gggtctggga cagagttcac tctcaccatc agcagcctgc agtctgaaga ttttgcagtt 720
tattactgtc agcagtacgc cgcctaccct acttttggcg gagggaccaa ggttgagatc 780
aaacgggccg ctgcccttga taatgaaaag tcaaacggaa caatcattca cgtgaagggc 840
aagcacctct gtccgtcacc cttgttccct ggtccatcca agccattctg ggtgttggtc 900
gtagtgggtg gagtcctcgc ttgttactct ctgctcgtca ccgtggcttt tataatcttc 960
tgggttagat ccaaaagaag ccgcctgctc catagcgatt acatgaatat gactccacgc 1020
cgccctggcc ccacaaggaa acactaccag ccttacgcac cacctagaga tttcgctgcc 1080
tatcggagca gggtgaagtt ttccagatct gcagatgcac cagcgtatca gcagggccag 1140
aaccaactgt ataacgagct caacctggga cgcagggaag agtatgacgt tttggacaag 1200
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt 1260
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa 1320
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg 1380
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa 1428
<210> 142
<211> 475
<212> PRT
<213> 人工序列
<220>
<223> AJ-21508CARHxL
<400> 142
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30
Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
35 40 45
Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln
50 55 60
Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Gly Gly Gly Ser Thr Ser
65 70 75 80
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser
85 90 95
Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Glu Ser Trp Pro Met Asp Val Trp Gly
115 120 125
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly
130 135 140
Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val Met Thr
145 150 155 160
Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu
165 170 175
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln
180 185 190
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr
195 200 205
Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
210 215 220
Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val
225 230 235 240
Tyr Tyr Cys Gln Gln Tyr Ala Ala Tyr Pro Thr Phe Gly Gly Gly Thr
245 250 255
Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn
260 265 270
Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu
275 280 285
Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly
290 295 300
Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe
305 310 315 320
Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn
325 330 335
Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr
340 345 350
Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser
355 360 365
Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr
370 375 380
Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
385 390 395 400
Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
405 410 415
Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
420 425 430
Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
435 440 445
His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
450 455 460
Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 143
<211> 1428
<212> DNA
<213> 人工序列
<220>
<223> AJ-21508CARDNALxH
<400> 143
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaaatag tgatgacgca gtctccagcc accctgtctg tgtctccagg ggaaagagcc 120
accctctcct gcagggccag tcagagtgtt agcagcaact tagcctggta ccagcagaaa 180
cctggccagg ctcccaggct cctcatctat ggtgcatcca ccagggccac tggtatccca 240
gccaggttca gtggcagtgg gtctgggaca gagttcactc tcaccatcag cagcctgcag 300
tctgaagatt ttgcagttta ttactgtcag cagtacgccg cctaccctac ttttggcgga 360
gggaccaagg ttgagatcaa acgggggtct acatccggct ccgggaagcc cggaagtggc 420
gaaggtagta caaaggggca ggtgcagctg gtgcagtctg gggctgaggt gaagaagcct 480
ggggcctcag tgaaggtttc ctgcaaggca tctggataca ccttcaccag ctactatatg 540
cactgggtgc gacaggcccc tggacaaggg cttgagtgga tgggaataat caaccctggt 600
ggtggtagca caagctacgc acagaagttc cagggcagag tcaccatgac cagggacacg 660
tccacgagca cagtctacat ggagctgagc agcctgagat ctgaggacac ggcggtgtac 720
tactgcgcca gagagagttg gccaatggac gtatggggcc agggaacaac tgtcaccgtc 780
tcctcagccg ctgcccttga taatgaaaag tcaaacggaa caatcattca cgtgaagggc 840
aagcacctct gtccgtcacc cttgttccct ggtccatcca agccattctg ggtgttggtc 900
gtagtgggtg gagtcctcgc ttgttactct ctgctcgtca ccgtggcttt tataatcttc 960
tgggttagat ccaaaagaag ccgcctgctc catagcgatt acatgaatat gactccacgc 1020
cgccctggcc ccacaaggaa acactaccag ccttacgcac cacctagaga tttcgctgcc 1080
tatcggagca gggtgaagtt ttccagatct gcagatgcac cagcgtatca gcagggccag 1140
aaccaactgt ataacgagct caacctggga cgcagggaag agtatgacgt tttggacaag 1200
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt 1260
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa 1320
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg 1380
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa 1428
<210> 144
<211> 475
<212> PRT
<213> 人工序列
<220>
<223> AJ-21508CARLxH
<400> 144
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110
Ala Ala Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
115 120 125
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
130 135 140
Lys Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
145 150 155 160
Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
165 170 175
Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
180 185 190
Trp Met Gly Ile Ile Asn Pro Gly Gly Gly Ser Thr Ser Tyr Ala Gln
195 200 205
Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr
210 215 220
Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
225 230 235 240
Tyr Cys Ala Arg Glu Ser Trp Pro Met Asp Val Trp Gly Gln Gly Thr
245 250 255
Thr Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn
260 265 270
Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu
275 280 285
Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly
290 295 300
Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe
305 310 315 320
Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn
325 330 335
Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr
340 345 350
Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser
355 360 365
Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr
370 375 380
Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
385 390 395 400
Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
405 410 415
Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
420 425 430
Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
435 440 445
His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
450 455 460
Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 145
<211> 1449
<212> DNA
<213> 人工序列
<220>
<223> NM-21517CARDNAHxL
<400> 145
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcagctgc agctgcagga gtcgggccca ggactggtga agccttcgga gaccctgtcc 120
ctcacctgca ctgtctctgg tggctccatc agcagtagta gttactactg gggctggatc 180
cgccagcccc cagggaaggg gctggagtgg attgggagta tctcctatag tgggagcacc 240
tactacaacc cgtccctcaa gagtcgagtc accatatccg tagacacgtc caagaaccag 300
ttctccctga agctgagttc tgtgaccgcc gcagacacgg cggtgtacta ctgcgccaga 360
ggcaggggat atgcaaccag cttagccttc gatatctggg gtcagggtac aatggtcacc 420
gtctcctcag ggtctacatc cggctccggg aagcccggaa gtggcgaagg tagtacaaag 480
ggggaaattg tgttgacaca gtctccagcc accctgtctt tgtctccagg ggaaagagcc 540
accctctcct gcagggccag tcagagtgtt agcagctact tagcctggta ccaacagaaa 600
cctggccagg ctcccaggct cctcatctat gatgcatcca acagggccac tggcatccca 660
gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctagag 720
cctgaagatt ttgcagttta ttactgtcag cagagacacg tctggcctcc tacttttggc 780
ggagggacca aggttgagat caaacgggcc gctgcccttg ataatgaaaa gtcaaacgga 840
acaatcattc acgtgaaggg caagcacctc tgtccgtcac ccttgttccc tggtccatcc 900
aagccattct gggtgttggt cgtagtgggt ggagtcctcg cttgttactc tctgctcgtc 960
accgtggctt ttataatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat 1020
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1080
ccacctagag atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca 1140
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1200
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1260
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1320
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1380
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca 1440
cctaggtaa 1449
<210> 146
<211> 482
<212> PRT
<213> 人工序列
<220>
<223> NM-21517CARHxL
<400> 146
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro
50 55 60
Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr
65 70 75 80
Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr
85 90 95
Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Tyr Ala Thr Ser Leu
115 120 125
Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly
130 135 140
Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
145 150 155 160
Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro
165 170 175
Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser
180 185 190
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
195 200 205
Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser
210 215 220
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
225 230 235 240
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg His Val Trp Pro
245 250 255
Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
260 265 270
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
275 280 285
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
290 295 300
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
305 310 315 320
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
325 330 335
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
340 345 350
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
355 360 365
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
370 375 380
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
385 390 395 400
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
405 410 415
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
420 425 430
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
435 440 445
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
450 455 460
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
465 470 475 480
Pro Arg
<210> 147
<211> 1449
<212> DNA
<213> 人工序列
<220>
<223> NM-21517CARDNALxH
<400> 147
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaaattg tgttgacaca gtctccagcc accctgtctt tgtctccagg ggaaagagcc 120
accctctcct gcagggccag tcagagtgtt agcagctact tagcctggta ccaacagaaa 180
cctggccagg ctcccaggct cctcatctat gatgcatcca acagggccac tggcatccca 240
gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctagag 300
cctgaagatt ttgcagttta ttactgtcag cagagacacg tctggcctcc tacttttggc 360
ggagggacca aggttgagat caaacggggg tctacatccg gctccgggaa gcccggaagt 420
ggcgaaggta gtacaaaggg gcagctgcag ctgcaggagt cgggcccagg actggtgaag 480
ccttcggaga ccctgtccct cacctgcact gtctctggtg gctccatcag cagtagtagt 540
tactactggg gctggatccg ccagccccca gggaaggggc tggagtggat tgggagtatc 600
tcctatagtg ggagcaccta ctacaacccg tccctcaaga gtcgagtcac catatccgta 660
gacacgtcca agaaccagtt ctccctgaag ctgagttctg tgaccgccgc agacacggcg 720
gtgtactact gcgccagagg caggggatat gcaaccagct tagccttcga tatctggggt 780
cagggtacaa tggtcaccgt ctcctcagcc gctgcccttg ataatgaaaa gtcaaacgga 840
acaatcattc acgtgaaggg caagcacctc tgtccgtcac ccttgttccc tggtccatcc 900
aagccattct gggtgttggt cgtagtgggt ggagtcctcg cttgttactc tctgctcgtc 960
accgtggctt ttataatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat 1020
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1080
ccacctagag atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca 1140
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1200
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1260
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1320
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1380
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca 1440
cctaggtaa 1449
<210> 148
<211> 482
<212> PRT
<213> 人工序列
<220>
<223> NM-21517CARLxH
<400> 148
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg
100 105 110
His Val Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140
Thr Lys Gly Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys
145 150 155 160
Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile
165 170 175
Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys
180 185 190
Gly Leu Glu Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr
195 200 205
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
210 215 220
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
225 230 235 240
Val Tyr Tyr Cys Ala Arg Gly Arg Gly Tyr Ala Thr Ser Leu Ala Phe
245 250 255
Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ala Ala
260 265 270
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
275 280 285
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
290 295 300
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
305 310 315 320
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
325 330 335
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
340 345 350
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
355 360 365
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
370 375 380
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
385 390 395 400
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
405 410 415
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
420 425 430
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
435 440 445
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
450 455 460
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
465 470 475 480
Pro Arg
<210> 149
<211> 1440
<212> DNA
<213> 人工序列
<220>
<223> TS-21522CARDNAHxL
<400> 149
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaggtgc agctggtgga gtctggggga ggcttggtac agcctggggg gtccctgaga 120
ctctcctgtg cagcctctgg attcaccttc agtagctata gcatgaactg ggtccgccag 180
gctccaggga aggggctgga gtgggtttca accattagta gtagtagtag taccatatac 240
tacgcagact ctgtgaaggg ccgattcacc atctccagag acaatgccaa gaactcactg 300
tatctgcaaa tgaacagcct gagagctgag gacacggcgg tgtactactg cgccagaggt 360
tctcaggagc acctgatttt cgattattgg ggacagggta cattggtcac cgtctcctca 420
gggtctacat ccggctccgg gaagcccgga agtggcgaag gtagtacaaa gggggaaatt 480
gtgttgacac agtctccagc caccctgtct ttgtctccag gggaaagagc caccctctcc 540
tgcagggcca gtcagagtgt tagcaggtac ttagcctggt accaacagaa acctggccag 600
gctcccaggc tcctcatcta tgatgcatcc aacagggcca ctggcatccc agccaggttc 660
agtggcagtg ggtctgggac agacttcact ctcaccatca gcagcctaga gcctgaagat 720
tttgcagttt attactgtca gcagagattc tactaccctt ggacttttgg cggagggacc 780
aaggttgaga tcaaacgggc cgctgccctt gataatgaaa agtcaaacgg aacaatcatt 840
cacgtgaagg gcaagcacct ctgtccgtca cccttgttcc ctggtccatc caagccattc 900
tgggtgttgg tcgtagtggg tggagtcctc gcttgttact ctctgctcgt caccgtggct 960
tttataatct tctgggttag atccaaaaga agccgcctgc tccatagcga ttacatgaat 1020
atgactccac gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga 1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat 1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac 1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac 1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa 1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc 1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa 1440
<210> 150
<211> 479
<212> PRT
<213> 人工序列
<220>
<223> TS-21522CARHxL
<400> 150
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
20 25 30
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ser Thr Ile Ser Ser Ser Ser Ser Thr Ile Tyr
65 70 75 80
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
85 90 95
Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gln Glu His Leu Ile Phe Asp
115 120 125
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser
130 135 140
Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile
145 150 155 160
Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg
165 170 175
Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp
225 230 235 240
Phe Ala Val Tyr Tyr Cys Gln Gln Arg Phe Tyr Tyr Pro Trp Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn
260 265 270
Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285
Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300
Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335
Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 151
<211> 1440
<212> DNA
<213> 人工序列
<220>
<223> TS-21522CARDNALxH
<400> 151
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaaattg tgttgacaca gtctccagcc accctgtctt tgtctccagg ggaaagagcc 120
accctctcct gcagggccag tcagagtgtt agcaggtact tagcctggta ccaacagaaa 180
cctggccagg ctcccaggct cctcatctat gatgcatcca acagggccac tggcatccca 240
gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctagag 300
cctgaagatt ttgcagttta ttactgtcag cagagattct actacccttg gacttttggc 360
ggagggacca aggttgagat caaacggggg tctacatccg gctccgggaa gcccggaagt 420
ggcgaaggta gtacaaaggg ggaggtgcag ctggtggagt ctgggggagg cttggtacag 480
cctggggggt ccctgagact ctcctgtgca gcctctggat tcaccttcag tagctatagc 540
atgaactggg tccgccaggc tccagggaag gggctggagt gggtttcaac cattagtagt 600
agtagtagta ccatatacta cgcagactct gtgaagggcc gattcaccat ctccagagac 660
aatgccaaga actcactgta tctgcaaatg aacagcctga gagctgagga cacggcggtg 720
tactactgcg ccagaggttc tcaggagcac ctgattttcg attattgggg acagggtaca 780
ttggtcaccg tctcctcagc cgctgccctt gataatgaaa agtcaaacgg aacaatcatt 840
cacgtgaagg gcaagcacct ctgtccgtca cccttgttcc ctggtccatc caagccattc 900
tgggtgttgg tcgtagtggg tggagtcctc gcttgttact ctctgctcgt caccgtggct 960
tttataatct tctgggttag atccaaaaga agccgcctgc tccatagcga ttacatgaat 1020
atgactccac gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga 1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat 1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac 1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac 1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa 1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc 1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa 1440
<210> 152
<211> 479
<212> PRT
<213> 人工序列
<220>
<223> TS-21522CARLxH
<400> 152
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg
100 105 110
Phe Tyr Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140
Thr Lys Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
145 150 155 160
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
165 170 175
Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
180 185 190
Glu Trp Val Ser Thr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala
195 200 205
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
210 215 220
Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
225 230 235 240
Tyr Tyr Cys Ala Arg Gly Ser Gln Glu His Leu Ile Phe Asp Tyr Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn
260 265 270
Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285
Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300
Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335
Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 153
<211> 1449
<212> DNA
<213> 人工序列
<220>
<223> RY-21527CARDNAHxL
<400> 153
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgga gtctggggga ggcgtggtcc agcctgggag gtccctgaga 120
ctctcctgtg cagcgtctgg attcaccttc agtagctatg gcatgcactg ggtccgccag 180
gctccaggca aggggctgga gtgggtggca gttatatcgt atgatggaag taataaatac 240
tatgcagact ccgtgaaggg ccgattcacc atctccagag acaattccaa gaacacgctg 300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgccagaact 360
gacttctgga gcggatcccc tccaggctta gattactggg gacagggtac attggtcacc 420
gtctcctcag ggtctacatc cggctccggg aagcccggaa gtggcgaagg tagtacaaag 480
ggggacatcc agttgaccca gtctccatct tccgtgtctg catctgtagg agacagagtc 540
accatcactt gtcgggcgag tcagggtatt agcagctggt tagcctggta tcagcagaaa 600
ccagggaaag cccctaagct cctgatctat ggtgcatcca gtttgcaaag tggggtccca 660
tcaaggttca gcggcagtgg atctgggaca gatttcactc tcaccatcag cagcctgcag 720
cctgaagatt ttgcaactta ttactgtcag cagatataca ccttcccttt cacttttggc 780
ggagggacca aggttgagat caaacgggcc gctgcccttg ataatgaaaa gtcaaacgga 840
acaatcattc acgtgaaggg caagcacctc tgtccgtcac ccttgttccc tggtccatcc 900
aagccattct gggtgttggt cgtagtgggt ggagtcctcg cttgttactc tctgctcgtc 960
accgtggctt ttataatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat 1020
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1080
ccacctagag atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca 1140
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1200
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1260
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1320
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1380
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca 1440
cctaggtaa 1449
<210> 154
<211> 482
<212> PRT
<213> 人工序列
<220>
<223> RY-21527CARHxL
<400> 154
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr
65 70 75 80
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Thr Asp Phe Trp Ser Gly Ser Pro Pro
115 120 125
Gly Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
145 150 155 160
Gly Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val
165 170 175
Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
180 185 190
Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
195 200 205
Ile Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
210 215 220
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
225 230 235 240
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile Tyr Thr Phe Pro
245 250 255
Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
260 265 270
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
275 280 285
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
290 295 300
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
305 310 315 320
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
325 330 335
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
340 345 350
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
355 360 365
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
370 375 380
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
385 390 395 400
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
405 410 415
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
420 425 430
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
435 440 445
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
450 455 460
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
465 470 475 480
Pro Arg
<210> 155
<211> 1449
<212> DNA
<213> 人工序列
<220>
<223> RY-21527CARDNALxH
<400> 155
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggacatcc agttgaccca gtctccatct tccgtgtctg catctgtagg agacagagtc 120
accatcactt gtcgggcgag tcagggtatt agcagctggt tagcctggta tcagcagaaa 180
ccagggaaag cccctaagct cctgatctat ggtgcatcca gtttgcaaag tggggtccca 240
tcaaggttca gcggcagtgg atctgggaca gatttcactc tcaccatcag cagcctgcag 300
cctgaagatt ttgcaactta ttactgtcag cagatataca ccttcccttt cacttttggc 360
ggagggacca aggttgagat caaacggggg tctacatccg gctccgggaa gcccggaagt 420
ggcgaaggta gtacaaaggg gcaggtgcag ctggtggagt ctgggggagg cgtggtccag 480
cctgggaggt ccctgagact ctcctgtgca gcgtctggat tcaccttcag tagctatggc 540
atgcactggg tccgccaggc tccaggcaag gggctggagt gggtggcagt tatatcgtat 600
gatggaagta ataaatacta tgcagactcc gtgaagggcc gattcaccat ctccagagac 660
aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga cacggcggtg 720
tactactgcg ccagaactga cttctggagc ggatcccctc caggcttaga ttactgggga 780
cagggtacat tggtcaccgt ctcctcagcc gctgcccttg ataatgaaaa gtcaaacgga 840
acaatcattc acgtgaaggg caagcacctc tgtccgtcac ccttgttccc tggtccatcc 900
aagccattct gggtgttggt cgtagtgggt ggagtcctcg cttgttactc tctgctcgtc 960
accgtggctt ttataatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat 1020
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1080
ccacctagag atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca 1140
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1200
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1260
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1320
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1380
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca 1440
cctaggtaa 1449
<210> 156
<211> 482
<212> PRT
<213> 人工序列
<220>
<223> RY-21527CARLxH
<400> 156
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
35 40 45
Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile
100 105 110
Tyr Thr Phe Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140
Thr Lys Gly Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
145 150 155 160
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
165 170 175
Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
180 185 190
Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
195 200 205
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
210 215 220
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
225 230 235 240
Tyr Tyr Cys Ala Arg Thr Asp Phe Trp Ser Gly Ser Pro Pro Gly Leu
245 250 255
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala
260 265 270
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
275 280 285
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
290 295 300
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
305 310 315 320
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
325 330 335
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
340 345 350
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
355 360 365
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
370 375 380
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
385 390 395 400
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
405 410 415
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
420 425 430
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
435 440 445
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
450 455 460
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
465 470 475 480
Pro Arg
<210> 157
<211> 1479
<212> DNA
<213> 人工序列
<220>
<223> PP-21528CARDNAHxL
<400> 157
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgca gtctggggct gaggtgaaga agcctgggtc ctcggtgaag 120
gtctcctgca aggcttctgg aggcaccttc agcagctatg ctatcagctg ggtgcgacag 180
gcccctggac aagggcttga gtggatggga gggatcatcc ctatctttgg tacagcaaac 240
tacgcacaga agttccaggg cagagtcacg attaccgcgg acgaatccac gagcacagcc 300
tacatggagc tgagcagcct gagatctgag gacacggcgg tgtactactg cgccagaact 360
cctgaatact cctccagcat atggcactat tactacggca tggacgtatg gggccaggga 420
acaactgtca ccgtctcctc agggtctaca tccggctccg ggaagcccgg aagtggcgaa 480
ggtagtacaa agggggacat cgtgatgacc cagtctccag actccctggc tgtgtctctg 540
ggcgagaggg ccaccatcaa ctgcaagtcc agccagagtg ttttatacag ctccaacaat 600
aagaactact tagcttggta ccagcagaaa ccaggacagc ctcctaagct gctcatttac 660
tgggcatcta cccgggaatc cggggtccct gaccgattca gtggcagcgg gtctgggaca 720
gatttcactc tcaccatcag cagcctgcag gctgaagatg tggcagttta ttactgtcag 780
cagttcgccc acactccttt cacttttggc ggagggacca aggttgagat caaacgggcc 840
gctgcccttg ataatgaaaa gtcaaacgga acaatcattc acgtgaaggg caagcacctc 900
tgtccgtcac ccttgttccc tggtccatcc aagccattct gggtgttggt cgtagtgggt 960
ggagtcctcg cttgttactc tctgctcgtc accgtggctt ttataatctt ctgggttaga 1020
tccaaaagaa gccgcctgct ccatagcgat tacatgaata tgactccacg ccgccctggc 1080
cccacaagga aacactacca gccttacgca ccacctagag atttcgctgc ctatcggagc 1140
agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg 1200
tataacgagc tcaacctggg acgcagggaa gagtatgacg ttttggacaa gcgcagagga 1260
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat 1320
gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg 1380
agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact 1440
tatgacgctc tccacatgca agccctgcca cctaggtaa 1479
<210> 158
<211> 492
<212> PRT
<213> 人工序列
<220>
<223> PP-21528CARHxL
<400> 158
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30
Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly
35 40 45
Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln
50 55 60
Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn
65 70 75 80
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser
85 90 95
Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Thr Pro Glu Tyr Ser Ser Ser Ile Trp
115 120 125
His Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
130 135 140
Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu
145 150 155 160
Gly Ser Thr Lys Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu
165 170 175
Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln
180 185 190
Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln
195 200 205
Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr
210 215 220
Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
225 230 235 240
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val
245 250 255
Tyr Tyr Cys Gln Gln Phe Ala His Thr Pro Phe Thr Phe Gly Gly Gly
260 265 270
Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser
275 280 285
Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
290 295 300
Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
305 310 315 320
Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
325 330 335
Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
340 345 350
Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
355 360 365
Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe
370 375 380
Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
385 390 395 400
Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415
Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430
Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445
Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460
Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480
Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 159
<211> 1479
<212> DNA
<213> 人工序列
<220>
<223> PP-21528CARDNALxH
<400> 159
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggacatcg tgatgaccca gtctccagac tccctggctg tgtctctggg cgagagggcc 120
accatcaact gcaagtccag ccagagtgtt ttatacagct ccaacaataa gaactactta 180
gcttggtacc agcagaaacc aggacagcct cctaagctgc tcatttactg ggcatctacc 240
cgggaatccg gggtccctga ccgattcagt ggcagcgggt ctgggacaga tttcactctc 300
accatcagca gcctgcaggc tgaagatgtg gcagtttatt actgtcagca gttcgcccac 360
actcctttca cttttggcgg agggaccaag gttgagatca aacgggggtc tacatccggc 420
tccgggaagc ccggaagtgg cgaaggtagt acaaaggggc aggtgcagct ggtgcagtct 480
ggggctgagg tgaagaagcc tgggtcctcg gtgaaggtct cctgcaaggc ttctggaggc 540
accttcagca gctatgctat cagctgggtg cgacaggccc ctggacaagg gcttgagtgg 600
atgggaggga tcatccctat ctttggtaca gcaaactacg cacagaagtt ccagggcaga 660
gtcacgatta ccgcggacga atccacgagc acagcctaca tggagctgag cagcctgaga 720
tctgaggaca cggcggtgta ctactgcgcc agaactcctg aatactcctc cagcatatgg 780
cactattact acggcatgga cgtatggggc cagggaacaa ctgtcaccgt ctcctcagcc 840
gctgcccttg ataatgaaaa gtcaaacgga acaatcattc acgtgaaggg caagcacctc 900
tgtccgtcac ccttgttccc tggtccatcc aagccattct gggtgttggt cgtagtgggt 960
ggagtcctcg cttgttactc tctgctcgtc accgtggctt ttataatctt ctgggttaga 1020
tccaaaagaa gccgcctgct ccatagcgat tacatgaata tgactccacg ccgccctggc 1080
cccacaagga aacactacca gccttacgca ccacctagag atttcgctgc ctatcggagc 1140
agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg 1200
tataacgagc tcaacctggg acgcagggaa gagtatgacg ttttggacaa gcgcagagga 1260
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat 1320
gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg 1380
agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact 1440
tatgacgctc tccacatgca agccctgcca cctaggtaa 1479
<210> 160
<211> 492
<212> PRT
<213> 人工序列
<220>
<223> PP-21528CARLxH
<400> 160
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu
20 25 30
Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln
35 40 45
Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln
50 55 60
Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr
65 70 75 80
Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
85 90 95
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val
100 105 110
Tyr Tyr Cys Gln Gln Phe Ala His Thr Pro Phe Thr Phe Gly Gly Gly
115 120 125
Thr Lys Val Glu Ile Lys Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro
130 135 140
Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Gln Leu Val Gln Ser
145 150 155 160
Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys
165 170 175
Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln
180 185 190
Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe
195 200 205
Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr
210 215 220
Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg
225 230 235 240
Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Pro Glu Tyr Ser
245 250 255
Ser Ser Ile Trp His Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly
260 265 270
Thr Thr Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser
275 280 285
Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
290 295 300
Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
305 310 315 320
Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
325 330 335
Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
340 345 350
Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
355 360 365
Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe
370 375 380
Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
385 390 395 400
Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415
Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430
Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445
Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460
Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480
Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 161
<211> 1452
<212> DNA
<213> 人工序列
<220>
<223> RD-21530CARDNAHxL
<400> 161
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgga gtctggggga ggcgtggtcc agcctgggag gtccctgaga 120
ctctcctgtg cagcgtctgg attcaccttc agtagctatg gcatgcactg ggtccgccag 180
gctccaggca aggggctgga gtgggtggca gttatatcgt atgatggaag taataaatac 240
tatgcagact ccgtgaaggg ccgattcacc atctccagag acaattccaa gaacacgctg 300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgtcaagggg 360
ccgttgcagg agccgccata cgattatgga atggacgtat ggggccaggg aacaactgtc 420
accgtctcct cagggtctac atccggctcc gggaagcccg gaagtggcga aggtagtaca 480
aagggggaaa tagtgatgac gcagtctcca gccaccctgt ctgtgtctcc aggggaaaga 540
gccaccctct cctgcagggc cagtcagagt gttagcagca acttagcctg gtaccagcag 600
aaacctggcc aggctcccag gctcctcatc tatagcgcat ccaccagggc cactggtatc 660
ccagccaggt tcagtggcag tgggtctggg acagagttca ctctcaccat cagcagcctg 720
cagtctgaag attttgcagt ttattactgt cagcagcacc acgtctggcc tctcactttt 780
ggcggaggga ccaaggttga gatcaaacgg gccgctgccc ttgataatga aaagtcaaac 840
ggaacaatca ttcacgtgaa gggcaagcac ctctgtccgt cacccttgtt ccctggtcca 900
tccaagccat tctgggtgtt ggtcgtagtg ggtggagtcc tcgcttgtta ctctctgctc 960
gtcaccgtgg cttttataat cttctgggtt agatccaaaa gaagccgcct gctccatagc 1020
gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggtctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452
<210> 162
<211> 483
<212> PRT
<213> 人工序列
<220>
<223> RD-21530CARHxL
<400> 162
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr
65 70 75 80
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp
115 120 125
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
130 135 140
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
145 150 155 160
Lys Gly Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser
165 170 175
Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser
180 185 190
Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
195 200 205
Leu Ile Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe
210 215 220
Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu
225 230 235 240
Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His His Val Trp
245 250 255
Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala
260 265 270
Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
465 470 475 480
Pro Pro Arg
<210> 163
<211> 1452
<212> DNA
<213> 人工序列
<220>
<223> RD-21530CARDNALxH
<400> 163
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaaatag tgatgacgca gtctccagcc accctgtctg tgtctccagg ggaaagagcc 120
accctctcct gcagggccag tcagagtgtt agcagcaact tagcctggta ccagcagaaa 180
cctggccagg ctcccaggct cctcatctat agcgcatcca ccagggccac tggtatccca 240
gccaggttca gtggcagtgg gtctgggaca gagttcactc tcaccatcag cagcctgcag 300
tctgaagatt ttgcagttta ttactgtcag cagcaccacg tctggcctct cacttttggc 360
ggagggacca aggttgagat caaacggggg tctacatccg gctccgggaa gcccggaagt 420
ggcgaaggta gtacaaaggg gcaggtgcag ctggtggagt ctgggggagg cgtggtccag 480
cctgggaggt ccctgagact ctcctgtgca gcgtctggat tcaccttcag tagctatggc 540
atgcactggg tccgccaggc tccaggcaag gggctggagt gggtggcagt tatatcgtat 600
gatggaagta ataaatacta tgcagactcc gtgaagggcc gattcaccat ctccagagac 660
aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga cacggcggtg 720
tactactgcg tcaaggggcc gttgcaggag ccgccatacg attatggaat ggacgtatgg 780
ggccagggaa caactgtcac cgtctcctca gccgctgccc ttgataatga aaagtcaaac 840
ggaacaatca ttcacgtgaa gggcaagcac ctctgtccgt cacccttgtt ccctggtcca 900
tccaagccat tctgggtgtt ggtcgtagtg ggtggagtcc tcgcttgtta ctctctgctc 960
gtcaccgtgg cttttataat cttctgggtt agatccaaaa gaagccgcct gctccatagc 1020
gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggtctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452
<210> 164
<211> 483
<212> PRT
<213> 人工序列
<220>
<223> RD-21530CARLxH
<400> 164
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His
100 105 110
His Val Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140
Thr Lys Gly Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
145 150 155 160
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
165 170 175
Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
180 185 190
Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
195 200 205
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
210 215 220
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
225 230 235 240
Tyr Tyr Cys Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly
245 250 255
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ala
260 265 270
Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
465 470 475 480
Pro Pro Arg
<210> 165
<211> 1440
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 165
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtcc aactgcaaga aagcggaccc ggactggtga agccttctga gacacttagt 120
ctgacgtgca cggtcagtgg cggctccatc tcctcctatt attggtcatg gatacgacaa 180
cccccaggta agggcctgga atggattggc tatatctact attcaggaag cacgaactac 240
aatcccagcc tgaagtcccg agtgacaatt tcagtagata ccagtaaaaa ccagttcagt 300
cttaaactgt caagcgtgac agctgccgac accgctgtgt attactgcgt ctcactggtg 360
tattgtggag gggattgtta tagcgggttc gattattggg gacagggaac cctggtgact 420
gtatcttccg gcggcggcgg ctcagggggt ggcggtagtg gcggtggggg ttccgatatt 480
caactgacac aatcccccag ctcactcagc gccagcgtgg gggacagggt tagctttacc 540
tgtcaagcct ctcaggatat aaataacttt ctgaactggt atcaacagaa gcctgggaag 600
gcgcccaaac tcctgatcta tgatgcgtcc aacctggaaa ctggcgtgcc ttcacgcttt 660
agcggctctg gcagtggtac agacttcact tttaccatct cttcacttca gccggaggac 720
atcgccacat attactgtca acagtacgga aacttgccct ttacttttgg aggcggcacc 780
aaagttgaaa tcaaaagggc cgctgccctg gataacgaaa agagcaatgg gactataata 840
catgttaaag gaaaacacct gtgtccatct cccctgttcc ctggaccgtc aaagccattt 900
tgggtgctcg tggttgtcgg tggcgttctc gcctgttata gcttgctggt gacagtagcc 960
ttcattatct tttgggtgag atccaaaaga agccgcctgc tccatagcga ttacatgaat 1020
atgactccac gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga 1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat 1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac 1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac 1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa 1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc 1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa 1440
<210> 166
<211> 479
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 166
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60
Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125
Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160
Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
165 170 175
Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
225 230 235 240
Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn
260 265 270
Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285
Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300
Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335
Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 167
<211> 1374
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 167
caggtccaac tgcaagaaag cggacccgga ctggtgaagc cttctgagac acttagtctg 60
acgtgcacgg tcagtggcgg ctccatctcc tcctattatt ggtcatggat acgacaaccc 120
ccaggtaagg gcctggaatg gattggctat atctactatt caggaagcac gaactacaat 180
cccagcctga agtcccgagt gacaatttca gtagatacca gtaaaaacca gttcagtctt 240
aaactgtcaa gcgtgacagc tgccgacacc gctgtgtatt actgcgtctc actggtgtat 300
tgtggagggg attgttatag cgggttcgat tattggggac agggaaccct ggtgactgta 360
tcttccggcg gcggcggctc agggggtggc ggtagtggcg gtgggggttc cgatattcaa 420
ctgacacaat cccccagctc actcagcgcc agcgtggggg acagggttag ctttacctgt 480
caagcctctc aggatataaa taactttctg aactggtatc aacagaagcc tgggaaggcg 540
cccaaactcc tgatctatga tgcgtccaac ctggaaactg gcgtgccttc acgctttagc 600
ggctctggca gtggtacaga cttcactttt accatctctt cacttcagcc ggaggacatc 660
gccacatatt actgtcaaca gtacggaaac ttgcccttta cttttggagg cggcaccaaa 720
gttgaaatca aaagggccgc tgccctggat aacgaaaaga gcaatgggac tataatacat 780
gttaaaggaa aacacctgtg tccatctccc ctgttccctg gaccgtcaaa gccattttgg 840
gtgctcgtgg ttgtcggtgg cgttctcgcc tgttatagct tgctggtgac agtagccttc 900
attatctttt gggtgagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 960
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1020
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag 1080
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt 1140
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc 1200
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata 1260
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1320
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc tagg 1374
<210> 168
<211> 458
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 168
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205
Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220
Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240
Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
245 250 255
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
260 265 270
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
275 280 285
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
290 295 300
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
305 310 315 320
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
325 330 335
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
340 345 350
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
355 360 365
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
370 375 380
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
385 390 395 400
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
405 410 415
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
420 425 430
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
435 440 445
Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455
<210> 169
<211> 1467
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 169
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctgcagga atccggaccg gggctggtga agcccagcga gactctgagt 120
ctcacgtgta cagtttctgg aggtagcatt agctcctact attggtcatg gataaggcag 180
ccccccggga agggattgga atggatcggc tatatttact acagtgggag caccaattac 240
aacccctcac tgaagtctag agttacaatc agcgttgaca cctcaaagaa tcagttcagt 300
ttgaaattgt ctagcgtcac agcagctgat acagccgtct attattgtgt ttctctggtc 360
tattgcggtg gggattgtta cagtggcttt gactattggg ggcagggtac tctggttaca 420
gtttcttccg gggggggagg ctctgggggc ggaggctcag gtggtggagg cagcgacatc 480
cagttgacac agagcccgag ttccttgtcc gcctccgtcg gggatagagt gtcatttacc 540
tgtcaggcct ctcaggatat taataacttt ctgaattggt atcagcaaaa gcccggaaag 600
gcacccaagc tgttgattta cgacgccagt aacctggaga caggcgtgcc ctcccggttt 660
agtggtagcg gaagcggtac ggattttacc tttactatca gctctctcca acccgaagac 720
attgcaacct actattgtca acaatatgga aacctgcctt ttacatttgg cggcggcacc 780
aaggtggaga ttaagcgggc ggcagctatt gaggtgatgt atccaccgcc ttacctggat 840
aacgaaaaga gtaacggtac catcattcac gtgaaaggta aacacctgtg tccttctccc 900
ctcttccccg ggccatcaaa gcccttctgg gttcttgtgg tcgtgggagg cgtgcttgct 960
tgttattctc tgctcgttac cgtggcgttt atcatttttt gggttagatc caaaagaagc 1020
cgcctgctcc atagcgatta catgaatatg actccacgcc gccctggccc cacaaggaaa 1080
cactaccagc cttacgcacc acctagagat ttcgctgcct atcggagcag ggtgaagttt 1140
tccagatctg cagatgcacc agcgtatcag cagggccaga accaactgta taacgagctc 1200
aacctgggac gcagggaaga gtatgacgtt ttggacaagc gcagaggacg ggaccctgag 1260
atgggtggca aaccaagacg aaaaaacccc caggagggtc tctataatga gctgcagaag 1320
gataagatgg ctgaagccta ttctgaaata ggcatgaaag gagagcggag aaggggaaaa 1380
gggcacgacg gtttgtacca gggactcagc actgctacga aggatactta tgacgctctc 1440
cacatgcaag ccctgccacc taggtaa 1467
<210> 170
<211> 488
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 170
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60
Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125
Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160
Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
165 170 175
Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
225 230 235 240
Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val
260 265 270
Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
275 280 285
Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly
290 295 300
Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala
305 310 315 320
Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg
325 330 335
Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro
340 345 350
Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro
355 360 365
Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala
370 375 380
Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu
385 390 395 400
Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
405 410 415
Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu
420 425 430
Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
435 440 445
Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
450 455 460
Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
465 470 475 480
His Met Gln Ala Leu Pro Pro Arg
485
<210> 171
<211> 1401
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 171
caggtgcagc tgcaggaatc cggaccgggg ctggtgaagc ccagcgagac tctgagtctc 60
acgtgtacag tttctggagg tagcattagc tcctactatt ggtcatggat aaggcagccc 120
cccgggaagg gattggaatg gatcggctat atttactaca gtgggagcac caattacaac 180
ccctcactga agtctagagt tacaatcagc gttgacacct caaagaatca gttcagtttg 240
aaattgtcta gcgtcacagc agctgataca gccgtctatt attgtgtttc tctggtctat 300
tgcggtgggg attgttacag tggctttgac tattgggggc agggtactct ggttacagtt 360
tcttccgggg ggggaggctc tgggggcgga ggctcaggtg gtggaggcag cgacatccag 420
ttgacacaga gcccgagttc cttgtccgcc tccgtcgggg atagagtgtc atttacctgt 480
caggcctctc aggatattaa taactttctg aattggtatc agcaaaagcc cggaaaggca 540
cccaagctgt tgatttacga cgccagtaac ctggagacag gcgtgccctc ccggtttagt 600
ggtagcggaa gcggtacgga ttttaccttt actatcagct ctctccaacc cgaagacatt 660
gcaacctact attgtcaaca atatggaaac ctgcctttta catttggcgg cggcaccaag 720
gtggagatta agcgggcggc agctattgag gtgatgtatc caccgcctta cctggataac 780
gaaaagagta acggtaccat cattcacgtg aaaggtaaac acctgtgtcc ttctcccctc 840
ttccccgggc catcaaagcc cttctgggtt cttgtggtcg tgggaggcgt gcttgcttgt 900
tattctctgc tcgttaccgt ggcgtttatc attttttggg ttagatccaa aagaagccgc 960
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1020
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1080
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1140
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1200
ggtggcaaac caagacgaaa aaacccccag gagggtctct ataatgagct gcagaaggat 1260
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1320
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1380
atgcaagccc tgccacctag g 1401
<210> 172
<211> 467
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 172
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205
Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220
Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240
Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
245 250 255
Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
260 265 270
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
275 280 285
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
290 295 300
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
305 310 315 320
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
325 330 335
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
340 345 350
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
355 360 365
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
370 375 380
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
385 390 395 400
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
405 410 415
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
420 425 430
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
435 440 445
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
450 455 460
Pro Pro Arg
465
<210> 173
<211> 1548
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 173
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc aattgcaaga gtccggcccc ggactcgtta aacccagtga gacgcttagc 120
ctgacctgta ccgtctcagg gggcagcatc tcctcttatt actggagctg gatcaggcag 180
cctccaggaa aaggccttga atggattggg tacatctact actctggctc aacaaattat 240
aatccatccc tgaagtcccg cgtgactatc tctgtggaca ccagcaagaa tcagttttca 300
ctgaagttgt ctagtgttac cgcggccgac accgccgtat actactgtgt gtctcttgtg 360
tactgtggcg gcgactgcta ttccgggttc gactactggg gccaagggac tctggtaacc 420
gtgtcctcag gcggcggcgg gtcaggagga ggcggcagtg gaggtggcgg ctccgacatc 480
cagctgacac aatcaccatc ttccctttca gcttcagtcg gggacagagt gtccttcaca 540
tgccaggcca gccaggatat caataacttc ctgaactggt accaacagaa acccggaaag 600
gctccaaagc tcctgatcta tgatgcttcc aacctggaga ccggcgtgcc ctccaggttc 660
agtggttcag gatcaggcac tgactttacg ttcaccatat ccagtcttca gcccgaagac 720
attgcaacct attactgcca acaatacggg aaccttccct ttacattcgg aggcggcacc 780
aaggtggaaa tcaaaagggc tgcagcattg agcaactcaa taatgtattt tagtcacttt 840
gtaccagtgt tcttgccggc taagcctact accacacccg ctccacggcc acctacccca 900
gctcctacca tcgcttcaca gcctctgtcc ctgcgcccag aggcttgccg accggccgca 960
gggggcgctg ttcataccag aggactggat ttcgcctgcg atatctatat ctgggcaccc 1020
ctggccggaa cctgcggcgt actcctgctg tccctggtca tcacgctcta ttgtaatcac 1080
aggaacagat ccaaaagaag ccgcctgctc catagcgatt acatgaatat gactccacgc 1140
cgccctggcc ccacaaggaa acactaccag ccttacgcac cacctagaga tttcgctgcc 1200
tatcggagca gggtgaagtt ttccagatct gcagatgcac cagcgtatca gcagggccag 1260
aaccaactgt ataacgagct caacctggga cgcagggaag agtatgacgt tttggacaag 1320
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt 1380
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa 1440
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg 1500
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa 1548
<210> 174
<211> 515
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 174
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60
Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125
Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160
Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
165 170 175
Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
225 230 235 240
Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn
260 265 270
Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys
275 280 285
Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
290 295 300
Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
305 310 315 320
Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
325 330 335
Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
340 345 350
Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg
355 360 365
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
370 375 380
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
385 390 395 400
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
485 490 495
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
500 505 510
Pro Pro Arg
515
<210> 175
<211> 1482
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 175
caggtgcaat tgcaagagtc cggccccgga ctcgttaaac ccagtgagac gcttagcctg 60
acctgtaccg tctcaggggg cagcatctcc tcttattact ggagctggat caggcagcct 120
ccaggaaaag gccttgaatg gattgggtac atctactact ctggctcaac aaattataat 180
ccatccctga agtcccgcgt gactatctct gtggacacca gcaagaatca gttttcactg 240
aagttgtcta gtgttaccgc ggccgacacc gccgtatact actgtgtgtc tcttgtgtac 300
tgtggcggcg actgctattc cgggttcgac tactggggcc aagggactct ggtaaccgtg 360
tcctcaggcg gcggcgggtc aggaggaggc ggcagtggag gtggcggctc cgacatccag 420
ctgacacaat caccatcttc cctttcagct tcagtcgggg acagagtgtc cttcacatgc 480
caggccagcc aggatatcaa taacttcctg aactggtacc aacagaaacc cggaaaggct 540
ccaaagctcc tgatctatga tgcttccaac ctggagaccg gcgtgccctc caggttcagt 600
ggttcaggat caggcactga ctttacgttc accatatcca gtcttcagcc cgaagacatt 660
gcaacctatt actgccaaca atacgggaac cttcccttta cattcggagg cggcaccaag 720
gtggaaatca aaagggctgc agcattgagc aactcaataa tgtattttag tcactttgta 780
ccagtgttct tgccggctaa gcctactacc acacccgctc cacggccacc taccccagct 840
cctaccatcg cttcacagcc tctgtccctg cgcccagagg cttgccgacc ggccgcaggg 900
ggcgctgttc ataccagagg actggatttc gcctgcgata tctatatctg ggcacccctg 960
gccggaacct gcggcgtact cctgctgtcc ctggtcatca cgctctattg taatcacagg 1020
aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1080
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1140
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1200
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1260
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1320
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1380
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1440
gatacttatg acgctctcca catgcaagcc ctgccaccta gg 1482
<210> 176
<211> 494
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 176
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205
Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220
Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240
Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
245 250 255
Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
260 265 270
Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
275 280 285
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
290 295 300
Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
305 310 315 320
Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
325 330 335
Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
340 345 350
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
355 360 365
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
370 375 380
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
385 390 395 400
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
405 410 415
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
420 425 430
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
435 440 445
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
450 455 460
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
465 470 475 480
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 177
<211> 1440
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 177
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggatatcc agctcacgca atccccctca agcttgagtg cctccgtggg cgaccgggtg 120
tccttcacat gtcaggcaag ccaagacata aataatttcc tgaattggta ccaacaaaaa 180
cccggcaagg ctcccaaact cctgatttat gatgcctcca atctggagac cggggtccct 240
tctagattca gcggaagtgg cagcggcaca gactttacat ttactatctc ttctctgcaa 300
ccagaggaca tcgccacata ctattgccag caatacggca atctgccctt caccttcgga 360
ggcggaacca aggtagaaat taaaaggggc ggtggaggct ccggaggggg gggctctggc 420
ggagggggct cccaagtaca attgcaggag tcagggcctg gactcgtgaa gccttcagaa 480
actttgtcac tgacatgtac agtgtccggc ggaagcattt ccagttacta ttggtcctgg 540
attagacagc cacccggcaa aggactggaa tggattggat atatctacta ctctggatct 600
acaaactata atcccagcct caaatccagg gtcactatta gtgtggatac atcaaagaat 660
cagttctcct tgaagctgag ctcagtcact gctgccgaca ccgcagtgta ctattgtgtg 720
agcctggtct actgcggcgg agattgctac agcggtttcg attactgggg ccagggcacc 780
ctggttaccg ttagttccgc ggctgctctt gataacgaga agtccaacgg tacgattatc 840
cacgttaagg gtaagcacct ttgccctagc ccgctgttcc caggccccag taagcccttt 900
tgggtcctcg ttgtggtagg tggggtactc gcctgctact ccctgctcgt cactgtcgca 960
ttcatcatct tctgggtcag atccaaaaga agccgcctgc tccatagcga ttacatgaat 1020
atgactccac gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga 1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat 1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac 1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac 1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa 1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc 1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa 1440
<210> 178
<211> 479
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 178
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln
35 40 45
Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
100 105 110
Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
145 150 155 160
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
165 170 175
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
180 185 190
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
195 200 205
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
210 215 220
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
225 230 235 240
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn
260 265 270
Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285
Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300
Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335
Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 179
<211> 1374
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 179
gatatccagc tcacgcaatc cccctcaagc ttgagtgcct ccgtgggcga ccgggtgtcc 60
ttcacatgtc aggcaagcca agacataaat aatttcctga attggtacca acaaaaaccc 120
ggcaaggctc ccaaactcct gatttatgat gcctccaatc tggagaccgg ggtcccttct 180
agattcagcg gaagtggcag cggcacagac tttacattta ctatctcttc tctgcaacca 240
gaggacatcg ccacatacta ttgccagcaa tacggcaatc tgcccttcac cttcggaggc 300
ggaaccaagg tagaaattaa aaggggcggt ggaggctccg gagggggggg ctctggcgga 360
gggggctccc aagtacaatt gcaggagtca gggcctggac tcgtgaagcc ttcagaaact 420
ttgtcactga catgtacagt gtccggcgga agcatttcca gttactattg gtcctggatt 480
agacagccac ccggcaaagg actggaatgg attggatata tctactactc tggatctaca 540
aactataatc ccagcctcaa atccagggtc actattagtg tggatacatc aaagaatcag 600
ttctccttga agctgagctc agtcactgct gccgacaccg cagtgtacta ttgtgtgagc 660
ctggtctact gcggcggaga ttgctacagc ggtttcgatt actggggcca gggcaccctg 720
gttaccgtta gttccgcggc tgctcttgat aacgagaagt ccaacggtac gattatccac 780
gttaagggta agcacctttg ccctagcccg ctgttcccag gccccagtaa gcccttttgg 840
gtcctcgttg tggtaggtgg ggtactcgcc tgctactccc tgctcgtcac tgtcgcattc 900
atcatcttct gggtcagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 960
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1020
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag 1080
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt 1140
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc 1200
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata 1260
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1320
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc tagg 1374
<210> 180
<211> 458
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 180
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125
Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140
Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175
Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190
Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys
210 215 220
Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
225 230 235 240
Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
245 250 255
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
260 265 270
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
275 280 285
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
290 295 300
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
305 310 315 320
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
325 330 335
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
340 345 350
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
355 360 365
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
370 375 380
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
385 390 395 400
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
405 410 415
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
420 425 430
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
435 440 445
Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455
<210> 181
<211> 1467
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 181
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggatatcc agctgaccca gtctccatcc tctttgagtg cctccgtggg tgaccgcgtc 120
tctttcactt gccaagccag ccaagacatc aacaactttc tgaattggta ccagcagaaa 180
ccaggcaaag caccaaagct cctcatctac gacgcctcca acctggaaac cggggtgccc 240
agcaggttta gcgggagcgg ttctggcacg gattttacgt tcaccatctc ctctctgcag 300
cccgaggata tagctactta ttactgtcag cagtacggga atctgccatt tacttttggg 360
ggtggaacta aggtggaaat caaaaggggc ggcgggggaa gcgggggcgg gggctcaggt 420
ggcggaggga gccaggtgca actccaggaa agtggcccag gattggtgaa gcccagcgag 480
accctttccc ttacttgtac tgttagcgga ggcagcataa gcagctacta ttggtcctgg 540
atcagacagc caccagggaa agggcttgaa tggattggct acatttacta ttccgggtcc 600
accaactaca acccatccct caagtcccgc gtgacaattt ccgtcgacac aagcaagaac 660
cagttctccc tgaaacttag tagcgtcact gctgcagata cagcagtgta ctattgtgtc 720
agccttgtct actgtggcgg cgactgctac agtggctttg attactgggg acagggcacg 780
ctcgtgacag tgtccagcgc tgcggctatc gaggtaatgt atccgccacc gtatctggac 840
aacgagaagt ctaatgggac aatcattcac gtgaagggga agcacctgtg tccatccccc 900
ctgtttccgg gtcccagtaa acccttctgg gtgcttgttg tcgttggcgg ggtgctggcc 960
tgctattccc tgctggtgac cgtcgcgttt attattttct gggttagatc caaaagaagc 1020
cgcctgctcc atagcgatta catgaatatg actccacgcc gccctggccc cacaaggaaa 1080
cactaccagc cttacgcacc acctagagat ttcgctgcct atcggagcag ggtgaagttt 1140
tccagatctg cagatgcacc agcgtatcag cagggccaga accaactgta taacgagctc 1200
aacctgggac gcagggaaga gtatgacgtt ttggacaagc gcagaggacg ggaccctgag 1260
atgggtggca aaccaagacg aaaaaacccc caggagggtc tctataatga gctgcagaag 1320
gataagatgg ctgaagccta ttctgaaata ggcatgaaag gagagcggag aaggggaaaa 1380
gggcacgacg gtttgtacca gggactcagc actgctacga aggatactta tgacgctctc 1440
cacatgcaag ccctgccacc taggtaa 1467
<210> 182
<211> 488
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 182
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln
35 40 45
Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
100 105 110
Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
145 150 155 160
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
165 170 175
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
180 185 190
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
195 200 205
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
210 215 220
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
225 230 235 240
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val
260 265 270
Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
275 280 285
Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly
290 295 300
Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala
305 310 315 320
Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg
325 330 335
Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro
340 345 350
Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro
355 360 365
Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala
370 375 380
Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu
385 390 395 400
Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
405 410 415
Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu
420 425 430
Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
435 440 445
Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
450 455 460
Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
465 470 475 480
His Met Gln Ala Leu Pro Pro Arg
485
<210> 183
<211> 1401
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 183
gatatccagc tgacccagtc tccatcctct ttgagtgcct ccgtgggtga ccgcgtctct 60
ttcacttgcc aagccagcca agacatcaac aactttctga attggtacca gcagaaacca 120
ggcaaagcac caaagctcct catctacgac gcctccaacc tggaaaccgg ggtgcccagc 180
aggtttagcg ggagcggttc tggcacggat tttacgttca ccatctcctc tctgcagccc 240
gaggatatag ctacttatta ctgtcagcag tacgggaatc tgccatttac ttttgggggt 300
ggaactaagg tggaaatcaa aaggggcggc gggggaagcg ggggcggggg ctcaggtggc 360
ggagggagcc aggtgcaact ccaggaaagt ggcccaggat tggtgaagcc cagcgagacc 420
ctttccctta cttgtactgt tagcggaggc agcataagca gctactattg gtcctggatc 480
agacagccac cagggaaagg gcttgaatgg attggctaca tttactattc cgggtccacc 540
aactacaacc catccctcaa gtcccgcgtg acaatttccg tcgacacaag caagaaccag 600
ttctccctga aacttagtag cgtcactgct gcagatacag cagtgtacta ttgtgtcagc 660
cttgtctact gtggcggcga ctgctacagt ggctttgatt actggggaca gggcacgctc 720
gtgacagtgt ccagcgctgc ggctatcgag gtaatgtatc cgccaccgta tctggacaac 780
gagaagtcta atgggacaat cattcacgtg aaggggaagc acctgtgtcc atcccccctg 840
tttccgggtc ccagtaaacc cttctgggtg cttgttgtcg ttggcggggt gctggcctgc 900
tattccctgc tggtgaccgt cgcgtttatt attttctggg ttagatccaa aagaagccgc 960
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1020
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1080
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1140
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1200
ggtggcaaac caagacgaaa aaacccccag gagggtctct ataatgagct gcagaaggat 1260
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1320
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1380
atgcaagccc tgccacctag g 1401
<210> 184
<211> 467
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 184
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125
Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140
Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175
Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190
Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys
210 215 220
Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
225 230 235 240
Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
245 250 255
Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
260 265 270
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
275 280 285
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
290 295 300
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
305 310 315 320
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
325 330 335
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
340 345 350
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
355 360 365
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
370 375 380
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
385 390 395 400
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
405 410 415
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
420 425 430
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
435 440 445
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
450 455 460
Pro Pro Arg
465
<210> 185
<211> 1548
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 185
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggacattc aattgaccca gtcccctagc agtctctcag caagtgtggg agatagggtg 120
tcattcacct gtcaggcttc acaggacatc aacaacttcc tcaattggta tcagcagaag 180
ccagggaagg caccaaagct gctcatatat gacgcttcaa accttgaaac cggagtacct 240
agccgcttca gcggaagcgg atcagggact gacttcactt ttaccatctc ttcactgcag 300
cccgaagaca tcgccacata ctactgccag cagtacggaa acttgccttt tacatttggg 360
ggcggcacca aagtggagat taagcgaggg ggaggcggct caggaggcgg tggctccgga 420
ggcgggggtt cccaggtcca gctccaggaa tccggcccag gtctggttaa gcccagtgaa 480
actttgtccc tcacgtgtac tgtgagcggt ggttcaatct cctcatacta ttggtcttgg 540
atacggcaac ctcctggaaa gggcctcgag tggatcggct atatctacta tagtggctcc 600
actaattaca acccttccct caagtccaga gtcaccattt ccgtggacac atctaagaac 660
cagttcagtc tgaagttgtc cagcgttaca gccgcagaca cagccgttta ttactgtgtg 720
tctcttgttt actgcggggg agactgttat agcggcttcg attactgggg ccagggcacc 780
ttggtcacag tctcttccgc ggccgccctc tctaacagta ttatgtactt ttctcatttt 840
gtacccgtgt tccttcccgc taagccaact actaccccgg ccccacggcc gcctacccct 900
gcacccacaa tagccagtca gcctttgagc ctgagacctg aggcttgtcg gccggctgct 960
gggggtgcag tgcacacacg aggtcttgat tttgcttgcg acatatacat ctgggcccct 1020
ctggccggga cctgtggggt gctgcttctg agcttggtca tcacgctcta ttgcaaccat 1080
cgcaacagat ccaaaagaag ccgcctgctc catagcgatt acatgaatat gactccacgc 1140
cgccctggcc ccacaaggaa acactaccag ccttacgcac cacctagaga tttcgctgcc 1200
tatcggagca gggtgaagtt ttccagatct gcagatgcac cagcgtatca gcagggccag 1260
aaccaactgt ataacgagct caacctggga cgcagggaag agtatgacgt tttggacaag 1320
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt 1380
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa 1440
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg 1500
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa 1548
<210> 186
<211> 515
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 186
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln
35 40 45
Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
100 105 110
Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
145 150 155 160
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
165 170 175
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
180 185 190
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
195 200 205
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
210 215 220
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
225 230 235 240
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Leu Ser Asn
260 265 270
Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys
275 280 285
Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
290 295 300
Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
305 310 315 320
Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
325 330 335
Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
340 345 350
Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg
355 360 365
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
370 375 380
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
385 390 395 400
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
485 490 495
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
500 505 510
Pro Pro Arg
515
<210> 187
<211> 1482
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 187
gacattcaat tgacccagtc ccctagcagt ctctcagcaa gtgtgggaga tagggtgtca 60
ttcacctgtc aggcttcaca ggacatcaac aacttcctca attggtatca gcagaagcca 120
gggaaggcac caaagctgct catatatgac gcttcaaacc ttgaaaccgg agtacctagc 180
cgcttcagcg gaagcggatc agggactgac ttcactttta ccatctcttc actgcagccc 240
gaagacatcg ccacatacta ctgccagcag tacggaaact tgccttttac atttgggggc 300
ggcaccaaag tggagattaa gcgaggggga ggcggctcag gaggcggtgg ctccggaggc 360
gggggttccc aggtccagct ccaggaatcc ggcccaggtc tggttaagcc cagtgaaact 420
ttgtccctca cgtgtactgt gagcggtggt tcaatctcct catactattg gtcttggata 480
cggcaacctc ctggaaaggg cctcgagtgg atcggctata tctactatag tggctccact 540
aattacaacc cttccctcaa gtccagagtc accatttccg tggacacatc taagaaccag 600
ttcagtctga agttgtccag cgttacagcc gcagacacag ccgtttatta ctgtgtgtct 660
cttgtttact gcgggggaga ctgttatagc ggcttcgatt actggggcca gggcaccttg 720
gtcacagtct cttccgcggc cgccctctct aacagtatta tgtacttttc tcattttgta 780
cccgtgttcc ttcccgctaa gccaactact accccggccc cacggccgcc tacccctgca 840
cccacaatag ccagtcagcc tttgagcctg agacctgagg cttgtcggcc ggctgctggg 900
ggtgcagtgc acacacgagg tcttgatttt gcttgcgaca tatacatctg ggcccctctg 960
gccgggacct gtggggtgct gcttctgagc ttggtcatca cgctctattg caaccatcgc 1020
aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1080
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1140
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1200
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1260
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1320
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1380
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1440
gatacttatg acgctctcca catgcaagcc ctgccaccta gg 1482
<210> 188
<211> 494
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 188
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125
Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140
Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175
Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190
Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys
210 215 220
Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
225 230 235 240
Val Thr Val Ser Ser Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
245 250 255
Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
260 265 270
Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
275 280 285
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
290 295 300
Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
305 310 315 320
Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
325 330 335
Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
340 345 350
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
355 360 365
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
370 375 380
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
385 390 395 400
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
405 410 415
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
420 425 430
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
435 440 445
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
450 455 460
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
465 470 475 480
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 189
<211> 1446
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 189
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtac agctgcagga atctgggccc ggacttgtca agccaagtca gacactttct 120
cttacatgta ccgtgagcgg cggaagtata agcagtggag gcttttactg gtcttggata 180
cggcagcacc caggcaaagg cttggagtgg attggataca ttcatcattc aggatctaca 240
cactataatc catcccttaa gtcccgggtc accattagca ttgatacgtc taagaatctg 300
ttcagtctca ggctgtcctc cgtcactgct gccgacacag ccgtgtacta ctgcgcctcc 360
ttggtttact gcggaggcga ctgttatagc ggctttgatt attgggggca ggggaccctc 420
gtaaccgtga gctctggagg gggtgggagc gggggaggag gttcaggggg gggcggctcc 480
gatatccagc tcactcaaag cccctctagt ctctctgcct cagtggggga tcgggtcagt 540
tttacttgtc aagcttcaca ggatatcaac aacttcctta attggtatca gcagaagcca 600
ggaaaagcac ccaagctgct catctatgat gcctcaaatt tggagacggg tgttcccagt 660
cgattctctg ggtcagggtc cgggaccgac tttacgttta cgatctcctc tctgcagccc 720
gaagacatcg ccacatacta ttgtcaacag tacggcaact tgcctttcac atttgggggc 780
gggactaagg ttgaaatcaa gagggccgct gcactggaca atgagaagtc caacggcacc 840
atcatccacg tgaagggcaa gcacctgtgc cctagtcctc tgttcccagg cccatccaaa 900
cctttttggg ttcttgttgt ggtcgggggg gtgctggcct gctattctct gctggtcacg 960
gtggccttca taattttctg ggttagatcc aaaagaagcc gcctgctcca tagcgattac 1020
atgaatatga ctccacgccg ccctggcccc acaaggaaac actaccagcc ttacgcacca 1080
cctagagatt tcgctgccta tcggagcagg gtgaagtttt ccagatctgc agatgcacca 1140
gcgtatcagc agggccagaa ccaactgtat aacgagctca acctgggacg cagggaagag 1200
tatgacgttt tggacaagcg cagaggacgg gaccctgaga tgggtggcaa accaagacga 1260
aaaaaccccc aggagggtct ctataatgag ctgcagaagg ataagatggc tgaagcctat 1320
tctgaaatag gcatgaaagg agagcggaga aggggaaaag ggcacgacgg tttgtaccag 1380
ggactcagca ctgctacgaa ggatacttat gacgctctcc acatgcaagc cctgccacct 1440
aggtaa 1446
<210> 190
<211> 481
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 190
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
50 55 60
Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
65 70 75 80
His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
85 90 95
Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
115 120 125
Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
210 215 220
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
225 230 235 240
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
245 250 255
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu
260 265 270
Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His
275 280 285
Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val
290 295 300
Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr
305 310 315 320
Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu
325 330 335
His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg
340 345 350
Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg
355 360 365
Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln
370 375 380
Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
385 390 395 400
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
405 410 415
Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
420 425 430
Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
435 440 445
Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
450 455 460
Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
465 470 475 480
Arg
<210> 191
<211> 1380
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 191
caggtacagc tgcaggaatc tgggcccgga cttgtcaagc caagtcagac actttctctt 60
acatgtaccg tgagcggcgg aagtataagc agtggaggct tttactggtc ttggatacgg 120
cagcacccag gcaaaggctt ggagtggatt ggatacattc atcattcagg atctacacac 180
tataatccat cccttaagtc ccgggtcacc attagcattg atacgtctaa gaatctgttc 240
agtctcaggc tgtcctccgt cactgctgcc gacacagccg tgtactactg cgcctccttg 300
gtttactgcg gaggcgactg ttatagcggc tttgattatt gggggcaggg gaccctcgta 360
accgtgagct ctggaggggg tgggagcggg ggaggaggtt cagggggggg cggctccgat 420
atccagctca ctcaaagccc ctctagtctc tctgcctcag tgggggatcg ggtcagtttt 480
acttgtcaag cttcacagga tatcaacaac ttccttaatt ggtatcagca gaagccagga 540
aaagcaccca agctgctcat ctatgatgcc tcaaatttgg agacgggtgt tcccagtcga 600
ttctctgggt cagggtccgg gaccgacttt acgtttacga tctcctctct gcagcccgaa 660
gacatcgcca catactattg tcaacagtac ggcaacttgc ctttcacatt tgggggcggg 720
actaaggttg aaatcaagag ggccgctgca ctggacaatg agaagtccaa cggcaccatc 780
atccacgtga agggcaagca cctgtgccct agtcctctgt tcccaggccc atccaaacct 840
ttttgggttc ttgttgtggt cgggggggtg ctggcctgct attctctgct ggtcacggtg 900
gccttcataa ttttctgggt tagatccaaa agaagccgcc tgctccatag cgattacatg 960
aatatgactc cacgccgccc tggccccaca aggaaacact accagcctta cgcaccacct 1020
agagatttcg ctgcctatcg gagcagggtg aagttttcca gatctgcaga tgcaccagcg 1080
tatcagcagg gccagaacca actgtataac gagctcaacc tgggacgcag ggaagagtat 1140
gacgttttgg acaagcgcag aggacgggac cctgagatgg gtggcaaacc aagacgaaaa 1200
aacccccagg agggtctcta taatgagctg cagaaggata agatggctga agcctattct 1260
gaaataggca tgaaaggaga gcggagaagg ggaaaagggc acgacggttt gtaccaggga 1320
ctcagcactg ctacgaagga tacttatgac gctctccaca tgcaagccct gccacctagg 1380
<210> 192
<211> 460
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 192
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160
Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220
Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240
Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser
245 250 255
Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
260 265 270
Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
275 280 285
Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
290 295 300
Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
305 310 315 320
Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
325 330 335
Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe
340 345 350
Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
355 360 365
Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
370 375 380
Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
385 390 395 400
Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
405 410 415
Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
420 425 430
Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
435 440 445
Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460
<210> 193
<211> 1473
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 193
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctgcagga aagcggtccg ggacttgtca agccgtccca aacgctgagt 120
ctgacgtgta ctgtctctgg tggctctatt tcttccgggg gcttttattg gtcttggatc 180
agacaacacc ctggcaaagg gctggagtgg atagggtata ttcaccactc tgggtccact 240
cactacaacc catcattgaa atccagagtg actatctcaa tcgacacatc caagaacctt 300
ttcagcctga ggttgtcatc agttaccgcc gctgacaccg cggtgtatta ttgcgcctct 360
ctcgtgtact gcggtggcga ttgttatagt ggctttgact actgggggca ggggacattg 420
gttaccgttt caagtggagg cggtgggtct ggcgggggcg gtagcggagg tggggggagc 480
gacatacagc ttacgcagag cccctccagc ctttcagcct ccgtggggga tagggtgtcc 540
tttacctgcc aggcttccca ggacataaac aacttcctca attggtatca gcaaaagccc 600
gggaaagcac caaagctgct catctacgat gccagcaacc tggaaaccgg agtgccgtct 660
cgcttctctg gaagtggcag tgggaccgat ttcactttta caatctcaag tttgcagcca 720
gaagacattg caacatacta ctgtcaacag tacggcaatc tcccctttac atttgggggg 780
ggaactaaag tggagattaa gcgcgctgca gccattgaag ttatgtatcc gcccccgtat 840
ctggataacg agaaatctaa tggtaccata atacatgtga aggggaagca cctctgtcca 900
tcaccgctgt tccccggccc ttcaaaacct ttctgggtac tcgttgtcgt gggtggagtt 960
ctggcctgct atagtctgct ggtgaccgtg gcgtttatca tcttctgggt aagatccaaa 1020
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca 1080
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagcagggtg 1140
aagttttcca gatctgcaga tgcaccagcg tatcagcagg gccagaacca actgtataac 1200
gagctcaacc tgggacgcag ggaagagtat gacgttttgg acaagcgcag aggacgggac 1260
cctgagatgg gtggcaaacc aagacgaaaa aacccccagg agggtctcta taatgagctg 1320
cagaaggata agatggctga agcctattct gaaataggca tgaaaggaga gcggagaagg 1380
ggaaaagggc acgacggttt gtaccaggga ctcagcactg ctacgaagga tacttatgac 1440
gctctccaca tgcaagccct gccacctagg taa 1473
<210> 194
<211> 490
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 194
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
50 55 60
Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
65 70 75 80
His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
85 90 95
Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
115 120 125
Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
210 215 220
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
225 230 235 240
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
245 250 255
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile
260 265 270
Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly
275 280 285
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
290 295 300
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
305 310 315 320
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
325 330 335
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
340 345 350
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
355 360 365
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
370 375 380
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
385 390 395 400
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
405 410 415
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
420 425 430
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
435 440 445
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
450 455 460
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
465 470 475 480
Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 195
<211> 1407
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 195
caggtgcagc tgcaggaaag cggtccggga cttgtcaagc cgtcccaaac gctgagtctg 60
acgtgtactg tctctggtgg ctctatttct tccgggggct tttattggtc ttggatcaga 120
caacaccctg gcaaagggct ggagtggata gggtatattc accactctgg gtccactcac 180
tacaacccat cattgaaatc cagagtgact atctcaatcg acacatccaa gaaccttttc 240
agcctgaggt tgtcatcagt taccgccgct gacaccgcgg tgtattattg cgcctctctc 300
gtgtactgcg gtggcgattg ttatagtggc tttgactact gggggcaggg gacattggtt 360
accgtttcaa gtggaggcgg tgggtctggc gggggcggta gcggaggtgg ggggagcgac 420
atacagctta cgcagagccc ctccagcctt tcagcctccg tgggggatag ggtgtccttt 480
acctgccagg cttcccagga cataaacaac ttcctcaatt ggtatcagca aaagcccggg 540
aaagcaccaa agctgctcat ctacgatgcc agcaacctgg aaaccggagt gccgtctcgc 600
ttctctggaa gtggcagtgg gaccgatttc acttttacaa tctcaagttt gcagccagaa 660
gacattgcaa catactactg tcaacagtac ggcaatctcc cctttacatt tgggggggga 720
actaaagtgg agattaagcg cgctgcagcc attgaagtta tgtatccgcc cccgtatctg 780
gataacgaga aatctaatgg taccataata catgtgaagg ggaagcacct ctgtccatca 840
ccgctgttcc ccggcccttc aaaacctttc tgggtactcg ttgtcgtggg tggagttctg 900
gcctgctata gtctgctggt gaccgtggcg tttatcatct tctgggtaag atccaaaaga 960
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg ccccacaagg 1020
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag cagggtgaag 1080
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag 1140
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct 1200
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag 1260
aaggataaga tggctgaagc ctattctgaa ataggcatga aaggagagcg gagaagggga 1320
aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct 1380
ctccacatgc aagccctgcc acctagg 1407
<210> 196
<211> 469
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 196
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160
Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220
Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240
Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro
245 250 255
Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
260 265 270
Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
275 280 285
Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
290 295 300
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
305 310 315 320
Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
325 330 335
Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
340 345 350
Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
355 360 365
Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
370 375 380
Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
385 390 395 400
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
405 410 415
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
420 425 430
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
435 440 445
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
450 455 460
Ala Leu Pro Pro Arg
465
<210> 197
<211> 1554
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 197
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttgcagga aagcgggcct ggccttgtga aaccaagcca gacactgagc 120
ctgacatgca ctgtgtccgg cgggtccata tcttccgggg gtttttattg gtcctggata 180
cgccagcatc ccgggaaagg acttgaatgg attggatata tccaccattc cggaagcacc 240
cactacaatc caagccttaa atcccgggtg acaatctcca tcgacacctc aaagaatctt 300
ttttccctgc ggttgtcttc agtaactgcc gccgataccg ctgtgtacta ctgtgccagc 360
ctcgtctatt gcggcggaga ttgttattct gggttcgatt attggggtca aggcacactg 420
gtaactgtca gcagcggagg cggcggttcc gggggcgggg gcagtggagg gggcggatct 480
gacattcagc ttacgcagtc cccatcttca cttagcgcca gcgttggcga tcgggtcagc 540
ttcacgtgtc aagcaagtca ggatatcaac aactttctta actggtacca gcagaagcca 600
ggcaaggcac ccaagttgct gatttacgat gcttctaacc tcgagacggg agtgcctagc 660
cgcttctccg ggagcggcag cggcacagac tttaccttta cgatttccag tctgcagcca 720
gaggatatag caacttatta ctgtcagcag tatggcaacc tcccttttac cttcggtggt 780
ggcacaaagg tcgagattaa aagagccgca gcgttgtcca actccataat gtatttttct 840
cattttgtgc ccgtctttct gcctgccaaa cctaccacca cccccgcccc acgaccacct 900
actccagccc ccaccatcgc ctcccagccc ctcagcctga ggccagaggc ttgtcgccct 960
gctgcggggg gcgctgtcca taccagagga ctcgacttcg cctgcgatat ttatatatgg 1020
gcccccctcg ccggcacctg cggagtcttg ctcctgagcc ttgtgatcac gctttattgt 1080
aaccatcgga atagatccaa aagaagccgc ctgctccata gcgattacat gaatatgact 1140
ccacgccgcc ctggccccac aaggaaacac taccagcctt acgcaccacc tagagatttc 1200
gctgcctatc ggagcagggt gaagttttcc agatctgcag atgcaccagc gtatcagcag 1260
ggccagaacc aactgtataa cgagctcaac ctgggacgca gggaagagta tgacgttttg 1320
gacaagcgca gaggacggga ccctgagatg ggtggcaaac caagacgaaa aaacccccag 1380
gagggtctct ataatgagct gcagaaggat aagatggctg aagcctattc tgaaataggc 1440
atgaaaggag agcggagaag gggaaaaggg cacgacggtt tgtaccaggg actcagcact 1500
gctacgaagg atacttatga cgctctccac atgcaagccc tgccacctag gtaa 1554
<210> 198
<211> 517
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 198
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
50 55 60
Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
65 70 75 80
His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
85 90 95
Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
115 120 125
Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
210 215 220
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
225 230 235 240
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
245 250 255
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu
260 265 270
Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro
275 280 285
Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro
290 295 300
Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro
305 310 315 320
Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
325 330 335
Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
340 345 350
Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg
355 360 365
Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
370 375 380
Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
385 390 395 400
Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
405 410 415
Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
420 425 430
Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
435 440 445
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
450 455 460
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
465 470 475 480
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
485 490 495
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
500 505 510
Ala Leu Pro Pro Arg
515
<210> 199
<211> 1488
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 199
caggtgcagt tgcaggaaag cgggcctggc cttgtgaaac caagccagac actgagcctg 60
acatgcactg tgtccggcgg gtccatatct tccgggggtt tttattggtc ctggatacgc 120
cagcatcccg ggaaaggact tgaatggatt ggatatatcc accattccgg aagcacccac 180
tacaatccaa gccttaaatc ccgggtgaca atctccatcg acacctcaaa gaatcttttt 240
tccctgcggt tgtcttcagt aactgccgcc gataccgctg tgtactactg tgccagcctc 300
gtctattgcg gcggagattg ttattctggg ttcgattatt ggggtcaagg cacactggta 360
actgtcagca gcggaggcgg cggttccggg ggcgggggca gtggaggggg cggatctgac 420
attcagctta cgcagtcccc atcttcactt agcgccagcg ttggcgatcg ggtcagcttc 480
acgtgtcaag caagtcagga tatcaacaac tttcttaact ggtaccagca gaagccaggc 540
aaggcaccca agttgctgat ttacgatgct tctaacctcg agacgggagt gcctagccgc 600
ttctccggga gcggcagcgg cacagacttt acctttacga tttccagtct gcagccagag 660
gatatagcaa cttattactg tcagcagtat ggcaacctcc cttttacctt cggtggtggc 720
acaaaggtcg agattaaaag agccgcagcg ttgtccaact ccataatgta tttttctcat 780
tttgtgcccg tctttctgcc tgccaaacct accaccaccc ccgccccacg accacctact 840
ccagccccca ccatcgcctc ccagcccctc agcctgaggc cagaggcttg tcgccctgct 900
gcggggggcg ctgtccatac cagaggactc gacttcgcct gcgatattta tatatgggcc 960
cccctcgccg gcacctgcgg agtcttgctc ctgagccttg tgatcacgct ttattgtaac 1020
catcggaata gatccaaaag aagccgcctg ctccatagcg attacatgaa tatgactcca 1080
cgccgccctg gccccacaag gaaacactac cagccttacg caccacctag agatttcgct 1140
gcctatcgga gcagggtgaa gttttccaga tctgcagatg caccagcgta tcagcagggc 1200
cagaaccaac tgtataacga gctcaacctg ggacgcaggg aagagtatga cgttttggac 1260
aagcgcagag gacgggaccc tgagatgggt ggcaaaccaa gacgaaaaaa cccccaggag 1320
ggtctctata atgagctgca gaaggataag atggctgaag cctattctga aataggcatg 1380
aaaggagagc ggagaagggg aaaagggcac gacggtttgt accagggact cagcactgct 1440
acgaaggata cttatgacgc tctccacatg caagccctgc cacctagg 1488
<210> 200
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 200
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160
Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220
Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240
Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met
245 250 255
Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr
260 265 270
Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
275 280 285
Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
290 295 300
Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
305 310 315 320
Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr
325 330 335
Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His
340 345 350
Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys
355 360 365
His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser
370 375 380
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
385 390 395 400
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
405 410 415
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
420 425 430
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
435 440 445
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
450 455 460
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
465 470 475 480
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490 495
<210> 201
<211> 1437
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 201
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtcc aactggtgca gtccggagcc gaagtcaaga aaccaggtgc ctccgttaaa 120
gtgagttgca aagtctctgg atacactctg accgagctct ctatgcactg ggtccggcag 180
gcccccggca agggattgga atggatgggc gggttcgatc ctgaggacgg agagactatc 240
tacgctcaaa aattccaggg acgagtgact gtgaccgaag acactagtac cgacactgcc 300
tacatggaac tttcctctct gcgatcagaa gataccgcag tgtactactg tgctactgaa 360
tctaggggca ttggatggcc ctacttcgat tactggggtc agggaactct ggtgactgtc 420
tccagcggtg gaggtggcag cggtggtggc ggaagcgggg ggggcggctc tgatattcag 480
atgactcaat ctccttcttc tctgtccgct tccgtgggcg atagagtgac cattacttgt 540
agggcgtccc agtcaatctc cagttatttg aattggtatc agcagaagcc cgggaaagca 600
cctaagctgt tgatcagcgg ggcttctagc ctgaagagtg gggtaccttc acggttcagc 660
ggaagcggaa gcggaaccga tttcaccctg actatcagca gcctgccacc tgaggacttt 720
gcaacttact actgccaaca gtcatacagc actccgatca ctttcggcca gggcacccgg 780
ctcgaaatca agcgcgctgc tgctttggac aatgagaagt caaacggcac catcatacat 840
gttaaaggta aacatctgtg tccctccccg ctgttccccg gcccttccaa accgttctgg 900
gttctggtgg tggtcggagg cgtactcgct tgctatagtc tgctggtaac tgtcgccttc 960
atcatctttt gggtgagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1080
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag 1140
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt 1200
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc 1260
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata 1320
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1380
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc taggtaa 1437
<210> 202
<211> 478
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 202
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30
Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr
35 40 45
Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile
65 70 75 80
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser
85 90 95
Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175
Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala
195 200 205
Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
225 230 235 240
Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
245 250 255
Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu
260 265 270
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
275 280 285
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
290 295 300
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
305 310 315 320
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
325 330 335
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
340 345 350
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
355 360 365
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
370 375 380
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
385 390 395 400
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
405 410 415
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
420 425 430
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
435 440 445
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
450 455 460
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 203
<211> 1371
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 203
caggtccaac tggtgcagtc cggagccgaa gtcaagaaac caggtgcctc cgttaaagtg 60
agttgcaaag tctctggata cactctgacc gagctctcta tgcactgggt ccggcaggcc 120
cccggcaagg gattggaatg gatgggcggg ttcgatcctg aggacggaga gactatctac 180
gctcaaaaat tccagggacg agtgactgtg accgaagaca ctagtaccga cactgcctac 240
atggaacttt cctctctgcg atcagaagat accgcagtgt actactgtgc tactgaatct 300
aggggcattg gatggcccta cttcgattac tggggtcagg gaactctggt gactgtctcc 360
agcggtggag gtggcagcgg tggtggcgga agcggggggg gcggctctga tattcagatg 420
actcaatctc cttcttctct gtccgcttcc gtgggcgata gagtgaccat tacttgtagg 480
gcgtcccagt caatctccag ttatttgaat tggtatcagc agaagcccgg gaaagcacct 540
aagctgttga tcagcggggc ttctagcctg aagagtgggg taccttcacg gttcagcgga 600
agcggaagcg gaaccgattt caccctgact atcagcagcc tgccacctga ggactttgca 660
acttactact gccaacagtc atacagcact ccgatcactt tcggccaggg cacccggctc 720
gaaatcaagc gcgctgctgc tttggacaat gagaagtcaa acggcaccat catacatgtt 780
aaaggtaaac atctgtgtcc ctccccgctg ttccccggcc cttccaaacc gttctgggtt 840
ctggtggtgg tcggaggcgt actcgcttgc tatagtctgc tggtaactgt cgccttcatc 900
atcttttggg tgagatccaa aagaagccgc ctgctccata gcgattacat gaatatgact 960
ccacgccgcc ctggccccac aaggaaacac taccagcctt acgcaccacc tagagatttc 1020
gctgcctatc ggagcagggt gaagttttcc agatctgcag atgcaccagc gtatcagcag 1080
ggccagaacc aactgtataa cgagctcaac ctgggacgca gggaagagta tgacgttttg 1140
gacaagcgca gaggacggga ccctgagatg ggtggcaaac caagacgaaa aaacccccag 1200
gagggtctct ataatgagct gcagaaggat aagatggctg aagcctattc tgaaataggc 1260
atgaaaggag agcggagaag gggaaaaggg cacgacggtt tgtaccaggg actcagcact 1320
gctacgaagg atacttatga cgctctccac atgcaagccc tgccacctag g 1371
<210> 204
<211> 457
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 204
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175
Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205
Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220
Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240
Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr
245 250 255
Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro
260 265 270
Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu
275 280 285
Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
290 295 300
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
305 310 315 320
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
325 330 335
Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
340 345 350
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
355 360 365
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
370 375 380
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
385 390 395 400
Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
405 410 415
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
420 425 430
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
435 440 445
Leu His Met Gln Ala Leu Pro Pro Arg
450 455
<210> 205
<211> 1464
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 205
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agcttgtgca gagcggggcc gaggtgaaga agcccggggc cagcgtcaaa 120
gtgtcctgta aggtcagcgg ttacaccctc accgagctga gcatgcactg ggtacggcag 180
gctcccggca aaggtcttga gtggatgggt ggatttgatc cagaagatgg agagactatc 240
tacgcccaga agttccaggg ccgggtcacc gtaacagaag acacctcaac tgacaccgct 300
tacatggagc tgagttcact gcggtccgag gacacggccg tgtattattg tgccaccgag 360
agccgcggaa tcggatggcc ttacttcgac tactggggac agggtacact tgttacagta 420
tcatccgggg gtggcggctc tggtgggggc ggctccggag ggggtggatc agatatccaa 480
atgactcaaa gtccaagttc cctgtctgcc tcagtcggag atagagtcac cataacctgc 540
agggcaagtc agtccatctc ctcctatctg aactggtacc aacagaaacc tggaaaggcg 600
cctaagctcc tgatctccgg agcctcatct ttgaaatccg gtgtcccatc tcgcttcagt 660
ggctctggaa gcggtacaga ttttactttg accattagca gcctcccacc ggaagacttt 720
gctacatatt actgccagca gtcttactca accccaatca ccttcgggca aggcaccaga 780
ctcgaaataa aaagagcagc tgctatcgag gttatgtacc caccgccgta cttggataac 840
gaaaaaagca atgggaccat cattcatgtg aagggtaagc acctttgccc tagcccactg 900
tttcctggcc cgagtaaacc cttttgggta cttgtggtcg tcggcggcgt gctggcctgc 960
tactcactcc tggttaccgt cgcattcatc atcttttggg tgagatccaa aagaagccgc 1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1140
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1200
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1260
ggtggcaaac caagacgaaa aaacccccag gagggtctct ataatgagct gcagaaggat 1320
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1380
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1440
atgcaagccc tgccacctag gtaa 1464
<210> 206
<211> 487
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 206
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30
Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr
35 40 45
Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile
65 70 75 80
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser
85 90 95
Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175
Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala
195 200 205
Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
225 230 235 240
Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
245 250 255
Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met
260 265 270
Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile
275 280 285
His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
290 295 300
Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320
Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335
Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350
Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365
Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
370 375 380
Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415
Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445
Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480
Met Gln Ala Leu Pro Pro Arg
485
<210> 207
<211> 1398
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 207
caggtgcagc ttgtgcagag cggggccgag gtgaagaagc ccggggccag cgtcaaagtg 60
tcctgtaagg tcagcggtta caccctcacc gagctgagca tgcactgggt acggcaggct 120
cccggcaaag gtcttgagtg gatgggtgga tttgatccag aagatggaga gactatctac 180
gcccagaagt tccagggccg ggtcaccgta acagaagaca cctcaactga caccgcttac 240
atggagctga gttcactgcg gtccgaggac acggccgtgt attattgtgc caccgagagc 300
cgcggaatcg gatggcctta cttcgactac tggggacagg gtacacttgt tacagtatca 360
tccgggggtg gcggctctgg tgggggcggc tccggagggg gtggatcaga tatccaaatg 420
actcaaagtc caagttccct gtctgcctca gtcggagata gagtcaccat aacctgcagg 480
gcaagtcagt ccatctcctc ctatctgaac tggtaccaac agaaacctgg aaaggcgcct 540
aagctcctga tctccggagc ctcatctttg aaatccggtg tcccatctcg cttcagtggc 600
tctggaagcg gtacagattt tactttgacc attagcagcc tcccaccgga agactttgct 660
acatattact gccagcagtc ttactcaacc ccaatcacct tcgggcaagg caccagactc 720
gaaataaaaa gagcagctgc tatcgaggtt atgtacccac cgccgtactt ggataacgaa 780
aaaagcaatg ggaccatcat tcatgtgaag ggtaagcacc tttgccctag cccactgttt 840
cctggcccga gtaaaccctt ttgggtactt gtggtcgtcg gcggcgtgct ggcctgctac 900
tcactcctgg ttaccgtcgc attcatcatc ttttgggtga gatccaaaag aagccgcctg 960
ctccatagcg attacatgaa tatgactcca cgccgccctg gccccacaag gaaacactac 1020
cagccttacg caccacctag agatttcgct gcctatcgga gcagggtgaa gttttccaga 1080
tctgcagatg caccagcgta tcagcagggc cagaaccaac tgtataacga gctcaacctg 1140
ggacgcaggg aagagtatga cgttttggac aagcgcagag gacgggaccc tgagatgggt 1200
ggcaaaccaa gacgaaaaaa cccccaggag ggtctctata atgagctgca gaaggataag 1260
atggctgaag cctattctga aataggcatg aaaggagagc ggagaagggg aaaagggcac 1320
gacggtttgt accagggact cagcactgct acgaaggata cttatgacgc tctccacatg 1380
caagccctgc cacctagg 1398
<210> 208
<211> 466
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 208
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175
Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205
Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220
Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240
Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr
245 250 255
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
260 265 270
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
275 280 285
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
290 295 300
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
305 310 315 320
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
325 330 335
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
340 345 350
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
355 360 365
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
370 375 380
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
385 390 395 400
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
405 410 415
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
420 425 430
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
435 440 445
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
450 455 460
Pro Arg
465
<210> 209
<211> 1545
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 209
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttggtgca aagcggcgca gaagttaaga aacctggggc gtcagttaag 120
gtgtcttgca aagtatctgg ctataccctc actgagctgt ccatgcattg ggtaaggcag 180
gctcctggaa aggggctcga atggatggga ggatttgacc ctgaagacgg agagaccatc 240
tacgcccaga aattccaggg tagagtaaca gtgactgagg acactagcac tgacacagcg 300
tacatggagc tgagttctct gagaagtgag gacacagccg tttactactg cgctaccgag 360
tccagaggta ttggctggcc atacttcgac tattggggtc agggcaccct ggttacagtg 420
agttcaggag gcgggggctc tggggggggc ggttccggag gggggggctc agatatacag 480
atgacgcaga gtccatcaag tctctcagcc agcgtgggag atcgcgtgac tattacttgc 540
cgcgccagcc agagtattag ctcctatctg aattggtacc agcaaaagcc cgggaaggcc 600
cctaagcttc tgatttctgg cgcctcctct ttgaagtcag gtgtgccaag cagatttagc 660
gggtctggaa gtggcactga ctttacactt actatctcca gcctgccccc agaggatttt 720
gccacatatt actgtcagca aagctactct actccaatca ctttcggcca gggcacaaga 780
ttggagatta agagggctgc cgcactttca aattccatca tgtatttcag ccattttgtg 840
cctgtttttc ttccggccaa acctacaacc actcccgccc cacgcccacc tactcccgcc 900
cctaccattg cctcccagcc tctgtctctt agacctgagg cttgtagacc tgctgccggc 960
ggagccgtgc acactcgcgg tctggacttc gcctgcgaca tctatatctg ggcccctctg 1020
gccggcacct gcggcgttct ccttctctca ctcgtaatca cactctattg caatcacagg 1080
aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1140
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1200
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1260
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1320
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1380
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1440
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1500
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa 1545
<210> 210
<211> 514
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 210
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30
Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr
35 40 45
Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile
65 70 75 80
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser
85 90 95
Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175
Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala
195 200 205
Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
225 230 235 240
Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
245 250 255
Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser
260 265 270
Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro
275 280 285
Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala
290 295 300
Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly
305 310 315 320
Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile
325 330 335
Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val
340 345 350
Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu
355 360 365
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
370 375 380
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
385 390 395 400
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
405 410 415
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
420 425 430
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
435 440 445
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
450 455 460
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
465 470 475 480
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
485 490 495
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
500 505 510
Pro Arg
<210> 211
<211> 1479
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 211
caggtgcagt tggtgcaaag cggcgcagaa gttaagaaac ctggggcgtc agttaaggtg 60
tcttgcaaag tatctggcta taccctcact gagctgtcca tgcattgggt aaggcaggct 120
cctggaaagg ggctcgaatg gatgggagga tttgaccctg aagacggaga gaccatctac 180
gcccagaaat tccagggtag agtaacagtg actgaggaca ctagcactga cacagcgtac 240
atggagctga gttctctgag aagtgaggac acagccgttt actactgcgc taccgagtcc 300
agaggtattg gctggccata cttcgactat tggggtcagg gcaccctggt tacagtgagt 360
tcaggaggcg ggggctctgg ggggggcggt tccggagggg ggggctcaga tatacagatg 420
acgcagagtc catcaagtct ctcagccagc gtgggagatc gcgtgactat tacttgccgc 480
gccagccaga gtattagctc ctatctgaat tggtaccagc aaaagcccgg gaaggcccct 540
aagcttctga tttctggcgc ctcctctttg aagtcaggtg tgccaagcag atttagcggg 600
tctggaagtg gcactgactt tacacttact atctccagcc tgcccccaga ggattttgcc 660
acatattact gtcagcaaag ctactctact ccaatcactt tcggccaggg cacaagattg 720
gagattaaga gggctgccgc actttcaaat tccatcatgt atttcagcca ttttgtgcct 780
gtttttcttc cggccaaacc tacaaccact cccgccccac gcccacctac tcccgcccct 840
accattgcct cccagcctct gtctcttaga cctgaggctt gtagacctgc tgccggcgga 900
gccgtgcaca ctcgcggtct ggacttcgcc tgcgacatct atatctgggc ccctctggcc 960
ggcacctgcg gcgttctcct tctctcactc gtaatcacac tctattgcaa tcacaggaac 1020
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 1080
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 1140
agcagggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa 1200
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgttttgga caagcgcaga 1260
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggtctctat 1320
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag 1380
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat 1440
acttatgacg ctctccacat gcaagccctg ccacctagg 1479
<210> 212
<211> 493
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 212
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175
Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205
Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220
Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240
Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser
245 250 255
His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala
260 265 270
Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
275 280 285
Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr
290 295 300
Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
305 310 315 320
Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
325 330 335
Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
340 345 350
Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
355 360 365
Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys
370 375 380
Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
385 390 395 400
Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
405 410 415
Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
420 425 430
Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
435 440 445
Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
450 455 460
Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
465 470 475 480
Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 213
<211> 1425
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 213
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtcc agttggtcga aagtggcggt ggtgtagtgc agccgggccg cagtttgagg 120
ctttcctgtg cggcttcagg ctttactttt tccagctatg gaatgcactg ggtgcggcag 180
gcccccggca aaggacttga gtgggtggcc gtcatttctt atgacggatc agataagtac 240
tacgtggaca gcgtcaaggg cagattcacc atctctaggg acaacagtaa aaatagactc 300
tacctccaga tgaatagcct cagagctgaa gacacggccg tctactattg tgctcgggag 360
cggtatagtg gcagagacta ctgggggcag ggcacactcg ttacagtgag tagcggcgga 420
ggagggagtg ggggcggtgg ctccggtgga ggaggttctg agattgttat gacccagagt 480
cctgcgaccc tctcagtcag ccccggggag cgcgcaactt tgtcttgcag agctagtcag 540
tccgtgtcct ctcttctgac atggtaccag caaaagcccg ggcaggctcc gcgccttttg 600
atctttgggg cttcaacaag agccactggg attcccgcac gattctctgg ctccgggagc 660
ggtactggtt tcaccctgac gattagcagt ctccagagcg aggacttcgc cgtatactac 720
tgccagcagt acgatacgtg gccattcact tttggaccag ggactaaagt ggattttaag 780
cgcgccgccg ctctcgataa cgaaaagtca aatggcacca taatccacgt caaaggcaag 840
cacctgtgcc cttccccgct cttccccgga cccagtaaac cattttgggt gctggttgtt 900
gtggggggcg tgctggcctg ctatagcctt ttggtcactg tagccttcat tattttttgg 960
gtcagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1020
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1080
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1140
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1200
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1260
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1320
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1380
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa 1425
<210> 214
<211> 474
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 214
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr
65 70 75 80
Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser
145 150 155 160
Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys
165 170 175
Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys
180 185 190
Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala
195 200 205
Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe
210 215 220
Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr
225 230 235 240
Cys Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys
245 250 255
Val Asp Phe Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
260 265 270
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
275 280 285
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
290 295 300
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
305 310 315 320
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
325 330 335
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
340 345 350
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
355 360 365
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
370 375 380
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
385 390 395 400
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
405 410 415
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
420 425 430
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
435 440 445
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
450 455 460
Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470
<210> 215
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 215
caggtccagt tggtcgaaag tggcggtggt gtagtgcagc cgggccgcag tttgaggctt 60
tcctgtgcgg cttcaggctt tactttttcc agctatggaa tgcactgggt gcggcaggcc 120
cccggcaaag gacttgagtg ggtggccgtc atttcttatg acggatcaga taagtactac 180
gtggacagcg tcaagggcag attcaccatc tctagggaca acagtaaaaa tagactctac 240
ctccagatga atagcctcag agctgaagac acggccgtct actattgtgc tcgggagcgg 300
tatagtggca gagactactg ggggcagggc acactcgtta cagtgagtag cggcggagga 360
gggagtgggg gcggtggctc cggtggagga ggttctgaga ttgttatgac ccagagtcct 420
gcgaccctct cagtcagccc cggggagcgc gcaactttgt cttgcagagc tagtcagtcc 480
gtgtcctctc ttctgacatg gtaccagcaa aagcccgggc aggctccgcg ccttttgatc 540
tttggggctt caacaagagc cactgggatt cccgcacgat tctctggctc cgggagcggt 600
actggtttca ccctgacgat tagcagtctc cagagcgagg acttcgccgt atactactgc 660
cagcagtacg atacgtggcc attcactttt ggaccaggga ctaaagtgga ttttaagcgc 720
gccgccgctc tcgataacga aaagtcaaat ggcaccataa tccacgtcaa aggcaagcac 780
ctgtgccctt ccccgctctt ccccggaccc agtaaaccat tttgggtgct ggttgttgtg 840
gggggcgtgc tggcctgcta tagccttttg gtcactgtag ccttcattat tttttgggtc 900
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 960
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 1020
agcagggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa 1080
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgttttgga caagcgcaga 1140
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggtctctat 1200
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag 1260
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat 1320
acttatgacg ctctccacat gcaagccctg ccacctagg 1359
<210> 216
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 216
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140
Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160
Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175
Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220
Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240
Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
245 250 255
Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
260 265 270
Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
275 280 285
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
290 295 300
Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
305 310 315 320
Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
325 330 335
Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
340 345 350
Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
355 360 365
Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
370 375 380
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
385 390 395 400
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
405 410 415
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
420 425 430
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
435 440 445
Ala Leu Pro Pro Arg
450
<210> 217
<211> 1452
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 217
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctcgtgga gtctggcggc ggcgtggtcc agcccggccg gtccctgcgc 120
ctgtcctgcg ccgccagcgg gtttactttt tcctcctacg gcatgcactg ggtgcgccag 180
gctcccggca agggcctcga gtgggtcgcc gtgatctcat acgatgggtc agacaaatac 240
tatgtcgatt ctgttaaagg gcggtttacc atttcaagag ataactctaa gaataggctg 300
tatttgcaga tgaacagcct gagggctgaa gataccgcag tgtactattg cgctagggag 360
cggtatagtg gccgcgatta ctggggacag ggtacactgg tgaccgtgag ctctgggggt 420
ggcggaagcg ggggtggcgg aagcggcgga gggggtagtg aaattgtgat gacccagtct 480
ccggctacac tttcagtctc ccctggggag agagctacac tgtcatgcag agcgtcccag 540
tccgtctctt ctctccttac ctggtatcag cagaagcccg gccaggctcc tcgactgctg 600
atcttcggtg cctccacaag ggcgaccggg attccagccc gcttctcagg ttctgggagc 660
ggaactggtt tcactttgac aatcagttca ctgcagtcag aggatttcgc cgtgtactac 720
tgccagcaat acgacacatg gccattcact ttcggacccg gtaccaaagt cgatttcaag 780
agagccgcgg ccatcgaggt tatgtaccca ccaccatatc tggacaatga aaaaagcaat 840
ggaaccatta tccatgtgaa gggtaaacac ctctgcccta gcccactttt ccctggccca 900
tcaaagccct tctgggtctt ggtggtcgtg gggggtgtgc tggcctgtta cagccttctg 960
gtgacggttg ctttcattat cttctgggtt agatccaaaa gaagccgcct gctccatagc 1020
gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggtctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452
<210> 218
<211> 483
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 218
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr
65 70 75 80
Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser
145 150 155 160
Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys
165 170 175
Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys
180 185 190
Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala
195 200 205
Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe
210 215 220
Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr
225 230 235 240
Cys Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys
245 250 255
Val Asp Phe Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
260 265 270
Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
465 470 475 480
Pro Pro Arg
<210> 219
<211> 1386
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 219
caggtgcagc tcgtggagtc tggcggcggc gtggtccagc ccggccggtc cctgcgcctg 60
tcctgcgccg ccagcgggtt tactttttcc tcctacggca tgcactgggt gcgccaggct 120
cccggcaagg gcctcgagtg ggtcgccgtg atctcatacg atgggtcaga caaatactat 180
gtcgattctg ttaaagggcg gtttaccatt tcaagagata actctaagaa taggctgtat 240
ttgcagatga acagcctgag ggctgaagat accgcagtgt actattgcgc tagggagcgg 300
tatagtggcc gcgattactg gggacagggt acactggtga ccgtgagctc tgggggtggc 360
ggaagcgggg gtggcggaag cggcggaggg ggtagtgaaa ttgtgatgac ccagtctccg 420
gctacacttt cagtctcccc tggggagaga gctacactgt catgcagagc gtcccagtcc 480
gtctcttctc tccttacctg gtatcagcag aagcccggcc aggctcctcg actgctgatc 540
ttcggtgcct ccacaagggc gaccgggatt ccagcccgct tctcaggttc tgggagcgga 600
actggtttca ctttgacaat cagttcactg cagtcagagg atttcgccgt gtactactgc 660
cagcaatacg acacatggcc attcactttc ggacccggta ccaaagtcga tttcaagaga 720
gccgcggcca tcgaggttat gtacccacca ccatatctgg acaatgaaaa aagcaatgga 780
accattatcc atgtgaaggg taaacacctc tgccctagcc cacttttccc tggcccatca 840
aagcccttct gggtcttggt ggtcgtgggg ggtgtgctgg cctgttacag ccttctggtg 900
acggttgctt tcattatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat 960
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1020
ccacctagag atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca 1080
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1140
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1200
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1260
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1320
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca 1380
cctagg 1386
<210> 220
<211> 462
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 220
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140
Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160
Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175
Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220
Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240
Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
245 250 255
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
260 265 270
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
275 280 285
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
290 295 300
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
305 310 315 320
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
325 330 335
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
340 345 350
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
355 360 365
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
370 375 380
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
385 390 395 400
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
405 410 415
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
420 425 430
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
435 440 445
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460
<210> 221
<211> 1533
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 221
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttggttga atcaggaggg ggtgtggtgc aacccggtcg gtcactgcgc 120
ctcagttgtg ctgcttccgg gtttactttc agctcatatg ggatgcactg ggtacggcag 180
gctccaggta aaggcttgga atgggtggcg gtgatcagct atgacggctc tgacaaatat 240
tatgtggact ccgtgaaagg cagattcacc atcagtcgag acaactcaaa gaatagactc 300
tacttgcaga tgaatagcct ccgggccgaa gatactgcag tctattattg cgcccgggag 360
cgctacagtg gaagagacta ttgggggcaa ggaactcttg tcacagtctc atctggcggc 420
ggcggcagcg gtgggggcgg atctggcggg ggcggcagcg aaatcgttat gactcagagt 480
cctgccacac tgagcgttag ccctggtgag agagcaacac ttagctgcag agctagtcag 540
agtgtttcca gtcttttgac atggtaccaa cagaagcccg gtcaagctcc acgactgctc 600
atcttcggtg catccacccg cgcaaccggg atacccgccc ggttttccgg ttctggaagt 660
ggcacaggat tcacgctcac catttcttct ctgcagtctg aagactttgc cgtgtattac 720
tgccagcagt acgatacctg gccctttacc tttggcccag gtactaaagt ggattttaaa 780
cgagctgctg cactttccaa tagtattatg tacttttcac attttgtgcc cgtgttcctg 840
cctgcgaagc ctacgacaac cccagcccct aggccgccca caccggcccc aactattgcc 900
tcccagccat tgtctctgag acccgaagct tgcagacctg ctgctggagg cgccgttcac 960
acccgaggat tggatttcgc atgtgacatt tacatctggg cccctttggc cggaacctgc 1020
ggtgtgctgc tgctgtcact cgtgattaca ctttactgca accaccgaaa cagatccaaa 1080
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca 1140
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagcagggtg 1200
aagttttcca gatctgcaga tgcaccagcg tatcagcagg gccagaacca actgtataac 1260
gagctcaacc tgggacgcag ggaagagtat gacgttttgg acaagcgcag aggacgggac 1320
cctgagatgg gtggcaaacc aagacgaaaa aacccccagg agggtctcta taatgagctg 1380
cagaaggata agatggctga agcctattct gaaataggca tgaaaggaga gcggagaagg 1440
ggaaaagggc acgacggttt gtaccaggga ctcagcactg ctacgaagga tacttatgac 1500
gctctccaca tgcaagccct gccacctagg taa 1533
<210> 222
<211> 510
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 222
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr
65 70 75 80
Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser
145 150 155 160
Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys
165 170 175
Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys
180 185 190
Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala
195 200 205
Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe
210 215 220
Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr
225 230 235 240
Cys Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys
245 250 255
Val Asp Phe Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
260 265 270
Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
275 280 285
Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
290 295 300
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
305 310 315 320
Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
325 330 335
Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
340 345 350
Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
355 360 365
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
370 375 380
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
385 390 395 400
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
405 410 415
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
420 425 430
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
435 440 445
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
450 455 460
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
465 470 475 480
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
485 490 495
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
500 505 510
<210> 223
<211> 1467
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 223
caggtgcagt tggttgaatc aggagggggt gtggtgcaac ccggtcggtc actgcgcctc 60
agttgtgctg cttccgggtt tactttcagc tcatatggga tgcactgggt acggcaggct 120
ccaggtaaag gcttggaatg ggtggcggtg atcagctatg acggctctga caaatattat 180
gtggactccg tgaaaggcag attcaccatc agtcgagaca actcaaagaa tagactctac 240
ttgcagatga atagcctccg ggccgaagat actgcagtct attattgcgc ccgggagcgc 300
tacagtggaa gagactattg ggggcaagga actcttgtca cagtctcatc tggcggcggc 360
ggcagcggtg ggggcggatc tggcgggggc ggcagcgaaa tcgttatgac tcagagtcct 420
gccacactga gcgttagccc tggtgagaga gcaacactta gctgcagagc tagtcagagt 480
gtttccagtc ttttgacatg gtaccaacag aagcccggtc aagctccacg actgctcatc 540
ttcggtgcat ccacccgcgc aaccgggata cccgcccggt tttccggttc tggaagtggc 600
acaggattca cgctcaccat ttcttctctg cagtctgaag actttgccgt gtattactgc 660
cagcagtacg atacctggcc ctttaccttt ggcccaggta ctaaagtgga ttttaaacga 720
gctgctgcac tttccaatag tattatgtac ttttcacatt ttgtgcccgt gttcctgcct 780
gcgaagccta cgacaacccc agcccctagg ccgcccacac cggccccaac tattgcctcc 840
cagccattgt ctctgagacc cgaagcttgc agacctgctg ctggaggcgc cgttcacacc 900
cgaggattgg atttcgcatg tgacatttac atctgggccc ctttggccgg aacctgcggt 960
gtgctgctgc tgtcactcgt gattacactt tactgcaacc accgaaacag atccaaaaga 1020
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg ccccacaagg 1080
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag cagggtgaag 1140
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag 1200
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct 1260
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag 1320
aaggataaga tggctgaagc ctattctgaa ataggcatga aaggagagcg gagaagggga 1380
aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct 1440
ctccacatgc aagccctgcc acctagg 1467
<210> 224
<211> 489
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 224
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140
Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160
Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175
Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220
Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240
Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
245 250 255
Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
260 265 270
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
275 280 285
Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
290 295 300
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320
Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
325 330 335
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
340 345 350
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
355 360 365
Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
370 375 380
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
385 390 395 400
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
405 410 415
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
420 425 430
Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
435 440 445
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
465 470 475 480
Leu His Met Gln Ala Leu Pro Pro Arg
485
<210> 225
<211> 1425
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 225
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggagattg tgatgaccca gtcccctgct accctgtccg tcagtccggg cgagagagcc 120
accttgtcat gccgggccag ccagtccgtc agcagtctcc tgacttggta tcagcaaaaa 180
ccagggcagg caccgcggct tttgattttt ggtgcaagca cacgcgccac tggcattcca 240
gctaggtttt ctggaagtgg atctgggaca ggcttcactc tgacaatcag tagcctgcag 300
agtgaggact ttgctgttta ctactgtcaa cagtacgaca cctggccatt cacattcggg 360
cccggcacca aggtcgactt caagaggggc ggtggaggtt caggtggtgg cgggtcaggc 420
ggcggtgggt ctcaggttca actggtggaa tcaggtggcg gcgttgtcca accggggcga 480
tcacttcgac tttcctgtgc tgcctcaggc tttacttttt catcctatgg gatgcactgg 540
gttcggcagg ctcccggaaa aggactcgag tgggttgcag tgatctctta cgatggctca 600
gacaagtatt atgtggactc agtcaagggg agattcacaa taagccgaga caactccaaa 660
aaccggcttt atctccagat gaacagcctt agagcggaag ataccgcggt atactactgt 720
gcccgcgaga ggtattccgg cagagactac tggggacagg gcacactggt caccgtgagt 780
tctgccgcag cgctcgataa cgaaaagagc aacggaacca ttatccacgt taagggcaag 840
cacctgtgcc ccagtcccct cttcccagga ccatctaaac ccttctgggt tctggtagta 900
gttggagggg tccttgcatg ttactccctt ttggtcaccg tcgccttcat tattttctgg 960
gtgagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1020
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1080
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1140
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1200
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1260
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1320
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1380
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa 1425
<210> 226
<211> 474
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 226
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110
Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
210 215 220
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
225 230 235 240
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
245 250 255
Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
260 265 270
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
275 280 285
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
290 295 300
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
305 310 315 320
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
325 330 335
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
340 345 350
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
355 360 365
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
370 375 380
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
385 390 395 400
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
405 410 415
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
420 425 430
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
435 440 445
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
450 455 460
Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470
<210> 227
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 227
gagattgtga tgacccagtc ccctgctacc ctgtccgtca gtccgggcga gagagccacc 60
ttgtcatgcc gggccagcca gtccgtcagc agtctcctga cttggtatca gcaaaaacca 120
gggcaggcac cgcggctttt gatttttggt gcaagcacac gcgccactgg cattccagct 180
aggttttctg gaagtggatc tgggacaggc ttcactctga caatcagtag cctgcagagt 240
gaggactttg ctgtttacta ctgtcaacag tacgacacct ggccattcac attcgggccc 300
ggcaccaagg tcgacttcaa gaggggcggt ggaggttcag gtggtggcgg gtcaggcggc 360
ggtgggtctc aggttcaact ggtggaatca ggtggcggcg ttgtccaacc ggggcgatca 420
cttcgacttt cctgtgctgc ctcaggcttt actttttcat cctatgggat gcactgggtt 480
cggcaggctc ccggaaaagg actcgagtgg gttgcagtga tctcttacga tggctcagac 540
aagtattatg tggactcagt caaggggaga ttcacaataa gccgagacaa ctccaaaaac 600
cggctttatc tccagatgaa cagccttaga gcggaagata ccgcggtata ctactgtgcc 660
cgcgagaggt attccggcag agactactgg ggacagggca cactggtcac cgtgagttct 720
gccgcagcgc tcgataacga aaagagcaac ggaaccatta tccacgttaa gggcaagcac 780
ctgtgcccca gtcccctctt cccaggacca tctaaaccct tctgggttct ggtagtagtt 840
ggaggggtcc ttgcatgtta ctcccttttg gtcaccgtcg ccttcattat tttctgggtg 900
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 960
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 1020
agcagggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa 1080
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgttttgga caagcgcaga 1140
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggtctctat 1200
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag 1260
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat 1320
acttatgacg ctctccacat gcaagccctg ccacctagg 1359
<210> 228
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 228
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
115 120 125
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175
Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220
Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240
Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
245 250 255
Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
260 265 270
Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
275 280 285
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
290 295 300
Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
305 310 315 320
Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
325 330 335
Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
340 345 350
Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
355 360 365
Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
370 375 380
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
385 390 395 400
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
405 410 415
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
420 425 430
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
435 440 445
Ala Leu Pro Pro Arg
450
<210> 229
<211> 1452
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 229
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggagatcg tcatgacaca gagtccagct accctgagcg tgtcccctgg agagagagcc 120
accctgtcct gtagggctag tcagagtgtg tccagcctcc tcacctggta tcaacagaag 180
cctggtcaag ctccccggct gcttatcttc ggggccagca cgcgagccac aggcatcccg 240
gccagattct ctggctctgg cagtggcacc gggttcactc tcacgatctc atccctgcag 300
tcagaggatt tcgctgtgta ttactgtcag cagtacgata catggccctt caccttcggc 360
ccgggcacaa aagtagattt caagcgcggc ggcgggggta gtgggggcgg gggatcagga 420
ggagggggct cccaagtaca gctggttgag agcggcggcg gggtggttca gcccgggcgc 480
agcctcaggc tgagttgcgc agcatcagga ttcacattca gttcttatgg aatgcattgg 540
gtcagacagg ctcccgggaa gggccttgaa tgggtggcag tcattagcta cgacggaagc 600
gataagtact atgtggactc agttaaaggg agatttacta tcagccgcga caattccaaa 660
aacagattgt atttgcagat gaactccctc agggcggagg acactgctgt atattactgc 720
gcacgagaga gatactccgg ccgagactat tggggccaag gaacattggt aactgtgagc 780
tccgccgcag ctattgaggt catgtacccc ccaccttatc tcgataatga gaagagtaat 840
gggactataa ttcacgtaaa gggcaaacac ctgtgccctt ccccgctgtt tccaggtcca 900
agtaagccgt tctgggtcct ggttgtggtg ggaggggtgc tggcctgcta ttctctgttg 960
gttaccgtgg cctttatcat tttctgggtg agatccaaaa gaagccgcct gctccatagc 1020
gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggtctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452
<210> 230
<211> 483
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 230
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110
Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
210 215 220
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
225 230 235 240
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
245 250 255
Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
260 265 270
Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
465 470 475 480
Pro Pro Arg
<210> 231
<211> 1386
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 231
gagatcgtca tgacacagag tccagctacc ctgagcgtgt cccctggaga gagagccacc 60
ctgtcctgta gggctagtca gagtgtgtcc agcctcctca cctggtatca acagaagcct 120
ggtcaagctc cccggctgct tatcttcggg gccagcacgc gagccacagg catcccggcc 180
agattctctg gctctggcag tggcaccggg ttcactctca cgatctcatc cctgcagtca 240
gaggatttcg ctgtgtatta ctgtcagcag tacgatacat ggcccttcac cttcggcccg 300
ggcacaaaag tagatttcaa gcgcggcggc gggggtagtg ggggcggggg atcaggagga 360
gggggctccc aagtacagct ggttgagagc ggcggcgggg tggttcagcc cgggcgcagc 420
ctcaggctga gttgcgcagc atcaggattc acattcagtt cttatggaat gcattgggtc 480
agacaggctc ccgggaaggg ccttgaatgg gtggcagtca ttagctacga cggaagcgat 540
aagtactatg tggactcagt taaagggaga tttactatca gccgcgacaa ttccaaaaac 600
agattgtatt tgcagatgaa ctccctcagg gcggaggaca ctgctgtata ttactgcgca 660
cgagagagat actccggccg agactattgg ggccaaggaa cattggtaac tgtgagctcc 720
gccgcagcta ttgaggtcat gtacccccca ccttatctcg ataatgagaa gagtaatggg 780
actataattc acgtaaaggg caaacacctg tgcccttccc cgctgtttcc aggtccaagt 840
aagccgttct gggtcctggt tgtggtggga ggggtgctgg cctgctattc tctgttggtt 900
accgtggcct ttatcatttt ctgggtgaga tccaaaagaa gccgcctgct ccatagcgat 960
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1020
ccacctagag atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca 1080
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1140
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1200
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1260
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1320
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca 1380
cctagg 1386
<210> 232
<211> 462
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 232
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
115 120 125
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175
Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220
Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240
Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
245 250 255
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
260 265 270
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
275 280 285
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
290 295 300
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
305 310 315 320
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
325 330 335
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
340 345 350
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
355 360 365
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
370 375 380
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
385 390 395 400
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
405 410 415
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
420 425 430
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
435 440 445
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460
<210> 233
<211> 1533
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 233
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaaatag tgatgactca gtccccggcc accctcagcg tgtcccccgg ggagcgagcg 120
accctgtcat gcagggcttc ccagagtgtc agctccctgc tcacttggta tcagcaaaag 180
ccggggcagg ctccccgcct cctcatcttc ggggcatcaa ctagggccac cggcattcct 240
gcaagatttt ccgggtctgg cagcggcacc ggcttcaccc ttaccattag ctctctgcag 300
tctgaggact tcgccgttta ctattgtcag cagtatgata cttggccctt taccttcggt 360
cccggaacta aggtggactt caagcgcggg gggggtggat ctggaggtgg tggctccggg 420
ggcggtggaa gccaggtcca gttggttgag agcggcggcg gagtggtgca gcccgggagg 480
tccttgcggc tgagctgtgc agcctccggt tttacttttt ctagctatgg aatgcattgg 540
gtaagacagg ctcccggaaa aggcctcgag tgggtggcgg tcattagcta tgatggatct 600
gataaatact atgtggactc agttaagggg cgcttcacaa tctcaagaga caatagcaaa 660
aatagactgt acctgcagat gaatagtctg cgcgccgagg acactgccgt gtactactgc 720
gcccgcgaga gatacagcgg acgggattac tggggccagg gtaccctcgt aacggtgtcc 780
tccgctgccg cccttagcaa cagcattatg tacttttctc atttcgtgcc agtctttctc 840
ccagcaaagc ccaccactac cccggccccc aggccgccta ctcctgcccc cactatcgcg 900
tctcagcctc tctccttgcg gcccgaggcc tgccggccag ccgcaggggg cgccgtacat 960
actcggggtt tggatttcgc ttgcgacata tatatttggg cccccctcgc cggcacatgt 1020
ggagtgctgc tcctgagtct cgttataacc ctctattgca accatagaaa cagatccaaa 1080
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca 1140
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagcagggtg 1200
aagttttcca gatctgcaga tgcaccagcg tatcagcagg gccagaacca actgtataac 1260
gagctcaacc tgggacgcag ggaagagtat gacgttttgg acaagcgcag aggacgggac 1320
cctgagatgg gtggcaaacc aagacgaaaa aacccccagg agggtctcta taatgagctg 1380
cagaaggata agatggctga agcctattct gaaataggca tgaaaggaga gcggagaagg 1440
ggaaaagggc acgacggttt gtaccaggga ctcagcactg ctacgaagga tacttatgac 1500
gctctccaca tgcaagccct gccacctagg taa 1533
<210> 234
<211> 510
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 234
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110
Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
210 215 220
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
225 230 235 240
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
245 250 255
Val Thr Val Ser Ser Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
260 265 270
Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
275 280 285
Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
290 295 300
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
305 310 315 320
Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
325 330 335
Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
340 345 350
Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
355 360 365
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
370 375 380
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
385 390 395 400
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
405 410 415
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
420 425 430
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
435 440 445
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
450 455 460
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
465 470 475 480
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
485 490 495
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
500 505 510
<210> 235
<211> 1467
<212> DNA
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 235
gaaatagtga tgactcagtc cccggccacc ctcagcgtgt cccccgggga gcgagcgacc 60
ctgtcatgca gggcttccca gagtgtcagc tccctgctca cttggtatca gcaaaagccg 120
gggcaggctc cccgcctcct catcttcggg gcatcaacta gggccaccgg cattcctgca 180
agattttccg ggtctggcag cggcaccggc ttcaccctta ccattagctc tctgcagtct 240
gaggacttcg ccgtttacta ttgtcagcag tatgatactt ggccctttac cttcggtccc 300
ggaactaagg tggacttcaa gcgcgggggg ggtggatctg gaggtggtgg ctccgggggc 360
ggtggaagcc aggtccagtt ggttgagagc ggcggcggag tggtgcagcc cgggaggtcc 420
ttgcggctga gctgtgcagc ctccggtttt actttttcta gctatggaat gcattgggta 480
agacaggctc ccggaaaagg cctcgagtgg gtggcggtca ttagctatga tggatctgat 540
aaatactatg tggactcagt taaggggcgc ttcacaatct caagagacaa tagcaaaaat 600
agactgtacc tgcagatgaa tagtctgcgc gccgaggaca ctgccgtgta ctactgcgcc 660
cgcgagagat acagcggacg ggattactgg ggccagggta ccctcgtaac ggtgtcctcc 720
gctgccgccc ttagcaacag cattatgtac ttttctcatt tcgtgccagt ctttctccca 780
gcaaagccca ccactacccc ggcccccagg ccgcctactc ctgcccccac tatcgcgtct 840
cagcctctct ccttgcggcc cgaggcctgc cggccagccg cagggggcgc cgtacatact 900
cggggtttgg atttcgcttg cgacatatat atttgggccc ccctcgccgg cacatgtgga 960
gtgctgctcc tgagtctcgt tataaccctc tattgcaacc atagaaacag atccaaaaga 1020
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg ccccacaagg 1080
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag cagggtgaag 1140
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag 1200
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct 1260
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag 1320
aaggataaga tggctgaagc ctattctgaa ataggcatga aaggagagcg gagaagggga 1380
aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct 1440
ctccacatgc aagccctgcc acctagg 1467
<210> 236
<211> 489
<212> PRT
<213> 人工序列
<220>
<223> 抗CLL-1 CAR构建体
<400> 236
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
115 120 125
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175
Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220
Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240
Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
245 250 255
Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
260 265 270
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
275 280 285
Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
290 295 300
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320
Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
325 330 335
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
340 345 350
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
355 360 365
Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
370 375 380
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
385 390 395 400
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
405 410 415
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
420 425 430
Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
435 440 445
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
465 470 475 480
Leu His Met Gln Ala Leu Pro Pro Arg
485
<210> 237
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> scFv G4s接头
<400> 237
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 238
<211> 288
<212> DNA
<213> 人工序列
<220>
<223> CD8细胞外和跨膜结构域
<400> 238
gctgcagcat tgagcaactc aataatgtat tttagtcact ttgtaccagt gttcttgccg 60
gctaagccta ctaccacacc cgctccacgg ccacctaccc cagctcctac catcgcttca 120
cagcctctgt ccctgcgccc agaggcttgc cgaccggccg cagggggcgc tgttcatacc 180
agaggactgg atttcgcctg cgatatctat atctgggcac ccctggccgg aacctgcggc 240
gtactcctgc tgtccctggt catcacgctc tattgtaatc acaggaac 288
<210> 239
<211> 96
<212> PRT
<213> 人工序列
<220>
<223> CD8细胞外和跨膜结构域
<400> 239
Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
1 5 10 15
Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
20 25 30
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
35 40 45
Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
50 55 60
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
65 70 75 80
Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
85 90 95
<210> 240
<211> 294
<212> DNA
<213> 人工序列
<220>
<223> 细胞外和细胞内结构域
<400> 240
cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60
tcacccttgt tccctggtcc atccaagcca ttctgggtgt tggtcgtagt gggtggagtc 120
ctcgcttgtt actctctgct cgtcaccgtg gcttttataa tcttctgggt tagatccaaa 180
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca 240
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagc 294
<210> 241
<211> 98
<212> PRT
<213> 人工序列
<220>
<223> 细胞外和细胞内结构域
<400> 241
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
1 5 10 15
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
20 25 30
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
35 40 45
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
50 55 60
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
65 70 75 80
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
85 90 95
Arg Ser
<210> 242
<211> 1482
<212> DNA
<213> 人工序列
<220>
<223> 10E3_CHD_DNA
<400> 242
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtga ccctcaaaga gtctggaccc gtgctcgtaa aacctacgga gaccctgaca 120
ctcacctgca cagtctccgg cttcagcctc atcaatgcca ggatgggagt ttcctggatc 180
aggcaaccgc ccggaaaggc cctggaatgg ctcgcacata ttttcagtaa cgctgaaaaa 240
agctatcgga cttctctgaa aagtcggctc acgattagta aggacacatc caagagccaa 300
gtggtgctta cgatgactaa catggaccct gtggatactg caacctatta ctgtgctcga 360
atccctggtt atggcggaaa tggggactac cactactacg gtatggatgt ctggggccaa 420
gggaccacgg ttactgtttc aagcggaggg ggagggagtg ggggtggcgg atctggcgga 480
ggaggcagcg atatccagat gacgcagtcc cctagttcac tttccgcatc cctgggggat 540
cgggttacca ttacatgccg cgcgtcacag ggtatccgga atgatctggg atggtaccag 600
cagaagccgg gaaaggctcc taagcgcctc atctacgcca gctccaccct gcagagtgga 660
gtgccctccc ggttttcagg cagtggctcc ggtacggagt ttactcttac aattagcagc 720
ctgcagccag aagattttgc aacttactac tgtttgcagc ataataattt cccctggacc 780
tttggtcagg gcaccaaggt ggagatcaaa agagcagccg ccatcgaagt aatgtatccc 840
cccccgtacc ttgacaatga gaagtcaaat ggaaccatta tccatgttaa gggcaaacac 900
ctctgccctt ctccactgtt ccctggccct agtaagccgt tttgggtgct ggtggtagtc 960
ggtggggtgc tggcttgtta ctctcttctc gtgaccgtcg cctttataat cttttgggtc 1020
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 1080
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 1140
agccgagtga aattttctag atcagctgat gctcccgcct atcagcaggg acagaatcaa 1200
ctttacaatg agctgaacct gggtcgcaga gaagagtacg acgttttgga caaacgccgg 1260
ggccgagatc ctgagatggg ggggaagccg agaaggaaga atcctcaaga aggcctgtac 1320
aacgagcttc aaaaagacaa aatggctgag gcgtactctg agatcggcat gaagggcgag 1380
cggagacgag gcaagggtca cgatggcttg tatcagggcc tgagtacagc cacaaaggac 1440
acctatgacg ccctccacat gcaggcactg cccccacgct ag 1482
<210> 243
<211> 493
<212> PRT
<213> 人工序列
<220>
<223> 10E3_CHD_AA
<400> 243
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu
20 25 30
Val Lys Pro Thr Glu Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe
35 40 45
Ser Leu Ile Asn Ala Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro
50 55 60
Gly Lys Ala Leu Glu Trp Leu Ala His Ile Phe Ser Asn Ala Glu Lys
65 70 75 80
Ser Tyr Arg Thr Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr
85 90 95
Ser Lys Ser Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp
100 105 110
Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Tyr Gly Gly Asn Gly
115 120 125
Asp Tyr His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val
130 135 140
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
145 150 155 160
Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
165 170 175
Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile
180 185 190
Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
195 200 205
Arg Leu Ile Tyr Ala Ser Ser Thr Leu Gln Ser Gly Val Pro Ser Arg
210 215 220
Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
225 230 235 240
Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Asn
245 250 255
Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala
260 265 270
Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys
275 280 285
Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser
290 295 300
Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val
305 310 315 320
Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile
325 330 335
Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
340 345 350
Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
355 360 365
Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys
370 375 380
Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
385 390 395 400
Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
405 410 415
Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
420 425 430
Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
435 440 445
Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
450 455 460
Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
465 470 475 480
Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 244
<211> 1455
<212> DNA
<213> 人工序列
<220>
<223> 10E3_THD_DNA
<400> 244
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaagtta ctttgaagga gtctggacct gtactggtga agccaaccga gacactgaca 120
ctcacgtgta cagtgagtgg tttttccttg atcaacgcaa ggatgggcgt cagctggatc 180
aggcaacccc ctggcaaggc tctggaatgg ctcgctcaca tattcagcaa tgccgaaaaa 240
agctaccgga caagcctgaa atcccgcctg actatttcca aggacacttc taagtctcag 300
gtggtgctga ccatgaccaa catggacccg gtggacaccg ccacctatta ctgcgcaaga 360
atccctgggt atggtgggaa tggtgactac cattattatg ggatggatgt gtgggggcaa 420
ggcacaaccg taacggtctc aagcggtggg ggaggctcag ggggcggagg ctccggaggt 480
ggcggctccg acattcagat gacccaaagc ccgtccagcc tgtccgccag cctgggagat 540
agagtgacaa tcacgtgtag agcttcccaa gggataagaa atgatctcgg gtggtatcag 600
cagaagcccg gcaaagcccc caaaaggctt atatatgcta gtagtacact gcagtctgga 660
gttccttccc gattttcagg tagcggctcc ggtacagagt tcaccctcac gataagctca 720
ctccagcctg aggatttcgc aacgtactac tgcctccagc acaacaattt tccctggact 780
ttcggccagg gcaccaaggt ggagatcaag agggccgctg cccttgataa tgaaaagtca 840
aacggaacaa tcattcacgt gaagggcaag cacctctgtc cgtcaccctt gttccctggt 900
ccatccaagc cattctgggt gttggtcgta gtgggtggag tcctcgcttg ttactctctg 960
ctcgtcaccg tggcttttat aatcttctgg gttagatcca aaagaagccg cctgctccat 1020
agcgattaca tgaatatgac tccacgccgc cctggcccca caaggaaaca ctaccagcct 1080
tacgcaccac ctagagattt cgctgcctat cggagccgag tgaaattttc tagatcagct 1140
gatgctcccg cctatcagca gggacagaat caactttaca atgagctgaa cctgggtcgc 1200
agagaagagt acgacgtttt ggacaaacgc cggggccgag atcctgagat gggggggaag 1260
ccgagaagga agaatcctca agaaggcctg tacaacgagc ttcaaaaaga caaaatggct 1320
gaggcgtact ctgagatcgg catgaagggc gagcggagac gaggcaaggg tcacgatggc 1380
ttgtatcagg gcctgagtac agccacaaag gacacctatg acgccctcca catgcaggca 1440
ctgcccccac gctag 1455
<210> 245
<211> 484
<212> PRT
<213> 人工序列
<220>
<223> 10E3_THD_AA
<400> 245
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu
20 25 30
Val Lys Pro Thr Glu Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe
35 40 45
Ser Leu Ile Asn Ala Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro
50 55 60
Gly Lys Ala Leu Glu Trp Leu Ala His Ile Phe Ser Asn Ala Glu Lys
65 70 75 80
Ser Tyr Arg Thr Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr
85 90 95
Ser Lys Ser Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp
100 105 110
Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Tyr Gly Gly Asn Gly
115 120 125
Asp Tyr His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val
130 135 140
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
145 150 155 160
Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
165 170 175
Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile
180 185 190
Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
195 200 205
Arg Leu Ile Tyr Ala Ser Ser Thr Leu Gln Ser Gly Val Pro Ser Arg
210 215 220
Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
225 230 235 240
Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Asn
245 250 255
Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala
260 265 270
Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys
275 280 285
Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro
290 295 300
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
305 310 315 320
Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser
325 330 335
Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly
340 345 350
Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala
355 360 365
Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala
370 375 380
Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
385 390 395 400
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu
405 410 415
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn
420 425 430
Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
435 440 445
Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
450 455 460
Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala
465 470 475 480
Leu Pro Pro Arg
<210> 246
<211> 1464
<212> DNA
<213> 人工序列
<220>
<223> 8B5_CHD_DNA
<400> 246
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcagatcc agttggtgga atcagggggc ggtgtggtgc agccgggtag gagcctgaga 120
ctgtcatgcg tggcgtctgg cttcacattc aagaactacg gcatgcactg ggtgcgacag 180
gcccccggaa agggtttgga gtgggtcgcc gtgatctggt acgacggatc taatgagtat 240
tacggagatc ctgtgaaggg aaggttcacc atctcccgcg acaatagcaa aaatatgctc 300
tacctgcaaa tgaactcact cagggcggat gatacggcgg tctactattg cgctcgctca 360
gggattgctg tggccggcgc attcgattac tggggacagg gtaccctggt gacagtatca 420
agcggaggcg gcggctctgg cggcggcgga tctggcgggg ggggaagtga gattgtgttg 480
acacagtctc ccgataccct gtcactgtca cccggcgaga aggcaacgct gagttgcaga 540
gcaagccagt cagtctcctc ttcttttctg gcctggtatc agcaaaaacc aggtcaggca 600
ccatctctcc tgatttacgt tgccagcaga cgggcggctg gcattcccga caggttctct 660
ggaagcggat ctgggaccga ttttaccctg acaattagcc gcttggagcc cgaagacttt 720
ggtatgtttt actgccagca ctacggaagg acacctttca catttggccc gggcacgaaa 780
gtcgatataa aacgcgcagc cgccattgaa gtaatgtacc caccacctta tttggacaat 840
gaaaagtcca atggtaccat tattcacgtc aagggaaagc atctctgtcc aagccctctg 900
ttccccggcc cctccaaacc attctgggtg ctggtggtcg tcggcggagt tctggcctgc 960
tattctctgc tcgtgactgt tgcattcatc attttctggg tgagatccaa aagaagccgc 1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagccgagt gaaattttct 1140
agatcagctg atgctcccgc ctatcagcag ggacagaatc aactttacaa tgagctgaac 1200
ctgggtcgca gagaagagta cgacgttttg gacaaacgcc ggggccgaga tcctgagatg 1260
ggggggaagc cgagaaggaa gaatcctcaa gaaggcctgt acaacgagct tcaaaaagac 1320
aaaatggctg aggcgtactc tgagatcggc atgaagggcg agcggagacg aggcaagggt 1380
cacgatggct tgtatcaggg cctgagtaca gccacaaagg acacctatga cgccctccac 1440
atgcaggcac tgcccccacg ctag 1464
<210> 247
<211> 487
<212> PRT
<213> 人工序列
<220>
<223> 8B5_CHD_AA
<400> 247
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Ile Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe
35 40 45
Thr Phe Lys Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Glu Tyr
65 70 75 80
Tyr Gly Asp Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Ser Gly Ile Ala Val Ala Gly Ala Phe
115 120 125
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
130 135 140
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu
145 150 155 160
Thr Gln Ser Pro Asp Thr Leu Ser Leu Ser Pro Gly Glu Lys Ala Thr
165 170 175
Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ser Leu Leu Ile Tyr Val Ala
195 200 205
Ser Arg Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe
225 230 235 240
Gly Met Phe Tyr Cys Gln His Tyr Gly Arg Thr Pro Phe Thr Phe Gly
245 250 255
Pro Gly Thr Lys Val Asp Ile Lys Arg Ala Ala Ala Ile Glu Val Met
260 265 270
Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile
275 280 285
His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
290 295 300
Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320
Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335
Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350
Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365
Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
370 375 380
Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415
Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445
Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480
Met Gln Ala Leu Pro Pro Arg
485
<210> 248
<211> 1437
<212> DNA
<213> 人工序列
<220>
<223> 8B5_THD_DNA
<400> 248
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcagattc agctcgtgga gtcaggtggt ggcgtggttc agcccggacg gtccctgcga 120
ctctcttgtg tggcaagcgg atttaccttt aagaactatg gcatgcactg ggtgaggcag 180
gcccctggaa aaggactgga gtgggttgct gtgatctggt acgacgggtc caacgaatat 240
tatggcgatc ctgtgaaggg acggtttaca atctcacgcg ataactcaaa gaacatgctg 300
tacctgcaaa tgaactctct gcgcgctgat gacactgccg tgtattattg cgctcggagt 360
ggtatcgccg tcgcaggagc atttgattat tgggggcaag ggaccctcgt gacagtgagt 420
tccggagggg gaggttctgg tggaggcggc tctggtgggg gaggcagcga gatcgttctg 480
acccagtctc ctgacacact gtcactgtcc cctggtgaaa aggccacact gtcttgtaga 540
gcgtcccaga gcgtttccag ttccttcctt gcatggtatc aacaaaaacc cgggcaggct 600
ccaagcttgc tgatctacgt ggccagccgc cgggccgcag gcatccctga taggtttagc 660
ggttctggga gcgggacgga cttcaccttg acaatatcac ggctggaacc cgaagacttc 720
ggaatgtttt attgccagca ctacggaaga actccattca cctttggccc gggaacgaag 780
gtagacatca agagagcagc agccctcgac aacgagaaat ccaatggaac cattatccat 840
gtgaagggga aacatctctg cccttcacca ttgttccctg gacccagcaa gcctttttgg 900
gttctggtcg tggtgggggg cgtcctggct tgttactccc tcctcgttac agtcgccttc 960
ataatctttt gggttagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1080
ttcgctgcct atcggagccg agtgaaattt tctagatcag ctgatgctcc cgcctatcag 1140
cagggacaga atcaacttta caatgagctg aacctgggtc gcagagaaga gtacgacgtt 1200
ttggacaaac gccggggccg agatcctgag atggggggga agccgagaag gaagaatcct 1260
caagaaggcc tgtacaacga gcttcaaaaa gacaaaatgg ctgaggcgta ctctgagatc 1320
ggcatgaagg gcgagcggag acgaggcaag ggtcacgatg gcttgtatca gggcctgagt 1380
acagccacaa aggacaccta tgacgccctc cacatgcagg cactgccccc acgctag 1437
<210> 249
<211> 478
<212> PRT
<213> 人工序列
<220>
<223> 8B5_THD_AA
<400> 249
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Ile Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe
35 40 45
Thr Phe Lys Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Glu Tyr
65 70 75 80
Tyr Gly Asp Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Ser Gly Ile Ala Val Ala Gly Ala Phe
115 120 125
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
130 135 140
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu
145 150 155 160
Thr Gln Ser Pro Asp Thr Leu Ser Leu Ser Pro Gly Glu Lys Ala Thr
165 170 175
Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ser Leu Leu Ile Tyr Val Ala
195 200 205
Ser Arg Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe
225 230 235 240
Gly Met Phe Tyr Cys Gln His Tyr Gly Arg Thr Pro Phe Thr Phe Gly
245 250 255
Pro Gly Thr Lys Val Asp Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu
260 265 270
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
275 280 285
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
290 295 300
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
305 310 315 320
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
325 330 335
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
340 345 350
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
355 360 365
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
370 375 380
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
385 390 395 400
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
405 410 415
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
420 425 430
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
435 440 445
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
450 455 460
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 250
<211> 9
<212> PRT
<213> 人
<400> 250
Ile Glu Val Met Tyr Pro Pro Pro Tyr
1 5
<210> 251
<211> 112
<212> PRT
<213> 人
<400> 251
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
Claims (40)
1.分离的多核苷酸,所述分离的多核苷酸编码嵌合抗原受体(CAR)或T细胞受体(TCR),其包含(i)抗原结合分子,(ii)共刺激结构域,和(iii)活化结构域,其中所述共刺激结构域包含细胞外结构域、跨膜结构域和细胞内结构域,其中所述细胞外结构域包含截短铰链结构域,所述截短铰链结构域基本上由以下各项组成或由以下各项组成:(i)与SEQ ID NO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列,和任选地(ii)一至六个氨基酸。
2.权利要求1的多核苷酸,其中所述一至六个氨基酸为异源的氨基酸。
3.权利要求1或2的多核苷酸,其中所述截短铰链结构域基本上由以下组成或由以下组成:与SEQ ID NO:1的氨基酸123至152至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
4.权利要求1或2的多核苷酸,其中所述氨基酸序列由以下核苷酸序列编码:与SEQ IDNO:2至少约60%,至少约70%,至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
5.权利要求1或2的多核苷酸,其中所述跨膜结构域为以下各项的跨膜结构域:4-1BB/CD137、T细胞受体的alpha链、T细胞受体的beta链、CD3epsilon、CD4、CD5、CD8alpha、CD9、CD16、CD19、CD22、CD33、CD37、CD45、CD64、CD80、CD86、CD134、CD137、CD154或T细胞受体的zeta链,或它们的任何组合。
6.权利要求1或2的多核苷酸,其中所述跨膜结构域包含与SEQ ID NO:5至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
7.权利要求6的多核苷酸,其中所述跨膜结构域由以下核苷酸序列编码:与SEQ ID NO:4至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
8.权利要求1或2的多核苷酸,其中所述细胞内结构域包含以下各项的信号传导区:4-1BB/CD137、活化性NK细胞受体、B7-H3、BAFFR、BLAME(SLAMF8)、BTLA、CD100(SEMA4D)、CD103、CD160(BY55)、CD18、CD19、CD19a、CD2、CD247、CD27、CD276(B7-H3)、CD29、CD3delta、CD3epsilon、CD3gamma、CD30、CD4、CD40、CD49a、CD49D、CD49f、CD69、CD7、CD84、CD8alpha、CD8beta、CD96(Tactile)、CDl la、CDl lb、CDl lc、CDl ld、CDS、CEACAM1、CRT AM、细胞因子受体、DAP-10、DNAM1(CD226)、Fc gamma受体、GADS、GITR、HVEM(LIGHTR)、IA4、ICAM-1、ICAM-1、Ig alpha(CD79a)、IL2R beta、IL2R gamma、IL7R alpha、免疫球蛋白样蛋白质、诱导性T细胞共刺激分子(ICOS)、整合素、ITGA4、ITGA4、ITGA6、ITGAD、ITGAE、ITGAL、ITGAM、ITGAX、ITGB2、ITGB7、ITGBl、KIRDS2、LAT、LFA-1、LFA-1、与CD83特异性结合的配体、LIGHT、LIGHT(肿瘤坏死因子超家族成员14;TNFSF14)、LTBR、Ly9(CD229)、淋巴细胞功能相关抗原-1(LFA-1(CDl la/CD18)、MHC I类分子、NKG2C、NKG2D、NKp30、NKp44、NKp46、NKp80(KLRF1)、OX-40、PAG/Cbp、程序性死亡-1(PD-1)、PSGL1、SELPLG(CD162)、信号传导淋巴细胞活化分子(SLAM蛋白)、SLAM(SLAMF1;CD150;IPO-3)、SLAMF4(CD244;2B4)、SLAMF6(NTB-A;Lyl08)、SLAMF7、SLP-76、TNF受体蛋白、TNFR2、Toll配体受体、TRANCE/RANKL、VLA1或VLA-6,或它们的组合。
9.权利要求1或2的多核苷酸,其中所述细胞内结构域包含4-1BB/CD137信号传导区。
10.权利要求1或2的多核苷酸,其中所述细胞内结构域包含与SEQ ID NO:7至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
11.权利要求1或2的多核苷酸,其中所述细胞内结构域包含由以下核苷酸序列编码的氨基酸序列:与SEQ ID NO:6至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
12.权利要求1或2的多核苷酸,其中所述抗原结合分子包含重链可变区(VH)和轻链可变区(VL),其中所述VH包含3个互补决定区(CDR)并且所述VL包含3个CDR。
13.权利要求1或2的多核苷酸,其中所述抗原结合分子特异性结合选自由以下各项组成的组的抗原:5T4、甲胎蛋白、B细胞成熟抗原(BCMA)、CA-125、癌胚抗原、CD19、CD20、CD22、CD23、CD30、CD33、CD56、CD123、CD138、c-Met、CSPG4、C型凝集素样分子1(CLL-1)、EGFRvIII、上皮肿瘤抗原、ERBB2、FLT3、叶酸结合蛋白、GD2、GD3、结合的HER1-HER2、结合的HER2-HER3、HER2/Neu、HERV-K、HIV-1包膜糖蛋白gp41、HIV-1包膜糖蛋白gpl20、IL-llRalpha、kappa链、lambda链、黑色素瘤相关抗原、间皮素、MUC-1、突变的p53、突变的ras、前列腺特异性抗原、ROR1或VEGFR2,或它们的组合。
14.权利要求1或2的多核苷酸,其中所述抗原结合分子特异性结合BCMA、CLL-1或FLT3。
15.权利要求1或2的多核苷酸,其中所述活化结构域包含与SEQ ID NO:9或SEQ ID NO:251至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
16.权利要求1或2的多核苷酸,其中所述活化结构域由以下核苷酸序列编码:与SEQ IDNO:8至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
17.权利要求1至16中任一项的多核苷酸,其中所述CAR或TCR进一步包含前导肽。
18.权利要求17的多核苷酸,其中所述前导肽包含与SEQ ID NO:11至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的氨基酸序列。
19.权利要求17的多核苷酸,其中所述前导肽由以下核苷酸序列编码:与SEQ ID NO:10至少约80%,至少约85%,至少约90%,至少约95%,至少约96%,至少约97%,至少约98%,至少约99%或约100%相同的核苷酸序列。
20.包含权利要求1至19中任一项的多核苷酸的载体。
21.权利要求20的载体,其中所述载体为腺病毒载体、腺病毒相关载体、DNA载体、慢病毒载体、质粒、逆转录病毒载体或RNA载体,或它们的任何组合。
22.由权利要求1至19中任一项的多核苷酸或权利要求20或21的载体编码的多肽。
23.包含权利要求1至19中任一项的多核苷酸、权利要求20或21的载体、权利要求22的多肽或它们的任何组合的细胞。
24.权利要求23的细胞,其中所述细胞为T细胞。
25.权利要求24的细胞,其中所述T细胞为同种异体T细胞、自体T细胞、工程化自体T细胞(eACT)或肿瘤浸润淋巴细胞(TIL)。
26.权利要求24或25的细胞,其中所述T细胞为CD4+T细胞。
27.权利要求24或25的细胞,其中所述T细胞为CD8+T细胞。
28.权利要求24或25的细胞,其中所述T细胞为体外细胞。
29.权利要求24或25的细胞,其中所述T细胞为自体T细胞。
30.包含权利要求1至19中任一项的多核苷酸、权利要求20或21的载体、权利要求22的多肽或权利要求23至29中任一项的细胞的组合物。
31.权利要求30的组合物,所述组合物经配制以递送至受试者,任选地,所述组合物包含至少一种药学上可接受的赋形剂。
32.制备表达CAR或TCR的细胞的方法,所述方法包含在适合的条件下用权利要求1至19中任一项的多核苷酸转导细胞。
33.权利要求32的方法,所述方法进一步包含分离所述细胞。
34.诱导针对肿瘤的免疫力的方法,所述方法包含向受试者施用有效量的细胞,所述细胞包含权利要求1至19中任一项的多核苷酸、权利要求20或21的载体、权利要求22的多肽或它们的任何组合。
35.权利要求1至19中任一项的多核苷酸、权利要求20或21的载体、权利要求22的多肽、权利要求23至29中任一项的细胞或权利要求30或31的组合物在制备用于治疗有需要的受试者中癌症的药物中的用途。
36.权利要求35的用途,其中所述癌症为血液学癌症。
37.权利要求35的用途,其中所述癌症为白细胞的癌症。
38.权利要求35的用途,其中所述癌症为浆细胞的癌症。
39.权利要求35至38中任一项的用途,其中所述癌症为白血病、淋巴瘤或骨髓瘤。
40.权利要求35至38中任一项的用途,其中所述癌症为急性淋巴母细胞白血病(ALL)(包括非T细胞ALL)、急性髓样白血病、B细胞幼淋巴细胞白血病、B细胞急性淋巴细胞白血病(“BALL”)、母细胞性浆细胞样树突状细胞肿瘤、伯基特淋巴瘤、慢性淋巴细胞白血病(CLL)、慢性髓细胞性白血病(CML)、慢性髓样白血病、慢性或急性白血病、弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤(FL)、毛细胞白血病、霍奇金病、恶性淋巴细胞增生性疾病、MALT淋巴瘤、套细胞淋巴瘤、边缘区淋巴瘤、意义不明的单克隆丙种球蛋白病(MGUS)、多发性骨髓瘤、骨髓增生异常和骨髓增生异常综合征、非霍奇金淋巴瘤(NHL)、浆细胞增生性疾病(包括无症状性骨髓瘤(郁积型多发性骨髓瘤或惰性骨髓瘤))、浆母细胞性淋巴瘤、浆细胞样树突状细胞肿瘤、浆细胞瘤(包括浆细胞恶液质;单发性骨髓瘤;单发性浆细胞瘤;髓外浆细胞瘤;和多发性浆细胞瘤)、POEMS综合征(也称为Crow-Fukase综合征;Takatsuki病;和PEP综合征)、原发性纵隔大B细胞淋巴瘤(PMBC)、小细胞或大细胞滤泡性淋巴瘤、脾边缘区淋巴瘤(SMZL)、系统性淀粉样蛋白轻链淀粉样变、T细胞急性淋巴细胞白血病(“TALL”)、T细胞淋巴瘤、转化滤泡性淋巴瘤或瓦氏巨球蛋白血症,或它们的组合。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317258P | 2016-04-01 | 2016-04-01 | |
US62/317,258 | 2016-04-01 | ||
PCT/US2017/025351 WO2017173256A1 (en) | 2016-04-01 | 2017-03-31 | Chimeric antigen and t cell receptors and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109328074A true CN109328074A (zh) | 2019-02-12 |
Family
ID=59960588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780030898.9A Pending CN109328074A (zh) | 2016-04-01 | 2017-03-31 | 嵌合抗原和t细胞受体及使用的方法 |
Country Status (29)
Country | Link |
---|---|
US (2) | US10603380B2 (zh) |
EP (2) | EP3436079B1 (zh) |
JP (2) | JP7034934B2 (zh) |
KR (2) | KR102584280B1 (zh) |
CN (1) | CN109328074A (zh) |
AR (2) | AR108427A1 (zh) |
AU (2) | AU2017240667C1 (zh) |
BR (1) | BR112018070073A2 (zh) |
CA (1) | CA3019149A1 (zh) |
CL (2) | CL2018002762A1 (zh) |
CO (1) | CO2018010453A2 (zh) |
CR (1) | CR20180461A (zh) |
CU (1) | CU20180121A7 (zh) |
DO (1) | DOP2018000213A (zh) |
EA (1) | EA201891965A1 (zh) |
EC (1) | ECSP18073833A (zh) |
ES (1) | ES2891578T3 (zh) |
IL (2) | IL303785A (zh) |
MX (2) | MX2018012017A (zh) |
PE (1) | PE20190173A1 (zh) |
PH (1) | PH12018550163A1 (zh) |
PL (1) | PL3436079T3 (zh) |
PT (1) | PT3436079T (zh) |
SA (1) | SA518400135B1 (zh) |
SG (2) | SG10201912489QA (zh) |
SI (1) | SI3436079T1 (zh) |
SV (1) | SV2018005756A (zh) |
TW (3) | TWI787599B (zh) |
WO (1) | WO2017173256A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111196858A (zh) * | 2020-02-05 | 2020-05-26 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
CN111748033A (zh) * | 2020-05-27 | 2020-10-09 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
WO2021169977A1 (zh) * | 2020-02-28 | 2021-09-02 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
WO2021223376A1 (zh) * | 2020-05-08 | 2021-11-11 | 浙江大学 | 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用 |
CN114121142A (zh) * | 2021-09-02 | 2022-03-01 | 四川大学华西医院 | 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用 |
WO2022063291A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
CN114502724A (zh) * | 2019-08-08 | 2022-05-13 | 新加坡国立大学 | 基因修饰的nk细胞及其用途 |
CN114829585A (zh) * | 2019-11-20 | 2022-07-29 | 吉爱希公司 | 用于培养t细胞的组合物及使用其来培养t细胞的方法 |
CN114502724B (zh) * | 2019-08-08 | 2024-06-11 | 新加坡国立大学 | 基因修饰的nk细胞及其用途 |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
FI3298033T4 (fi) | 2015-05-18 | 2023-09-22 | Tcr2 Therapeutics Inc | Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille |
AU2016268863B2 (en) | 2015-05-28 | 2022-06-23 | Kite Pharma, Inc. | Diagnostic methods for T cell therapy |
JP7197979B2 (ja) | 2015-05-28 | 2022-12-28 | カイト ファーマ インコーポレイテッド | T細胞療法のために患者をコンディショニングする方法 |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
AU2017242893A1 (en) | 2016-03-31 | 2018-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indole derivatives as dengue viral replication inhibitors |
CR20180496A (es) | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
KR20200068750A (ko) | 2016-04-01 | 2020-06-15 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
KR102359766B1 (ko) | 2016-04-01 | 2022-02-07 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체 |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
AU2017240667C1 (en) | 2016-04-01 | 2022-11-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
CN116425876A (zh) | 2016-04-01 | 2023-07-14 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
MX2018012318A (es) | 2016-04-08 | 2019-07-04 | Immunocore Ltd | Receptores de celulas t. |
AU2017306432A1 (en) * | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
AU2017332161A1 (en) * | 2016-09-21 | 2019-04-04 | The United States Government As Represented By The Department Of Veterans Affairs | Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use |
EP3515503A4 (en) | 2016-09-23 | 2020-09-23 | The Regents Of The University Of Michigan | MANIPULATED LYMPHOCYTES |
AU2017341048A1 (en) | 2016-10-07 | 2019-05-23 | TCR2 Therapeutics Inc. | Compositions and methods for T-cell receptors reprogramming using fusion proteins |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CA3061945A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
CA3062506A1 (en) | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
UA125407C2 (uk) | 2017-05-22 | 2022-03-02 | Янссен Фармасьютікалз, Інк. | Заміщені похідні індоліну як інгібітори реплікації вірусів денге |
CN110753682B (zh) | 2017-05-22 | 2023-06-30 | 杨森制药公司 | 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物 |
US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
CN109748968B (zh) * | 2017-11-03 | 2020-12-01 | 西安宇繁生物科技有限责任公司 | Bcma特异性嵌合抗原受体t细胞及其应用 |
AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
WO2019099707A1 (en) * | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
CA3084445A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
CN109957021A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd38的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
CN109957016A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd38的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
WO2019136273A1 (en) * | 2018-01-05 | 2019-07-11 | NantBio Inc. | Reprogrammed t cell-like nk cells |
CN111918877A (zh) * | 2018-03-14 | 2020-11-10 | 美国卫生和人力服务部 | 抗cd33嵌合抗原受体及其用途 |
MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
US20200003758A1 (en) | 2018-06-01 | 2020-01-02 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
CN112601546B (zh) * | 2018-06-12 | 2024-04-16 | 湖南远泰生物技术有限公司 | Plap-car-效应细胞 |
CN112638428A (zh) * | 2018-06-12 | 2021-04-09 | H·李·莫菲特癌症中心和研究所公司 | 嵌合抗原受体肿瘤浸润淋巴细胞 |
CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
CN110623980A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
SG11202101067XA (en) * | 2018-07-04 | 2021-03-30 | Cytoimmune Therapeutics Inc | Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1 |
JP2021533746A (ja) | 2018-08-09 | 2021-12-09 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞およびその組成物を生成するための方法 |
MX2021001519A (es) | 2018-08-09 | 2021-05-27 | Juno Therapeutics Inc | Metodos para valorar acidos nucleicos integrados. |
WO2020072352A1 (en) * | 2018-10-01 | 2020-04-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car-t cells targeting glioma stem cells for the treatment of glioblastoma multiforme |
SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
CN113646335A (zh) | 2018-11-01 | 2021-11-12 | 朱诺治疗学股份有限公司 | 使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法 |
US20210393689A1 (en) | 2018-11-01 | 2021-12-23 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
MX2021010670A (es) | 2019-03-05 | 2021-11-12 | Nkarta Inc | Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia. |
CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
AU2020262111A1 (en) * | 2019-04-22 | 2021-12-02 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
SG11202112032WA (en) | 2019-04-30 | 2021-11-29 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
JP2022539248A (ja) | 2019-07-02 | 2022-09-07 | フレッド ハッチンソン キャンサー リサーチ センター | 組換えad35ベクター及び関連遺伝子治療改善 |
TW202124444A (zh) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | 抗cd39抗體組合物及方法 |
KR20220146480A (ko) | 2020-01-28 | 2022-11-01 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 형질도입 방법 |
IL295381A (en) | 2020-02-12 | 2022-10-01 | Juno Therapeutics Inc | bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof |
CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
US20230140976A1 (en) * | 2020-03-30 | 2023-05-11 | Oregon Health & Science University | Monoclonal antibodies for intracellular delivery of payloads |
KR20230009386A (ko) | 2020-04-10 | 2023-01-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도 |
MX2022013530A (es) | 2020-04-28 | 2023-02-01 | Juno Therapeutics Inc | Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador. |
WO2021228999A1 (en) * | 2020-05-12 | 2021-11-18 | Institut Curie | Neoantigenic epitopes associated with sf3b1 mutations |
US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
DE21880926T1 (de) * | 2020-10-12 | 2024-01-11 | Hpvvax, Llc | Zusammensetzung und verfahren zur behandlung von krebs mit einem impfstoff als erster therapeutischer wirkstoff in kombination mit einem zweiten wirkstoff |
CN116802203A (zh) | 2020-11-04 | 2023-09-22 | 朱诺治疗学股份有限公司 | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
CN117396607A (zh) | 2020-12-30 | 2024-01-12 | 阿劳诺斯治疗公司 | 包含多顺反子表达盒的重组载体及其使用方法 |
US20240108654A1 (en) | 2021-03-03 | 2024-04-04 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
JP2024511420A (ja) | 2021-03-22 | 2024-03-13 | ジュノー セラピューティクス インコーポレイテッド | ウイルスベクター粒子の効力を評価する方法 |
EP4314814A1 (en) | 2021-03-22 | 2024-02-07 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
AU2022258832A1 (en) | 2021-04-16 | 2023-10-19 | Celgene Corporation | Combination therapies with bcma-directed t cell therapy |
CA3214280A1 (en) | 2021-04-16 | 2022-10-20 | Julie Ann RYTLEWSKI | T cell therapy in patients who have had prior stem cell transplant |
EP4334341A2 (en) | 2021-05-06 | 2024-03-13 | Juno Therapeutics GmbH | Methods for stimulating and transducing t cells |
WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024044670A1 (en) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Improving immune cell function |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040043401A1 (en) * | 2002-05-28 | 2004-03-04 | Sloan Kettering Institute For Cancer Research | Chimeric T cell receotors |
US20130309258A1 (en) * | 2010-12-09 | 2013-11-21 | The Trustees Of The University Of Pennsylvania | Methods for Treatment of Cancer |
CN104395344A (zh) * | 2012-05-07 | 2015-03-04 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
US20150225480A1 (en) * | 2012-10-05 | 2015-08-13 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
CN105384825A (zh) * | 2015-08-11 | 2016-03-09 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | 細胞の同時の刺激および濃縮 |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
EP2322547A1 (en) | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
JP6061469B2 (ja) | 2009-03-10 | 2017-01-25 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗bcma抗体 |
WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
CA2780707A1 (en) | 2009-11-17 | 2011-05-26 | Basf Plant Science Company Gmbh | Plants with increased yield |
WO2011138414A1 (en) | 2010-05-05 | 2011-11-10 | Addex Pharma Sa | Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
US9845362B2 (en) * | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
CA2824997C (en) | 2011-01-18 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
WO2012103279A2 (en) | 2011-01-26 | 2012-08-02 | Ariad Pharmaceuticals, Incorporated | Methods and compositions for the synthesis of multimerizing agents |
CN106074601A (zh) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
HUE063461T2 (hu) | 2011-05-27 | 2024-01-28 | Glaxo Group Ltd | BCMA (CD269/TNFRSF17)-kötõ fehérjék |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
CA3116051C (en) * | 2012-03-23 | 2023-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
AU2013243946A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
SG11201406414WA (en) | 2012-04-11 | 2014-11-27 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
EP2953475B1 (en) | 2013-02-06 | 2019-07-03 | Celgene Corporation | Modified t lymphocytes having improved specificity |
CN105142677B (zh) | 2013-02-15 | 2019-08-30 | 加利福尼亚大学董事会 | 嵌合抗原受体及其使用方法 |
US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
JP6543626B2 (ja) | 2013-07-29 | 2019-07-10 | ブルーバード バイオ, インコーポレイテッド | 多部分シグナル伝達タンパク質およびその使用 |
CA2930587A1 (en) * | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
KR20220119176A (ko) | 2014-02-04 | 2022-08-26 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
JP6772063B2 (ja) | 2014-02-14 | 2020-10-21 | ベリカム ファーマシューティカルズ, インコーポレイテッド | 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法 |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
JP6698546B2 (ja) | 2014-04-14 | 2020-05-27 | セレクティスCellectis | 癌免疫療法のためのbcma(cd269)特異的キメラ抗原受容体 |
KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
RU2741120C2 (ru) * | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
KR102523934B1 (ko) | 2014-07-24 | 2023-04-20 | 2세븐티 바이오, 인코포레이티드 | Bcma 키메릭 항원 수용체 |
WO2016044745A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
CN107002084B (zh) | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
CA2969704C (en) | 2014-12-05 | 2023-05-02 | City Of Hope | Cs1 targeted chimeric antigen receptor-modified t cells |
EP3230321B1 (en) | 2014-12-12 | 2019-08-28 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
EP3283106B1 (en) | 2015-04-13 | 2021-12-22 | Pfizer Inc. | Therapeutic antibodies and their uses |
CN107980046B (zh) | 2015-04-13 | 2021-12-24 | 辉瑞公司 | 靶向b细胞成熟抗原的嵌合抗原受体 |
JP7197979B2 (ja) | 2015-05-28 | 2022-12-28 | カイト ファーマ インコーポレイテッド | T細胞療法のために患者をコンディショニングする方法 |
KR20200068750A (ko) * | 2016-04-01 | 2020-06-15 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
AU2017240667C1 (en) | 2016-04-01 | 2022-11-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
CN116425876A (zh) | 2016-04-01 | 2023-07-14 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
WO2017173410A1 (en) * | 2016-04-01 | 2017-10-05 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
-
2017
- 2017-03-31 AU AU2017240667A patent/AU2017240667C1/en active Active
- 2017-03-31 CU CU2018000121A patent/CU20180121A7/es unknown
- 2017-03-31 US US15/475,681 patent/US10603380B2/en active Active
- 2017-03-31 SG SG10201912489QA patent/SG10201912489QA/en unknown
- 2017-03-31 JP JP2018550787A patent/JP7034934B2/ja active Active
- 2017-03-31 TW TW109112511A patent/TWI787599B/zh active
- 2017-03-31 BR BR112018070073-8A patent/BR112018070073A2/pt not_active Application Discontinuation
- 2017-03-31 TW TW106111228A patent/TWI691596B/zh active
- 2017-03-31 EP EP17776766.2A patent/EP3436079B1/en active Active
- 2017-03-31 SG SG11201808411RA patent/SG11201808411RA/en unknown
- 2017-03-31 CR CR20180461A patent/CR20180461A/es unknown
- 2017-03-31 PT PT17776766T patent/PT3436079T/pt unknown
- 2017-03-31 CA CA3019149A patent/CA3019149A1/en active Pending
- 2017-03-31 EA EA201891965A patent/EA201891965A1/ru unknown
- 2017-03-31 EP EP21192459.2A patent/EP3984559A1/en active Pending
- 2017-03-31 TW TW111146001A patent/TW202313671A/zh unknown
- 2017-03-31 KR KR1020227026040A patent/KR102584280B1/ko active IP Right Grant
- 2017-03-31 IL IL303785A patent/IL303785A/en unknown
- 2017-03-31 KR KR1020187031270A patent/KR102427334B1/ko active IP Right Grant
- 2017-03-31 CN CN201780030898.9A patent/CN109328074A/zh active Pending
- 2017-03-31 AR ARP170100823A patent/AR108427A1/es unknown
- 2017-03-31 SI SI201730928T patent/SI3436079T1/sl unknown
- 2017-03-31 IL IL261941A patent/IL261941B2/en unknown
- 2017-03-31 MX MX2018012017A patent/MX2018012017A/es unknown
- 2017-03-31 WO PCT/US2017/025351 patent/WO2017173256A1/en active Application Filing
- 2017-03-31 ES ES17776766T patent/ES2891578T3/es active Active
- 2017-03-31 PL PL17776766T patent/PL3436079T3/pl unknown
- 2017-03-31 PE PE2018001933A patent/PE20190173A1/es not_active Application Discontinuation
-
2018
- 2018-09-27 CL CL2018002762A patent/CL2018002762A1/es unknown
- 2018-09-27 PH PH12018550163A patent/PH12018550163A1/en unknown
- 2018-09-28 CO CONC2018/0010453A patent/CO2018010453A2/es unknown
- 2018-09-30 SA SA518400135A patent/SA518400135B1/ar unknown
- 2018-10-01 EC ECSENADI201873833A patent/ECSP18073833A/es unknown
- 2018-10-01 SV SV2018005756A patent/SV2018005756A/es unknown
- 2018-10-01 MX MX2022003995A patent/MX2022003995A/es unknown
- 2018-10-01 DO DO2018000213A patent/DOP2018000213A/es unknown
-
2019
- 2019-09-13 US US16/570,645 patent/US20200108142A1/en not_active Abandoned
- 2019-09-26 CL CL2019002739A patent/CL2019002739A1/es unknown
-
2021
- 2021-02-11 AR ARP210100357A patent/AR121318A2/es unknown
-
2022
- 2022-03-02 JP JP2022031538A patent/JP7379561B2/ja active Active
- 2022-06-23 AU AU2022204423A patent/AU2022204423A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040043401A1 (en) * | 2002-05-28 | 2004-03-04 | Sloan Kettering Institute For Cancer Research | Chimeric T cell receotors |
US20130309258A1 (en) * | 2010-12-09 | 2013-11-21 | The Trustees Of The University Of Pennsylvania | Methods for Treatment of Cancer |
CN104395344A (zh) * | 2012-05-07 | 2015-03-04 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
US20150225480A1 (en) * | 2012-10-05 | 2015-08-13 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
CN105384825A (zh) * | 2015-08-11 | 2016-03-09 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114502724A (zh) * | 2019-08-08 | 2022-05-13 | 新加坡国立大学 | 基因修饰的nk细胞及其用途 |
CN114502724B (zh) * | 2019-08-08 | 2024-06-11 | 新加坡国立大学 | 基因修饰的nk细胞及其用途 |
CN114829585A (zh) * | 2019-11-20 | 2022-07-29 | 吉爱希公司 | 用于培养t细胞的组合物及使用其来培养t细胞的方法 |
CN111196858A (zh) * | 2020-02-05 | 2020-05-26 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
CN111196858B (zh) * | 2020-02-05 | 2021-02-09 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
WO2021155670A1 (zh) * | 2020-02-05 | 2021-08-12 | 武汉科技大学 | 治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体 |
WO2021169977A1 (zh) * | 2020-02-28 | 2021-09-02 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
WO2021223376A1 (zh) * | 2020-05-08 | 2021-11-11 | 浙江大学 | 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用 |
CN111748033A (zh) * | 2020-05-27 | 2020-10-09 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
WO2022063291A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
CN114121142A (zh) * | 2021-09-02 | 2022-03-01 | 四川大学华西医院 | 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用 |
CN114121142B (zh) * | 2021-09-02 | 2023-10-31 | 四川大学华西医院 | 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109328074A (zh) | 嵌合抗原和t细胞受体及使用的方法 | |
JP7451627B2 (ja) | キメラ受容体及びその使用方法 | |
TWI707950B (zh) | 結合分子和使用彼之方法 | |
JP7386382B2 (ja) | キメラ抗原受容体及びt細胞受容体並びに使用方法 | |
TWI814525B (zh) | Cd70結合分子及使用彼之方法 | |
JP2020517302A (ja) | Cd19に対するヒト化抗原結合ドメイン及び使用方法 | |
CN115052902B (zh) | 淋巴细胞-抗原提呈细胞共刺激因子及其应用 | |
CN110494451A (zh) | 靶向tim-1的嵌合抗原受体 | |
CN115322257B (zh) | Bcma靶向抗体、嵌合抗原受体及其应用 | |
TWI835141B (zh) | 人類化抗原-結合域及使用方法 | |
CN116745325A (zh) | Bcma靶向抗体、嵌合抗原受体及其应用 | |
CN116018351A (zh) | 靶向cd123的抗体、嵌合抗原受体及其用途 | |
OA19499A (en) | Chimeric antigen and T cell receptors and methods of use. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1261480 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190212 |
|
WD01 | Invention patent application deemed withdrawn after publication |